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“Everyone strives after the law,” says the man, “so how is that in these many years no one 
except me has requested entry?” The gatekeeper sees that the man is already dying and, in 
order to reach his diminishing sense of hearing, he shouts at him: “Here no one else can 
gain entry, since this entrance was assigned only to you.” 
Kafka, Before the law 
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Abstract	  
 
 
This dissertation charts the rise and articulation of induced Pluripotent Stem Cells 
(iPSCs) as a prominent translational technology, invested with high expectations to finally 
deliver the as yet mostly unfulfilled promise of stem cell research. In a field catalyzed by 
the therapeutic promise, iPSCs have been adopted for widespread translational efforts, in 
the areas of disease modeling, drug discovery and regenerative medicine, and have 
progressively positioned themselves, through the mobilization of several biomedical 
platforms, as a key resource of stem cell-based bioeconomies. 
Specifically, drawing from extensive ethnographic fieldwork, this work targets distinct 
iPSC innovation pathways across the United States and the European Union, and conducts 
the analysis of distinct models of iPSC–based innovation implemented by three leading 
iPSC research organizations that have been spearheading translational iPSC research: the 
New York Stem Cell Foundation, the Harvard Stem Cell Institute, and the European Bank 
for induced Pluripotent Stem Cells – respectively, the largest stem cell research 
organization in the world; the largest private translational stem cell research institution in 
the United States; and one of the two flagship stem cell consortia launched in recent years 
at EU level.  
Through a comparative approach, this dissertation explores the co-productive 
relationship between scientific and governance innovation, and probes the distinct ways in 
which some of the leading research institutions in the field design and implement 
governance arrangements and practices of standardization in order to harness the 
innovation potential of iPSC-based technologies. Furthermore, it accounts for the socio-
political salience of these emerging institutional configurations, and traces the assembly of 
distinct constituencies claiming jurisdiction in this domain of biomedicine. 
	   8	  
 
Introduction	  
	  	  
It was June 2006 when Japanese scientist Shinya Yamanaka, speaking at the 4th 
International Society for Stem Cell Research (ISSCR) annual meeting in Toronto, Ontario, 
reported the soon-to-be-published discovery (Takahashi and Yamanaka 2006) that induced 
expression of just four genes was enough to "reprogram" terminally differentiated murine 
adult cells to a state of pluripotency, yielding induced Pluripotent Stem Cells (iPSCs). 
Received as the pinnacle, and the point of synthesis (Stadtfeld and Hochedlinger 2010), of 
five decades of research into cellular development and cloning technologies1, as well as in 
techniques for the establishment and maintenance of a pluripotent state in ‘immortalized’ 
cell lines2, Yamanaka's announcement astounded as much as it inspired the packed 
audience reunited in Toronto. "We had the distinct feeling that we were witnessing a 
historic moment unfolding", a scientist attending the event recalled (field notes 2015). A 
year later, at the end of 2007, after a frenzy of attempts, Yamanaka's group, along with a 
pool of other leading stem cell labs, reported the derivation of iPSCs from human somatic 
cells (Takahashi et al. 2007; Yu et al. 2007; Park et al. 2008), thus paving the way to the 
portability of iPSCs technologies into the clinical domain. And it did not take long - a mere 
six years since his landmark 2006 publication - for Yamanaka to be awarded the utmost 
stamp of scientific recognition, the 2012 Nobel Prize in Physiology or Medicine (jointly 
with John Gurdon, for his own pioneering research on nuclear transplantation half a 
century earlier): not only did iPSCs rewrite chapters in biology textbooks; also - and 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 See Briggs and King 1952, 1955; Gurdon 1962; Gurdon et al. 1975; Wilmut et al. 1997; Cowan et 
al. 2005. 
2 See Stevens and Little 1954; Kleinsmith and Pierce 1964; Evans and Kaufman 1981; Martin 
1981; Thomson et al. 1998. 
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crucially - they were to open up "a whole new frontier of research into potential clinical 
applications" (Nobel Assembly 2012).  
 
This dissertation is aimed at charting the rise and articulation of iPSCs as a prominent 
translational technology, invested with high expectations to finally deliver the as yet 
mostly unfulfilled promise of stem cell research (Wu and Hochedlinger 2011).  
In a field catalyzed by the therapeutic promise, iPSCs have been swiftly heralded as the 
"holy grail" of stem cell technologies (Hauskeller and Weber 2011), and have 
consequently been adopted for widespread translational efforts, in the distinct, yet 
interlinked areas of disease modeling, drug discovery and regenerative medicine. In the 
study of human diseases, iPSCs are proving to be meaningful models to elucidate disease 
pathogenesis and progression (Han et al. 2011), since they allow to make genetic variation 
experimentally tractable, while also providing access to previously inaccessible cell types 
(e.g. neurons); on the therapeutic side, they have raised prospects for both drug screening, 
by enabling testing for drug efficacy and toxicity in a disease- and patient-relevant context 
(Engle and Puppala 2013), and the potential treatment of degenerative diseases, through 
replacement of affected cell types (Cyranoski 2014). 
In light of these features, iPSC research has progressively positioned itself as a mainstay 
of advanced as well as developing bioeconomies and knowledge-based societies 
worldwide. Governmental agencies and private investors, in Western and Asian countries 
alike, have mobilized a large amount of material, financial and cognitive resources towards 
the establishment of state-of-the-art biomedical platforms (Keating and Cambrosio 2003), 
as well as bio-networks (Patra and Sleeboom-Faulkner 2009; Sleeboom-Faulkner and Patra 
2011) operating on iPSC research at the transnational scale (e.g. Mikami 2014; Sleeboom-
Faulkner and Hwang 2012; Thompson 2010, 2013; Zhang 2011). While iPSC research 
initiatives taking place in Japan stand out owing to sustained state-led efforts at primacy in 
the field (Mikami 2014), iPSC research platforms worldwide both collaborate and compete 
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in standardization practices aimed at stabilizing the field (Webster and Eriksson 2008; 
Webster 2013). Also, they strive to develop models of governance that could successfully 
advance desired framings of iPSC-based innovation, so as to gain competitive advantage in 
the distinct yet interlinking markets of scientific credibility, intellectual property rights, 
biomedical commodities and socio-political prestige (Salter 2013). 
 
Against this momentous development, this dissertation intends to provide an insight into 
the dynamics of the innovation journey (Van de Ven et al. 1999) of iPSCs, as they evolved 
from being a novel technoscientific breakthrough at Takahashi and Yamanaka's bench at 
Kyoto University to being a widely circulating technology in research and clinical centers 
worldwide. Specifically, drawing from extensive ethnographic fieldwork, this work targets 
distinct iPSC innovation pathways across the United States (US) and the European Union 
(EU), two important political and geographical areas in which iPSC research has 
developed. The US in particular, owing to a longstanding primacy in biomedical 
innovation (Salter 2013), hold the lion share in terms of diffusion of this technology, as 
measured by the patented inventions filed for iPSCs since 2006 (Roberts et al. 2014).  
More specifically, this dissertation conducts the analysis of distinct models of iPSC–
based innovation implemented by three leading iPSC research organizations that have been 
spearheading translational iPSC research: the New York Stem Cell Foundation 
(henceforth: NYSCF), the Harvard Stem Cell Institute (henceforth: HSCI), and the 
European Bank for induced Pluripotent Stem Cells (henceforth: EBiSC) – respectively, the 
largest stem cell research organization in the world; the largest private translational stem 
cell research institution in the United States; and one of the two flagship stem cell 
consortia launched in recent years at EU level.  
Japan – a country whose strong state commitment in translational iPSC research has 
even led to what Mikami (2014) designs as an ‘imaginary lock–in’ in science policy – 
would surely have warranted attention to broaden the scope of the analysis. However, the 
	   11	  
ineludible logistic difficulties inherent in arranging an in–depth study of Japanese iPSC 
research (ranging from funding to the language barrier) made such option impracticable. 
Part of the follow up work of this dissertation will thus focus on analysis of Japanese iPSC 
research3. 
 
0.1 Adjusting the analytic gaze. 
The choice of these case studies, the focus on these organizations, as well as the 
methodology adopted for my analysis: these are all relevant aspects of this work that 
warrant a preliminary clarification. 
For one thing, the choice of these three case studies, HSCI, NYSCF and EBiSC, owe to 
their neglect in social sciences studies of stem cell innovation (contrary, for instance, to the 
equally relevant case of the California Institute for Regenerative Medicine (CIRM), 
extensively analyzed by Thompson (2013) and Benjamin (2013)), as well as to their 
relevance and profound impact in the field of iPSC research. In different ways that I 
elucidate in the course of the dissertation, all these three leading iPSC research centers 
have been playing a crucial role in shaping the standardization trajectory of iPSC–based 
innovation, and are thus privileged sites for analyzing the consolidation of the field. 
Second, the choice of focusing on these organizations hinges on a twofold 
consideration, partially related to the methodology being adopted.  
Consistent with a well–established stance developed in the field of Science and 
Technology Studies (henceforth: STS), in which this dissertation is firmly rooted, I 
maintain that biomedical innovation, far from solely owing to technical advances, has a 
strong normative component embedded into it. And the focus on these iPSC research 
centers – which represent a meso–level of analysis, in between the micro–level of 
individual iPSC research laboratories, and the macro–level of practices and regulations 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 However, I have conducted a first inroad into Japanese stem cell research in a forthcoming co-
authored paper revolving around the recent STAP scandal. See Meskus et al. forthcoming. 
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that play out at the national and supranational level and cut tangentially across the whole 
iPSC research field – is the one that, I contend, is best suited to capture both the epistemic 
and the normative import of iPSC research. For, on the one hand, what remains 
analytically invisible at the level of the individual stem cell laboratory is the normativity 
that steers research practices through a variety of governance mechanisms. On the other 
hand, what escapes the analytic gaze by focusing on institutional and diffused macro–
structures is the nitty–gritty of experimental practices – one that, in shaping the epistemic 
and technical component of emerging technologies, undoubtedly represents as well a 
central aspect of biomedical innovation.  
Specifically, to account for both these dynamics, in this dissertation I build on Keating 
and Cambrosio's notion of biomedical platforms (Keating and Cambrosio 2003) and 
deploy it within Jasanoff's co-productionist framework (Jasanoff 2004), to probe 
symmetrically the mutual constitution of governance and epistemic standards within the 
three leading iPSC research centers. Not only, by resorting to different strategies of 
standardization, these organizations pursue distinct paths to iPSC–based innovation. Also, 
they design and adopt distinctive models of governance, through which different 
constituencies advance different normative commitments and visions that they strive to 
materialize by means of iPSC research. 
Building on this analysis, I then seek to bring to the fore questions of macro–order to 
which major endeavors in the life sciences inevitably led – especially in a time when 
human cells have been increasingly replacing coal and steel as the main threads in the 
fabric of economic development and the forging of new political identities. Hence, I probe 
the intimate connection that ties these models of iPSC–based innovation to the public 
sphere, tracing the assembly of distinct constituencies claiming jurisdiction in this domain 
of biomedicine and thereby enacting distinct 'constitutional' dispensations of the role of 
science within society (Jasanoff 2003).  
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0.2 Entering a field I never left. From project conception to empirical access 
and data collection. 
In ways that go beyond my formal affiliation with the European School of Molecular 
Medicine (SEMM) at the European Institute of Oncology (IEO) in Milan, this project owes 
a lot to the setting in which it was conceived, took a tentative inception, gained 
momentum, and fully developed. 
Since its conception in the late spring of 2012, the idea to provide an as yet unattempted 
cartography of the field of iPSC research needed the completion of some fundamental 
groundwork in order to develop into a full-fledged research project. In particular, aside 
from methodological fine-tuning and full immersion into relevant STS as well as scientific 
literature, a robust, first-hand knowledge of iPSC research practices was needed, if I were 
to gain a sufficient understanding of the key issues at stake so as to develop and refine my 
research questions prior to my entering the field of empirical enquiry. In that regard, the 
physical proximity with - when not outright embeddedness into - a leading biomedical 
institution proved to be a catalyzing factor to develop these enabling skills.  
In particular, my supervisor's dual role as an STS scholar and biomedical scientist 
conducting cutting-edge iPSC research provided me with the perfect opportunity to match 
my intellectual aspirations with a sound preparatory work that helped me to familiarize 
with the bread and butter of iPSC research. From June 2012, I started what proved to be a 
year-long internship (lasting until August 2013, with a brief interruption from July to 
September 2012, when I took up a visiting teaching position in Hermeneutics and Post-
Modern Philosophy at Saengtham College in Nakhon Pathom, Thailand), during which I 
regularly attended weekly group meetings in Giuseppe Testa's lab (henceforth: GT lab), 
and also devoted around 50% of my work time to work at the bench. Not only, as in 
Latour's famous preaching, was I to follow scientists. All of a sudden, in a way totally 
unforeseen just a few months before, I was acting as one of them. 
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While this experience would require an ethnographic account of its own (something 
beyond the scope of this dissertation), I am here going to limit myself to highlight its 
relevance for the subsequent part of my fieldwork. 
 
First and foremost, the lab internship allowed me to get acquainted with the most 
widespread experimental practices occurring in a tissue culture facility – the physical place 
where the ontology of iPS cells is crafted in its materiality. While embedded in GT lab, my 
main task was indeed to provide assistance at first, and replacement soon thereafter, to 
some PhD students and a post-docs for the processes of iPSC derivation, culture, and 
expansion. Among the main tasks that I had to perform were daily media change, iPSC 
colonies selection and picking (this refers to the visual inspection and manual selection, 
through a needle and a pipette, of the best clusters of cells, i.e., those that have been fully 
reprogrammed to become bona fide pluripotent stem cells), iPSC colonies expansion, and 
formation and differentiation of embryoid bodies (i.e., spheroid structures derived from 
clusters of stem cells that, upon differentiation into the three germ layers, can provide a 
first proof-of-principle of their pluripotency). In doing so, I achieved experimental fluency 
in dealing with a number of different protocols, media and techniques. 
  
Figure	  1.	  Embryoid	  bodies	  formation.	  June	  2013. 
Adjacent to this, and consistent with my position at the bottom of the hierarchical ladder 
within the lab (which often entails the involvement in riskier kinds of projects (see Knorr-
Cetina 1999)), I was handed the attempts to test (in fall 2012) a new culture condition for 
the cells (a cheaper one compared to the one that was currently in use in the lab, and that 
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also required less hands-on time), and, most notably (in spring and summer 2013), to 
replicate a recently published protocol revolving around the modeling of human cortical 
development in vitro using induced pluripotent stem cells (Mariani et al. 2012). The 
replication attempt required intensive tinkering with both the cells and the equipment, and 
allowed me to familiarize with some of the widespread techniques in molecular biology, 
other than those commonly employed in culturing cells. Unsuccessful in the end, this 
endeavor allowed me to widen my perspective outside the confined walls of a tissue 
culture facility, as well to confront issues arising in the design and set up phase of 
experimental systems. 
 
Figure	  2.	  EBs	  stainings.	  Slide	  from	  presentation	  given	  at	  GT	  lab	  meeting	  in	  July	  2013. 
Overall, insofar as it provided me with a unique vista on iPSC research practices, the 
knowledge that I gained throughout such intensive - and, at times, rather daunting - 
internship was enabling for the development of my project for a number of reasons. First, it 
helped to redefine and adjust my research questions, bringing issues of standardization at 
the center of my focus. Second, it also played an important part in the choice of the unit of 
analysis to adopt: iPSC platforms rather than individual labs, so as to better account for the 
macro-political normativity accompanying standardization practices, something which 
remains analytically invisible within the walls of the lab. Third - and for the very same 
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reason - it prompted a reassessment of the qualitative techniques to employ in my 
fieldwork, where - with the notable exception of attendance to closed doors meeting at the 
iPS Core Facility and to meetings of Kevin Eggan's group at HSCI - I gave preference to 
interviews rather than observations of the work of the scientists – since acquaintance with 
the latter had already being achieved while in GT lab. Fourth, it primed my understanding 
of the situation I was going to encounter in the field, thus facilitating and streamlining the 
process of data acquisition. 
As such, and contrary to my first descent to the tissue culture facility at the first floor of 
my own building at the Ifom-Ieo Campus, the moment I entered the iPS Core Facility at 
the Harvard Stem Cell Institute in September 2013 - the ‘official‘ beginning of my 
fieldwork - did not feel at all as awkward. It rather felt as if I never left the lab. 
 
0.3 Methodological note on fieldwork arrangements. 
A year-long fellowship in the Program on Science, Technology and Society, directed by 
Prof. Sheila Jasanoff, at the John F. Kennedy School of Government at Harvard University 
provided me with the perfect springboard for my HSCI fieldwork. Affiliation to the same 
institution I was going to study greatly helped in streamlining the process of data 
acquisition. 
In particular, through connections already established by my supervisor with the leader 
of the iPS Core facility, Chad Cowan, I was able to set up multiple visits to the Core. 
Furthermore, other than holding frequent meetings with the head of the facility, from 
October 2013 to October 2014 I was able to attend close–door meetings that took place 
among participants to its various projects, and also conduct separate semi–structured 
interviews with the main actors involved.  
While at Harvard, adopting snowball techniques I was also able to reach out to various 
HSCI scientists, working in various departments and affiliated hospitals.  
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From October to December 2013, I also attended weekly lab meetings at a leading iPSC 
lab directed by Kevin Eggan. During that time, I could attend two meetings devoted 
entirely to standardization. During these meetings, the normal routine of individual 
projects' presentation was suspended, and the whole lab, led by the P.I., engaged in 
discussions on how to better standardize lab protocols. This experience, coupled with my 
previous experience at the GT lab (and my ongoing attendance of its weekly lab meetings), 
helped me to reinforce my understanding of the multi-faceted standardization landscape of 
iPSC research.  
 
As for NYSCF, protracted negotiations were eventually conducive to set up a visit to 
the facilities in April 2014. The visit took a full day, involved both observations of 
scientists at work, informal discussions at lunchtime and during coffee breaks, and semi-
structured interviews with relevant members of the organization. In particular, the visit 
allowed me to become acquainted with their main laboratory equipment, the robotic 
system for iPSC derivation, expansion and differentiation (the Global Stem Cell Array, 
described here in detail in chapter 4). During the visit, I established connections that 
allowed me to set up further interviews with members of the organization, and to get 
access, upon my return to New York City in October 2014, in order to attend NYSCF’s 
annual translational stem cell conference, to closed-door events related to the conference. 
 
Upon my return to Italy, in August 2014, I started making arrangements for my EBiSC 
fieldwork. My supervisor’s membership in EBiSC Ethical Advisory Board (EAB), and 
support from the Center of Ethics and Law in the Life Sciences (CELLS) at Hannover 
University (from February to August 2015), a partner in the EBiSC consortium, facilitated 
access to the organization. Furthermore, a visiting period at the Science and Technology 
Studies Unit (SATSU) at the University of York, directed by Prof. Andrew Webster, in 
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April and May 2015 represented an ideal platform for conducting fieldwork in the UK, 
where a number of EBiSC partners were based. 
 
Finally, a methodological overview, with a complete list of the interviews conducted 
and the relevant meetings attended, can be found at the end of the dissertation (see 
Appendix I). 
 
0.4 Structure of the dissertation. 
The dissertation sets out by providing a contextualization for the rise of translational 
iPSC research, and the emergence and consolidation of translational iPSC research 
platforms. To this purpose, chapter 1 is aimed at exploring the scope and significance of 
the phenomenon of clinical translation, for, I contend, the push to accelerate biomedical 
innovation (i.e. the translation of laboratory findings into tangible therapeutic products) has 
greatly informed the developmental trajectory of iPSCs. In particular, I focus on the 
narratives and metaphors through which the push to translation is articulated, and look at 
how these discursive practices are materialized into strategic programs, governance 
reforms, and novel material and epistemic cultures that have significantly altered, in the 
last decade, the landscape of biomedical research.  
Chapter 2 provides an overview of the iPSC research landscape, so as to acquaint the 
reader with its jargon, concepts and practices. I thus sketch here the core features of the 
iPSC research platform, and trace the key junctures of the iPSC developmental trajectory, 
while providing a brief overview of some of the main issues that have been confronted by 
stem cell laboratories worldwide to standardize iPSCs. In addition, I analyze the main 
epistemic tenets of iPSC–based disease modeling, reconstruct the narratives and 
expectations around iPSCs’ therapeutic potential, and provide a closer look at the use of 
iPSCs in clinical research. 
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In chapter 3, I expound my analytic approach, developed for the analysis of my case 
studies, which builds on the notion of biomedical platforms proposed by Peter Keating and 
Alberto Cambrosio (2003) and the co–productionist program advanced by Sheila Jasanoff 
(2004). Specifically, in this chapter I trace the distinction between two distinct ways of 
applying the co–productionist lens to the analysis of biomedical platforms (see also Marelli 
and Testa forthcoming). First, I argue that biomedical platforms propel what I term the 
endogenous co-production of scientific innovation and regimes of governance, through the 
adoption of mutually constitutive standardization and governance practices. Second, I 
contend that reprogramming-based platforms are also conspicuous examples of a higher, 
meta-level of ‘reprogramming’, through which platforms are sculpted by and in turn re-
shape their broader socio-political context, and that I propose as an exogenous form of co-
production. Finally, I argue that both kinds of co–productionist accounts are needed in 
order to capture the dynamics of innovation revolving around biomedical platforms in 
contemporary biomedical research, as well as their relevant socio–political implications. 
 
The second part of the dissertation deals with the empirical analysis of my case studies. 
Chapter 4 sets out by outlining the most significant junctures in the chain of events leading 
to the current policy configuration of the field of stem cell research. Next, it expounds how 
they have been brought to bear on the establishment of a leading iPSC research institution 
in the US, the New York Stem Cell Foundation, a venture philanthropy–backed 
organization distinctively advancing a disruptive innovation approach to translational iPSC 
research. 
Chapter 5 attends to the progressive entrenchment of stem cell research at a bastion of 
American academic research, Harvard University, by focusing on the establishment of the 
Harvard Stem Cell Institute. While similarly advancing a translational stem cell research 
agenda, HSCI maintains in many significant respects a different approach from the one 
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articulated by NYSCF, one aimed at sustaining – rather than disrupting – established 
research practices in the field of stem cell research.  
Chapter 6 accounts for how translational iPSC research is enrolled and mobilized in the 
process of renegotiation of the ‘European’ economic – but also political – identity. The 
chapter focuses on the revealing case study of the European Bank for induced Pluripotent 
Stem Cells (EBiSC), established in 2014 within the framework of the Innovative 
Medicines Initiative (IMI), a Public Private Partnership – the world’s largest – between the 
European Commission and the European Federation of Pharmaceutical Industry and 
Associations (EFPIA). Here, I expound how, through EBiSC’s endeavor, the stabilization 
of a new and enticing field of research is co-produced along with the structuring of a 
significant portion of the European science policy. 
Finally, in the conclusions I make explicit what had been left implicit in the previous 
chapters. Accordingly, I trace comparisons between the three iPSC research platforms 
analyzed in the dissertation, and I bring to the fore the way they distinctively embody 
different visions concerning the role that ought to be played by stem cell research within 
the broader socio–economic–political order. 
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Chapter	  1.	  Accelerating	  Biomedical	  Innovation:	  
the	  Translational	  Turn	  in	  Biomedicine1	  
	  
 
In a 2003 Policy Forum in Science, then NIH director Elias Zerhouni announced the 
launch of the 'NIH Roadmap' (Zerhouni 2003). Comprising a series of initiatives intended 
to "transform the nation's medical research capabilities and speed the translation of 
discoveries from the bench to the bedside" (NIH Press Release 2007), the NIH Roadmap 
marks the beginning of a 'translational turn' in biomedicine. From that moment, clinical 
translation emerged as a new field of sociotechnical practice – one that acquired 
significance well beyond the confined walls of laboratory and clinical facilities. ‘Clinical 
translation’ has since become a widely circulating buzzword, a touchstone – not immune 
from controversy (Maienschein et al. 2008, Jogalekar 2011) – for biomedical, patients’ and 
policy communities alike. As it has been said, "translational research means different 
things to different people, but it seems important to almost everyone" (Woolf 2008). 
The present chapter is aimed at exploring the scope and significance of the phenomenon 
of clinical translation, focusing in particular on its discursive embodiments that convey and 
recast the interests, expectations and commitments of a broad array of communities within 
and around biomedical research and, at the same time, re–produce those stances into 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 The reflections presented in this chapter owe in a significant way to a collaborative project on 
clinical translation undertaken with colleagues at INSERM (France), University of Vienna 
(Austria), and Harvard Medical School (USA). In particular, I draw here extensively from a co–
authored, equally contributed paper, in review at the moment of writing, quoted as Aarden, 
Blasimme, Holloway and Marelli (forthcoming). In preparing this chapter, I also benefited from 
participation at two events where I presented parts of the present work: first, a workshop on 
'Making sense of clinical translation: ethical, regulatory and policy challenges for Europe and the 
US', held at the Brocher Foundation in Hermance, Geneva, on May 18–19, 2015, which I have co–
organized along with the aforementioned colleagues; second, a panel on "Politics and Ethics of 
Translational Medicine", held at the Science and Democracy Network 14th Annual Meeting, that 
took place at Harvard University on June 25–27, 2015.  
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strategic programs, governance reforms, and novel material and epistemic cultures in 
biomedicine. 
The underlying assumption that informs this chapter is that it would not be possible to 
appreciate the noticeable excitement raised in biomedical constituencies by the advent of 
iPSCs, as well as to attend to the trajectory taken by their standardization pathways 
(Webster 2013), without contextualizing their emergence and stabilization within the 
underlying conceptual and normative framework of clinical translation. Since the onset of 
the new millennium, following the first sequencing of the entire human genome (Lander et 
al. 2001; Venter et al. 2001) and the launch of the NIH Roadmap in 2003 (Zerhouni 2003), 
a vast array of socio–technical practices revolving around biomedicine has been moulded, 
and profoundly reconfigured, by the imperative to "accelerate translation", i.e. the clinical 
application of scientific discoveries. Not only does the push to translation performs a 
central role in shaping the current evolution of the biomedical enterprise writ large. In the 
case of iPSC–based technologies, I argue (and will show in the next chapter), it has 
pervasively informed the dynamics of their innovation journey (Van de Ven et al. 1999), 
steering their development from an emerging technoscientific breakthrough at Takahashi 
and Yamanaka's bench at Kyoto University to a widely adopted technology in clinical and 
research centers worldwide. 
Providing an overview of the phenomenon of clinical translation represents, 
accordingly, an obvious entry point for – one could even possibly say an obligatory 
passage point (Callon 1986) into – the rest of the present dissertation.  
For one thing, the momentous development of iPSC research, as I will expound at 
greater length in the next chapter, has been greatly informed by the translational ethos that 
upholds "the implicit value that science that can be translated into results is the best 
science, and everything else is second–tier" (Maienschein et al. 2008). Not only the greater 
translational potential that induced pluripotent stem cells carry vis–à–vis their 
embryonically or clonally derived counterparts (see chapter 2) has significantly 
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streamlined the rapid uptake of iPSC–based technologies by laboratories worldwide. Also, 
their standardization trajectory – from the quest for reprogramming methods geared to 
augment the efficiency and completeness of reprogramming, while preserving genomic 
integrity so as to avoid tumorigenicity upon injection in the body; to the development of 
characterization assays enabling a shift from a qualitative to a digitized assessment of 
pluripotency, thus allowing the handling of a higher number of cell lines; to the attempt to 
devise consenting procedures for donors geared to facilitate the commercialization of 
research findings – has been shaped by the intent, from the part of scientists, industrial 
representatives and investors alike, to greatly accelerate their clinical deployment, be it in 
the form of cell–based therapeutics or as tools for modeling diseases and testing for new 
compounds. 
Secondly, the establishment and consolidation of leading iPSC research platforms in the 
United States and the European Union, whose detailed characterization constitutes the core 
of the present work, has been significantly influenced by the translational imperative. From 
the New York Stem Cell Foundation, to the Harvard Stem Cell Institute, to the European 
Bank for induced Pluripotent Stem Cells, each and every one of these leading iPSC 
research platforms variously resort – to both set forth their objectives, and carve out for 
themselves a space of public legitimacy – to the framings, norms and expectations encoded 
in the translational discourse. In particular, whether it is by developing innovative modes 
of governance, the blurring of entrenched disciplinary boundaries, or the creation of 
synergies among public and private actors, they all assume upon themselves what 
constitutes the kernel of the translational trope, namely, the mandate to accelerate the pace 
of (stem cell–based) biomedical innovation. 
Against this backdrop, the present chapter is devoted to sketching the contours of the 
conceptual and normative framework of clinical translation. Specifically, in section (1.1), I 
trace the origins of the translational turn in biomedicine in the framing of biomedical 
innovation first explicitly advanced by the NIH Roadmap in 2003, and argue that, in its 
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broader connotation2, clinical translation increasingly represents the underlying organizing 
principle of contemporary biomedical research. Next, in section (1.2), I show that clinical 
translation presents itself primarily as a discursive phenomenon, and contend that the 
extensive use of rhetorical practices and metaphors – to which the translational discourse 
abundantly resorts – to characterize the obstacles hindering biomedical innovation has a 
profound impact in the way both the ontology and the agenda of clinical translation is 
defined. In particular, these metaphors point to what, drawing from Aarden, Blasimme, 
Holloway and Marelli (forthcoming), can be designed as the translational lag narrative, 
i.e. the idea that the pace of clinical innovation lags behind that of scientific discoveries, 
and should be accelerated accordingly. It is this narrative that, so I argue, acts as a potent 
driver for the enactment of profound scientific and organizational reconfigurations in 
biomedicine (section 1.3). Also, it advances distinct normative agendas and collectively 
held visions of desirable socio–political orders to be attained by means of accelerated 
biomedical innovation (section 1.4). 
Throughout the chapter, I thus aim to bring to the fore some of the widespread 
normative commitments and expectations underpinning the standardization trajectory of 
iPSCs, as well as the establishment and consolidation of iPSC research platforms, so as to 
lay the groundwork for the analysis conducted in the following chapters.  
 
1.1 The translational turn in biomedicine. 
In its current form, clinical translation finds its inception, following in the footsteps of 
the first sequencing of the human genome, in the launch, spearheaded by then NIH 
Director Elias Zerhouni (a Bush administration appointee), of the NIH Roadmap. The 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 As noted by Vignola–Gagnè (2013), the notion of clinical translation maintains many different 
connotations, and is equally characterzied as a 'discipline', 'experimental practice' as well as 
'political agenda'. The analytic rendering of this notion proposed in this chapter (see section 1.1) is 
aimed at distinguishing, within its semantic breadth, a narrow connotation of the term, as a specific 
disciplinary approach in biomedical research, from a broader connotation referring to its character 
as an overarching framework structuring a broad variety of practices in contemporary biomedicine. 
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result of a year–long reflection involving scientific as well as lay constituencies ranging 
from academia to governmental agencies and the private sector, the NIH Roadmap set out 
from the realization that, notwithstanding the ever–increasing epistemic and cultural 
authority commanded by the life sciences at the onset of the 21st Century, "critical 
scientific gaps" (Zerhouni 2003) preventing the streamlined transition from discovery to 
application still had to be addressed. In Zerhouni's own words, while the sequencing of the 
entire human genome, announced in June 2000, triggered visions of unprecedented 
scientific and medical opportunities, it also created "a series of challenges that will 
redefine the ways that medical research is conducted and, ultimately, how research leads to 
improvements in health" (Zerhouni 2003). As noted in Aarden, Blasimme, Holloway and 
Marelli (forthcoming): 
In an unexpected twist of positivist optimism, all of a sudden, progress ceased to 
appear as the natural output of scientific ingenuity. Even more importantly, for the first 
time a discrepancy was detected: that between the "unprecedented acceleration of 
scientific discovery" and the lagging pace of "clinical translation" (Zerhouni 2003). The 
latter expression began to circulate and came to designate an area of unfulfilled 
promise – one that called for urgent remediation. According to the new vision sketched 
by the roadmap, the relation between discovery and delivery had to be re–engineered. 
"Roadblocks" had to be removed (ibid.). 
The relevance of the NIH Roadmap should not be underestimated. Since its launch, 
clinical translation, first introduced as a concept in the 1990s (Encyclopædia Britannica), 
came to be widely recognized as a scientific and social priority, to be vigorously pursued 
by creating the conditions to streamline the delivery of new therapies onto the market and 
into the clinic. In particular, the consolidation of the translational field occurred through 
two conjoined, but in fact distinct trajectories. On the one hand, clinical translation 
emerged, out of a process of professionalization, as an autonomous discipline, possessing 
peculiar methodologies and objects of enquiry (Cambrosio et al. 2006a), as well as 
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dedicated research and funding institutions (e.g., The National Center for Advancing 
Translational Science (NCATS), established in 2011 within the NIH), journals (e.g., the 
American Journal of Translational Research, Translational Research, Science 
Translational Medicine, the Journal of Translational Medicine, Clinical and Translational 
Medicine, Stem Cells Translational Medicine, etc.)3 and career patterns (see Nathan 2002). 
On the other hand – and most notably for the purposes of the present dissertation – the 
impetus towards translation became both a widespread ethos (Maienschein et al. 2008) and 
style of reasoning, introducing "new criteria determining what counted as the solution of a 
problem"4 (Crombie 1994; see also Hacking 1985, 1994, 2004, 2012; and Boem 2015), 
that came to underpin policy and funding programs while organizing a broad variety of 
research practices as well as collective priorities in biomedicine (Vignola–Gagné 2013). 
Therefore, in this second broader connotation, clinical translation not only represents 
the latest stage in the incremental realignment of biology and medicine that characterizes 
the advent and consolidation of biomedicine itself (Cambrosio et al. 2006b), but also marks 
a fundamental moment of sociotechnical transition, one that significantly reconfigures, not 
without resistance from some biomedical constituencies (Jogalekar 20115), the approaches, 
scope, and practices of the life sciences, while bringing forth profound changes in 
biomedicine's own epistemic culture (Knorr–Cetina 1999). As such, the translational 
enterprise is geared to have a structuring effect on the whole biomedical research 
enterprise. Contextually to enacting profound changes in biomedicine's contexts of 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 Journals dedicated to translation started to appear in the early 2000s and have been listed in 
Thomson Reuters’ Journal Citation Report only since 2009. 
4 In particular, as the empirical chapters of this dissertation will attest, in translationally–oriented 
endeavors emphasis has progressively shied away from traditional forms of peer recognition (i.e., 
the peer–reviewed publication) towards therapeutic innovation. 
5 For instance, notes Jogalekar, “what is wrong is that translational research is being seen as a 
panacea that will address the flagging rate of new biomedical advances. The thinking seems to 
declare that if only more people were given more money and deliberately focused on direct 
application, we would suddenly see a windfall of new therapies against disease. This thinking 
suffers from two major problems. The first is that history is not really on the side of translational 
research. Most inventions and practical applications of science and technology which we take for 
granted have come not from people sitting in a room trying to invent new things, but as fortuitous 
offshoots of curiosity-driven research. […]The second important problem with translational 
research is that it puts the cart before the horse. First come the ideas, then come the applications.” 
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discovery and justification (Reichenbach 1938), i.e. in the ways new experimental 
hypotheses are generated, and regarded as methodologically sound, it sets forth and widely 
disseminates, as argued (and decried) by Maienschein and colleagues (2008), those 
constitutive and epistemic values (Longino 1990; Daston 1992; Daston and Gallison 2007) 
definitory of contemporary 'good biomedical science', while also reshaping social relations 
in biomedicine's underpinning institutional context. 
Accordingly – it ought to be noted – clinical translation so understood maintains a 
difference in kind with respect to other novel approaches in the biosciences, such as 
'personalized' or 'precision' medicine, that are oftentimes spearheaded by strategic 
initiatives of institutional connotation, similar in nature to the NIH Roadmap (see, e.g., the 
Personalised Medicine for the European Citizen (Look 2012), and the Precision Medicine 
Initiative in the US (NIH 2015)). Whilst notions such as 'precision' and 'personalized' 
medicine are meant to define new practices and programs of intervention, oftentimes said 
to be re–envisioning no less than the future of medicine itself (see, e.g. NIH 2015), they 
still owe in significant ways to the overarching framework of clinical translation (whose 
main tenets I trace below), thus configuring themselves as specific means to achieve the 
broader translational objective of shortening the distance from discovery to application. 
For, in the spirit of the latter, such approaches are meant to devise outcome–driven 
programs of intervention intended to maximize the clinical actionability of post–genomics 
technologies and discoveries6, and to produce new types of biomedical knowledge more 
amenable to clinical translation7. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
6 For instance, precision medicine's prevention and treatment strategies that take individual 
variability into account (Collins and Varmus 2015) are seen as a way to "to leverage advances in 
genomics [...] and health information technology" in order "to accelerate our understanding of 
disease onset and progression, treatment response, and health outcomes" (NIH 2015, italics mine). 
7 As stated in the Personalised Medicine for the European Citizen report: "Personalised medicine is 
a new approach to classifying, understanding, treating and preventing disease based on data and 
information on individual biological and environmental differences. It seeks to integrate data on the 
entire dynamic biological makeup of each individual as well as the environmental and lifestyle 
factors that interface with this makeup to generate a complex, individual phenotype. Using this 
information, models can be generated to identify the most appropriate healthcare choices, from 
treatment to prevention, in individual citizens." (ESF 2012, italics mine) 
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 In what follows, I thus aim to expound the twofold significance of clinical translation 
as a conceptual and normative framework that, while it crystallizes a multiplicity of 
discourses on the problems faced by contemporary biomedical research into the narrative 
and interpretive schema of the translational lag (i.e., the notion that the pace of clinical 
innovation lags behind that of scientific discovery), at the same time reproduces and 
performs the stances coming from a broad variety of constituencies into strategic 
programs, governance reforms, and novel material cultures in biomedicine, all geared to 
accelerate the pace of biomedical innovation. 
 
1.2 Articulating clinical translation: the t rans lat ional  lag narrat ive .  
As an actor category mobilized in biomedical as well as policy settings, clinical 
translation is typically articulated according to a widespread conceptual dichotomy, and is 
imagined to operate as either a linear (unidirectional) pathway or as an iterative process, in 
the space defined by the clinical and laboratory poles, of which it would itself occupy the 
middle ground8.  
In its linear framing, most famously epitomized by the "bench–to–the–bedside" 
metaphor, clinical translation is conceptualized as the effort to bring breakthroughs in basic 
biomedical sciences to bear on clinical outcomes, through distinct translational phases 
corresponding to identified ‘translational blocks’ that have to be overcome. In particular, 
commentators have identified the T1 phase concerning the production and 
commercialization of new drugs, devices, and treatment options for patients, and the T2 
phase concerning the reorganization of systems of care so as to effectively accommodate 
the new treatments in the day–to–day clinical practice (Sung et al 2003; Woolf 2008). 
More to the point, the T2 model shares with T1 the intuition that our ability to understand 
human biology and pathology is unmatched by our current capacity to alleviate the burden 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
8 While these framings can be (largely) compatible, commentators typically draw from, and give 
prominence to, either one or the other to conceptualize clinical translation. 
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of disease on people’s life. However, T2 is not concerned with accelerating the pace of the 
transition from discovery to invention – as T1 arguably does. Rather, this other model has 
to do with the dissemination of innovation and the fair allocation of medical resources to 
the sick population. While these two models can be seen as compatible, and in fact 
coexistent in the process of bringing basic research to bear on clinical outcomes, T2 has 
been at times articulated in rather oppositional terms with respect to T1. For example, it 
has been noticed that "[s]cientific discoveries and spectacular new devices are more 
fascinating to the public and more lucrative for industry, [whereas it is t]he betterment of 
health [that] should dictate priorities in health research" (Woolf 2008). Such a public 
health–oriented approach to understanding the meaning of translation, albeit having been 
circulating for more than a decade now, has however exerted a smaller influence on the 
overall articulation of the problem of translation. 
In its iterative framing, on the other hand, translation is understood as a two–way traffic 
between the lab and the clinic, whereby concepts are brought from the laboratory into the 
clinic, and insights generated from clinical observations are recursively brought to bear on 
laboratory practices. Only through the close–hand, synergistic, and iterative interaction of 
the biological and clinical poles of research, so the argument goes, can rapid development 
and commercialization of new therapeutic products be achieved.  
However, in spite of their differences, what both these conceptualizations entail, and 
reinforce, is a dichotomous and compartimentalized perspective on the process of 
knowledge–translation, whereby translation implies a clear–cut distinction between two 
domains, and an in–between hiatus to be filled up by translational programs and practices, 
operating either in a linear or iterative way.  
Such conceptualizations owes, in many respects, to the discursive premises onto 
which clinical translation is deeply rooted. Indeed, the translational turn is being heavily 
propelled through a proliferation of linguistic formations and rhetorical metaphors that, as 
Vignola–Gagné persuasively observes, "solicit adhesion to an agenda by emphasizing the 
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threat of a purported alternative" (Vignola–Gagné 2013). Scouring scientific publications 
and policy documents, one thus finds patent "cliffs" to be overcome, "gaps" to be 
"bridged", and "bottlenecks" and "roadblocks" to be removed. Conversely, one witnesses 
the acclaim of "roadmaps", "catalysts" and "pathfinders" promising to move knowledge 
across the most formidable obstacle of all, the "valley of death" hampering the clinical and 
commercial uptake of scientific findings. Far from just playing an ancillary role in 
advancing and giving urgency to the translational research program, these discursive 
practices define the very ontology of the translational paradigm itself. The specific locution 
of gaps, valleys, pipelines, pathways and roadblocks imbues translation with a spatial and 
temporal dimension, and advance a well–defined framing of the problems facing 
biomedicine, while shaping accordingly the translational research agenda.  
Urgency to overcome the purported dichotomy between the "bench" and the "bedside" 
is perhaps most vividly evoked by the representation that what separates them is, in fact, a 
"valley of death" (see e.g. Butler 2008). What this metaphor suggests is the idea that major 
hindrances are situated on the way from laboratory to clinic, or from discovery to 
application. Thus, the way to address them is to find a way to bring the poles of the lab and 
the clinic closer together. As such, the translational agenda has its solution built into the 
problem definition. If the problem with clinical application of biomedical knowledge is the 
opening (and widening) of a space between bench and bedside, this space–between 
becomes a site of intervention – and opportunity – for translationally–oriented programs 
and practices. 
 Most importantly, all these metaphors converge to construct a translational lag 
narrative (Aarden, Blasimme, Holloway and Marelli forthcoming): the notion that the pace 
of clinical innovation lags behind that of scientific discovery. Constant breakthroughs in 
laboratory research and technological advances are thought to be producing, at an 
increasing rate, possibilities for new treatments. What the lag narrative portrays, though, is 
that too few of them are developed into tangible treatments, and those of them that do take 
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far too long to reach patients. Accordingly, what the narrative advocates as means to 
bridge the gap are innovation – which refers to strategies of turning knowledge into things, 
biomedical insights into therapeutics – and acceleration – which refers to strategies of 
doing so faster. As a consequence, since the launch of the NIH Roadmap, proposals to 
solve the problem have constantly focused on closing the gap by accelerating and 
innovating: the need to accelerate biomedical innovation has thus become a widely 
repeated mantra (Maienschein et al. 2008), with that of clinical translation coming to 
embody a prominent instantiation of the late modern imaginary of accelerated techno–
scientific progress (Rosa and Scheuerman 2009; Rosa 2013; see also Virilio 1997). 
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Figure	   3.	   Different	   visual	   renderings	   of	   the	   ‘valley	   of	   death’.	   (1a)	   Photo	   taken	   in	   NYSCF’s	  
laboratory.	  (1b)	  Butler	  2008	  	  
As many of such kind, the translational lag narrative relies heavily on the mobilization 
of the future as justification for investments in programs aimed at repairing the lag and 
innovation strategies geared to promissory and highly speculative projects filled with 
uncertainty. This mobilization is enacted through the construction and performance of 
expectations that encode visions of future orders to be attained as well as dystopic 
projections – as the varied renderings of the valley metaphor attest – of unwanted 
consequences to be avoided (Brown and Michael 2003; Borup et al. 2006; Jasanoff and 
Kim 2009, 2015). At the same time, the framing of translational projects as functional and 
conducive to desirable sociotechnical futures is co–constructed along the 'translation' of 
wants into needs, or what may be desirable to achieve in the future into what is actually 
“NIH stands for the National Institutes of Health, not the National Institutes 
of Biomedical Research, or the 
National Institutes of Basic Biomedi-
cal Research.” This jab, by molecular 
biologist Alan Schechter at the NIH, 
is a pointed one. The organization was formally 
established in the United States more than half a 
century ago to serve the nation’s public health, 
and its mission now is to pursue fundamental 
knowledge and apply it “to reduce the burdens 
of illness and disability”. So when employees at 
the agency have to check their name tag, some 
soul searching must be taking place. 
There is no question that the NIH excels 
in basic research. What researchers such as 
Schechter are asking is whether it has neglected 
the mandate to apply that knowledge. Outside 
the agency too there is a growing 
perception that the enormous 
resources being put into biomedi-
cal research, and the huge strides 
made in understanding disease 
mechanisms, are not resulting in 
commensurate gains in new treat-
ments, diagnostics and prevention. 
“We are not seeing the breakthrough therapies 
that people can rightly expect,” says Schechter, 
head of molecular biology and genetics at the 
National Institute of Diabetes and Digestive 
and Kidney Diseases in Bethesda, Maryland. 
Medical-research agencies worldwide are 
experiencing a similar awakening. Over the 
past 30 or so years, the ecosystems of basic 
and clinical research have diverged. The phar-
maceutical industry, which for many years 
was expected to carry discoveries across the 
divide, is now hard pushed to do so. The abyss 
left behind is sometimes labelled the ‘valley 
of death’ — and neither basic researchers, 
busy with discoveries, nor physicians, busy 
with patients, are keen to venture there. “The 
clinical and basic scientists don’t really com-
municate,” says Barbara Alving, director of the 
NIH’s National Center for Research Resources 
in Bethesda. 
Alving is a key part in the NIH’s attempt to 
bridge the gap with ‘translational research’. 
Director Elias Zerhouni made this bridge-
building a focus in his signature ‘roadmap’ for 
the agency, announced in 2003 (see Nature 425, 
438; 2003). Spearheading the NIH effort will be 
a consortium of 60 Clinical and Translational 
Science Centers (CTSCs) at universities and 
medical centres across the country, which will 
share some US$500 million annually when they 
are all in operation by 2012. Late last month, 
the NIH doled out the most recent grants in 
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A chasm has opened up between biomedical researchers and the patients who need their 
discoveries. Declan Butler asks how the ground shifted and whether the US National 
Institutes of Health can bridge the gap.
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needed. Accordingly, advancing a framing of the present in terms of scarcity, the 
discourses revolving around translation are pervaded by a rhetoric of acceleration (Rosa 
2013). As noted by Aarden, Blasimme, Holloway and Marelli (forthcoming): 
The clinical translation of knowledge into medical innovation embodies one of the 
contemporary incarnations of the modern myth of endless progress. At a careful 
examination, however, it appears to be driven equally by the hope of development as by 
the dread of stagnation. The more ideals of enhanced biomedical possibilities take 
shape, roughing out a future of prosperity and health, the more present forms and 
values assume the semblance of impediments. This trait explains why a narrative of 
acceleration dominates the discursive landscape of clinical translation. Hence, in the 
quest for clinical translation, the promise of development incorporates one of radical 
change. 
The idea that clinical application does not follow naturally from the sheer accumulation 
of biological knowledge constitutes the stable core of the lag narrative and of its associated 
metaphors. This "story line" (Hajer 2006) is associated with the idea that the transition 
from discovery to innovation needs to be dramatically accelerated. 
Historically, the sense of urgency built into the translational discourse, rather than the 
outcome of a predominant master narrative stemming from a well–defined socio–technical 
world, emerged, in recent decades, from the crystallization and convergence of several 
strands of critique and concerns about the production and application of medical 
knowledge.  
In the 1980s, HIV–AIDS patient–advocacy groups played an important role in 
expanding and accelerating access to experimental drugs. Confronting an entrenched 
medical elitism, they successfully strived for recognition and scientific credibility (Epstein 
1996; Dresser 2001; Daemmrich 2004) paving the way to the establishment of new 
patient–centered biomedical collectives (Rabeharisoa and Bourret 2009) often endowed 
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with the capacity to significantly impact the orientation (and acceleration) of research 
programs concerning their diseases (Rabeharisoa and Callon 2004). At the policy level, the 
thrust towards translation emerged as the byproduct of (top–down) legislative actions 
undertaken in the 1980s, aimed at forging closer ties between academia and industry in 
order to speed up the commercial uptake of "basic" scientific discoveries (Guston 2000) – 
with the Bayh–Dole Act (1980) most famously spearheading such initiatives (Cooper 
2008; Loewenberg 2009). In parallel, emphasis on the creation of closer academy–industry 
collaborations was heightened by industrial actors themselves, willing to access previously 
untapped academic innovation as a mean to reverse an enduring and widely publicized 
productivity crisis (Stinchcomb 2009; Stevens et al. 2011). Finally, as far as experimental 
practices themselves are concerned, the affirmation of the translational paradigm is rooted 
in developments occurring in cancer research in the 1990s, aimed at creating synergies 
between (the then segregated) laboratory and clinical types of research, which resulted in 
the consolidation of a translational interface that was de facto non–existent a few decades 
before (Cambrosio et al. 2006a).  
Even though it was not until the 2000s, after the first sequencing of the human genomes 
and through the undertaking of initiatives such as the NIH Roadmap, that clinical 
translation started becoming the shibboleth that it is today, its process of consolidation 
owes in many significant respects to the multiplicity of its historical roots. Stemming from 
these distinct perspectives, that around translation emerged indeed as a multi–layered 
narrative. In it, a variety of technical and lay discourses – ranging from those revolving 
around the productivity crisis in the pharmaceutical industry, to those encoded in strategic 
programs advanced by governmental agencies, to participatory claims advanced by patient 
advocacy groups, etc. –converge onto the idea that clinical innovation is stagnating and 
should be geared up towards the accelerated production of tangible outputs. As it has been 
noted, "although different, these interpretations [of translation] are not mutually exclusive. 
Rather, they reflect different priorities for achieving a common goal" (Encyclopædia 
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Britannica). Thus, while the kernel of the translational trope has remained considerably 
stable over the years, its perduring solidity owes to the multiplicity of the intertwined 
discursive strands of which it is composed – in a way similar to what Meloni and Testa 
observe with regard to the "blurring of meanings as a critical asset" for the structuration of 
the field of epigenomics (Meloni and Testa 2014). As argued in that regard by Aarden, 
Blasimme, Holloway and Marelli (forthcoming): 
Far from being a precisely defined space of sociotechnical interaction, clinical 
translation is thus best understood as a landscape onto which different discursive 
articulations of the [translational] lag struggle to find some sort of correspondence 
with social and political reality. Translation, so characterized, is not understandable 
independently of the multiple discursive practices that constitute and travel its 
extension. [...] Analysis shall therefore do justice to the multiplicity of meanings, 
expectations, values and regulatory commitments that are currently being traded 
around the metaphors and scenarios that translation evokes. Each technical world 
produces its own version of the valley metaphor, as in an effort to claim epistemic 
authority and social credibility over the project of translation itself. The proliferation of 
metaphors in this area corresponds to the multiplicity of technical discourses that 
coexist on the territory of clinical translation. 
Within most biomedical constituencies, and beyond, that of the translational lag 
arguably became, in recent times, the most prominent conceptual and normative 
framework to both represent the maladies ailing biomedicine, and to orient the deployment 
of material and cognitive resources in a variety of programs aimed at addressing them. 
Having provided an overview of the discourses and conceptual coordinates of clinical 
translation, in the next section I focus on its sociotechnical performativity, i.e. on how 
clinical translation re–produces those stances into strategic programs, regulatory reforms, 
and novel material cultures within and around biomedicine. 
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 1.3 The manifold performativities of clinical translation. 
Scholars in the social sciences and the humanities have variously interrogated, and 
critically addressed, the manifold sociotechnical transformations instigated by clinical 
translation, as well as their implications for biomedicine and society. 
The thrust towards translation has been variously framed as a vivid manifestation of a 
rampant neoliberal capitalism, and seen as geared to a privatization of biomedical goods 
(Kahn 2014), an increased capitalization and globalization of the life sciences (Sunder–
Rajan and Leonelli 2013), and the generation of biovalue (Waldby 2002) through 
exploitative forms of clinical labor (Cooper and Waldby 2014). Moreover, the translational 
rush is seen as reinforcing entrenched geopolitical asymmetries, through the establishment 
of bio–networks operating across different countries (Patra and Sleeboom–Faulkner 2009; 
Sleeboom–Faulkner and Patra, 2011). In a similar fashion, scholars within the sociology of 
medicine have shown how a "neoliberal corporate bias" plays out in upholding industry's 
interests in drug development and (de)regulation carried out in the name of accelerated 
translation (Lewis and Abraham 2001; Abraham 2002, 2008), while others have 
questioned what may get "lost in translation" (i.e., which kinds of science are no longer 
considered to be legitimate uses of public and private resources), vis–à–vis the emergence 
of a "translational ethos", advanced by what they call the research–medical–industrial 
enterprise writ large (Maienschein et al. 2008). Other strands of analysis have attended to 
the bioconstitutional transformations (Jasanoff 2011) fostered by efforts at translation, 
through a redistribution of power and agency among actors and 'stakeholders' involved in 
the biomedical enterprise, in a way conducive to a redefinition of the scope and boundaries 
of citizenship on a national (Benjamin 2013) and global scale (Sunder Rajan 2011).  
Lastly, Aarden, Blasimme, Holloway and Marelli (forthcoming) propose a topographic 
analysis aimed at charting how the discursive practices and metaphors revolving around 
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translation are articulated in a variety of sociotechnical worlds while retaining a distinctive 
capacity to perform the co–production of multiple epistemic and normative orders 
(Jasanoff 2004). In particular, the latter approach is geared to address the shortcomings of 
the aforementioned analytic perspectives, that, in spite of the distinct explanatory pathways 
they articulate, tend to similarly reify specific explanatory categories (such as corporate 
bias, neoliberal capitalism, etc.) and posit them as static, stable and pre–defined explanans 
of clinical translation (Dussauge, Helgesson and Lee 2015). As such, these approaches fail 
to account for the multiplicity of transformations instigated by the translational discourse 
in the domain of biomedical research, and for the broader reconfigurations it triggers in the 
socio–political landscape. 
In particular, Aarden, Blasimme, Holloway and Marelli (forthcoming) identify four 
domains in which distinct articulations of the lag narrative, each highlighting diverse sets 
of problems hampering the smooth translation of scientific knowledge into tangible clinical 
outputs, propel profound socio–technical reconfigurations within and around biomedicine. 
These different, often connected, but not necessarily convergent perspectives casting 
distinct diagnoses of the maladies affecting the biomedical enterprise points to: (i) 
scientific, (ii) regulatory, (iii) ethical, and (iv) organizational impediments as major 
obstacles to be overcome so as to foster clinical translation. More to the point for our 
present discussion, two of these translational discourses, those revolving around the 
scientific and organizational hindrances slowing down the effective translation of novel 
biomedical insights, perform a key function in shaping iPSC research with its attending 
epistemology, as well as in propelling reconfigurations in its underpinning organizational 
arrangements. Accordingly, in what follows I briefly sketch the conceptual and rhetorical 
perimeters of these discourses, before analyzing, in the following chapters, how they are 
brought to bear on iPSC research practice and its underpinning institutional configurations. 
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(i) Scientific impediments. 
A common thread in the discourse on translation points to obstacles in knowledge–flow 
as a major impediment to the transition from discovery to clinical application. A first, 
popular version of this narrative centers on the conventional division of scientific labor as a 
major epistemic hindrance for clinical translation. Traditionally, the production of 
scientific knowledge has been structured around disciplines with a high degree of 
specialization. However, notwithstanding the manifold advances witnessed in the last 
decades in the life sciences, so the discourse goes, this paradigm has been showing signs of 
wear. Not only has a 'siloed' approach to research, based on the experimental apparatuses 
of highly segregated disciplines, being challenged, and proved inadequate, by the advent of 
the so called 'big data biology' with its panoply of new 'omics technologies (Stevens 2013; 
Hood and Rowen 2013; Ratti 2015). Moreover, such approach has lead to major issues, 
such as the experimental reproducibility (or lack thereof) of scientific knowledge and its 
material inscriptions (Latour 1986), as they are made to move from the laboratory to the 
clinical domain to be transformed into fungible, clinically actionable (Nelson et al. 2013) 
products (Begley and Ellis 2012). As argued by Garret Fitzgerald, director of the Institute 
of Translational Medicine and Therapeutics at the University of Pennsylvania, in an op–ed 
published in Nature in 2010 and devoted to the difficulties facing pharmaceutical research 
in the transition from the pre–clinical to the clinical phase of experimentation: 
Too many steps are pursued in specialist isolation, in both academia and industry. 
Too few people can bridge the translational and interdisciplinary divides. This has led 
to crucial and expensive mistakes in phase II of drug development — when there is 
often a failure to see an impact on efficacy, a propensity to ignore risks, or a danger of 
making errors in dose selection for phase III. 
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Accordingly, such narrative has in recent years fed into an imagination of a future 
science that has fewer boundaries and moves towards the thorough interweaving, and 
seamless integration, of the diverse material and epistemic components of the life sciences.  
Moreover, increased efforts at removing the obstacles in knowledge–flow, and creating 
synergies among the diverse phases of the biomedical innovation pipeline, have begin to 
blur the boundaries between research and treatment, whereby the two previously distinct – 
and diachronically ordered – moments become aligned within the same biomedical 
platforms (Keating and Cambrosio 2003). As attested by the advent of new sociotechnical 
practices revolving around novel technologies with their accompanying social innovations, 
such as direct–to–consumer (DTC) genetic testing (Parthasarathy 2010; Curnutte and Testa 
2012), iPSC–based technologies (Saha and Hurlbut 2011; Marelli and Testa forthcoming), 
and body–on–chip models (The Economist 2015; Bhatia and Ingber 2014; Maschmeyer et 
al. 2015) – to name but a few relevant examples –, the seemingly solid division between 
research and treatment falls away as the clinic becomes a primary site of innovation. Thus, 
epistemically, every patient can, at the same time, become a source and a target of 
extrapolation (Germain 2013), whereby real–time data and the clinical knowledge 
generated from her/his lived–experience (Canguilhem 1978) maintain a key function for 
both design and interpretation of experiments in the laboratory (Coleman and Dreesen 
2009), which, in turn, can be more swiftly translated into clinically–relevant knowledge. 
From a socio–political perspective, the advent of practices such as DTC genetic testing 
propels the emergence of new sites in the production of both biological and clinical 
knowledge, while reconfiguring the role of the patient–consumer as a prominent actor – in 
fact a work provider (Cooper and Waldby 2014) – in biomedical innovation (Curnutte and 
Testa 2012). 
How these aspects play out in the development of iPSC–based technologies is what I 
address in the next chapter. 
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(ii) Organizational hindrances and reconfigurations. 
Another prominent account of translation frames the latter as a domain that demands an 
organizational gearshift. The mandate to accelerate translation, so a widespread narrative 
goes, requires, in parallel to removing the obstacles in knowledge–flow, profound 
institutional transformations in biomedical research, leading to what has been framed as 
the co–production of the life sciences' epistemic content and institutional arrangements 
(Cambrosio et al. 2014).  
Notably, the development of new modes of governance is often seen as a necessary 
prerequisite to both foster the delivery of new therapies onto the market and into the clinic 
(Salter 2013) and to accompany the introduction of novel, and potentially disruptive, 
technologies so as to "bring them in harmony with human existence" (Nowotny and Testa 
2010). Moreover, in the name of accelerated translation, advocacy organizations coalesce 
around specific diseases and areas of enquiry (e.g., see Rabeharisoa and Bourret 2009); 
research collaborations, spanning institutional and national boundaries (e.g., see Sleebom–
Faulkner and Patra 2011), are established, along with state–sponsored programs aimed at 
fostering competitiveness in enticing new (bio)economic territories, in advanced and in 
developing countries alike (Salter 2013).  
Among the problems identified in the 'organizational discourse' around translation is the 
lack of support for truly innovative research, aimed at forging new paths of inquiry. This 
feature is mainly manifested in the policy of funding agencies, which, according to this 
narrative, tend to privilege research projects showing the most solid foundations over those 
with a path–breaking potential (Ledford 2012). This feature of contemporary funding 
programs has thus propelled the intervention of new actors, such as philanthropic 
organizations (Bartek 2014; Marelli and Testa forthcoming), eager to support high return, 
high risk projects that would normally not receive funding or attention by risk–adverse 
funding institutions (Johnson 2010). In turn – as I address at a fine–grained level of 
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analysis in Chapter 4, focusing on the revealing case study of NYSCF – the increasing 
involvement of new constituencies in the steering of biomedical research entails a 
privatization of the agenda setting prerogatives. As the latter move under the control of the 
private sector, they are subject to little or no public oversight, in a potentially costly trade–
off between innovation and public governance of controversial yet highly promising fields 
of research (Krimsky 2007; Thompson 2013; Broad 2014). 
Moreover, overcoming the disciplinary separations described above requires adapting 
the structure of scientific communities to novel epistemic needs. Under the translational 
paradigm, "the research teams of the future [are imagined to] look and feel vastly different 
from their predecessors" (Zerhouni 2003). In particular, trans–disciplinary and trans–
departmental collaborations, aimed at addressing research questions going beyond 
entrenched disciplinary confines, have altered, in significant ways, the traditional 
landscape of biomedical research. Chapter 5, presenting a detailed account of the creation 
and consolidation of HSCI, analyzes one of the most relevant examples of such 
reconfigurations, occurring at a bastion of academic research in the US, Harvard 
University. 
A further layer of the organizational diagnosis for the stagnating rate of translation has 
to do with the allegedly scarce level of public–private partnership (PPP) in the biomedical 
sciences. The efficient translation of basic knowledge into therapeutic outputs, so the 
argument goes, would benefit from a closer collaboration between academia and private 
actors, such as small biotechnology companies, venture capital and the pharmaceutical 
industry. Accordingly, chapter 6 focuses on a prime instantiation of the thrust towards 
trans–institutional collaborations, represented by the establishment, in 2008, of the 
Innovative Medicine Initiative (IMI) (Goldman 2012). The latter can count on joint yearly 
endowments from the European Commission and from the European Association of 
Pharmaceutical Industries and Associations (Efpia) and is the world’s largest PPP in the 
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life sciences. Very much in line with the core of the translational narrative, IMI’s mission 
is to "speed up the development of, and patient access to, innovative medicines, 
particularly in areas where there is an unmet medical or social need" (IMI 2014).  
Crucially, these kinds of organizational reconfigurations aim at breaking new paths of 
discovery and innovation, but also have a broader, if less explicit impact. As I address in 
greater details in the following chapters, the re–organization of research instigated by the 
translational paradigm reaches beyond the organizational outlook of research teams. 
Translation–oriented endeavors bring about a redistribution of agency and power between 
different groups of stakeholders; propel the emergence and consolidation of innovative 
biomedical platforms (Keating and Cambrosio 2003), thus reconfiguring the roles and 
functions performed by the lab, the clinic, and the market in the biomedical research 
landscape; and, on a broader scale, redefine national priorities and collectively held 
representations of national futures (Jasanoff and Kim 2009, 2015). 
 
1.4 Conclusions. The socio–political relevance of clinical translation. 
In the first part of this chapter, I have touched upon the defining features of the 
discourse revolving around translation, identifying in the translational lag narrative the 
kernel of the conceptual and normative framework it advances, while, in the second part, I 
have accounted for its performativity in propelling novel sociotechnical configurations and 
reconfigurations in biomedicine. While certainly not exhaustive – something that would 
have been beyond the scope of the present work –, this overview serves the purpose of 
highlighting the significance of the translational turn in biomedicine. From the moment 
when, in 2003, the NIH Roadmap crystallizes the stances coming from a broad variety of 
communities into a well–defined schema to interpret and address the shortcomings of the 
present configurations of biomedical research, clinical translation, i.e. the faster clinical 
and market delivery of new therapies, has been increasingly envisioned as the ultimate 
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organizing principle of present–day scientific discovery,  In this perspective, translation 
appears as the regulative ideal to which a disparate set of activities, from research to 
ethical oversight, from scientific organization to national science policy, must conform.  
 Moreover, not only does the translational discourse provide the interpretive lenses for 
identifying the hindrances to biomedical innovation, and a rationale, as well as a bauplan, 
for devising programs intended to address them, but it also acts performatively to 
materialize, through its envisioned reframing of the biomedical research enterprise, visions 
of desirable futures and normative stances concerning social and political order and the 
collective good. 
As the distinct strands of the translational discourse attest, around translation coalesce 
distinct commitments and expectations advanced by a broad variety of constituencies. 
From pharmaceutical industries envisioning a future of increased profit–maximization 
beckoning them from beyond the valley of death, to governments of advanced and 
emerging economies alike embracing the narrative of accelerated biomedical innovation as 
they strive to preserve, or challenge, leadership positions in global knowledge–based 
markets; from private capital–backed foundations leveraging on the states' budgetary 
constraints in dire times of austerity, to assert a more prominent role in the steering of 
emerging technologies and fields of research, to biomedical communities increasingly 
envisioning their endeavors through the conceptual lenses, borrowed from the economic 
life, of "higher throughput" and "scaleable production": all these different instantiations of 
the thrust toward translation attest how the latter, far from merely revolving around the 
streamlined delivery of therapeutic outputs, is also a potent vehicle for advancing a number 
of distinct normative agendas and collectively held visions of desirable socio–political 
orders (Jasanoff and Kim 2015) to be attained by means of accelerated biomedical 
innovation.  
In its universalizing aspiration – accelerating the clinical application of scientific 
discoveries – clinical tranlsation thus remains a particular and situated phenomenon, 
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which is continuously rearticulated in practice at a variety of sites, from boards of directors 
in multinational corporations and philanthropic organizations, to governmental science 
policy offices. A fundamental aim of the present work, accordingly, is to analyze how the 
diverse platforms, and the diverse constituencies they represent, re–articulate clinical 
translation in a variety of ways to fit their diverse normative commitments, or, differently 
put, how translation redefines, in distinct ways according to its different framings and 
practical implementations, the constitutional position of science within society (Jasanoff 
2003).	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Chapter	  2.	  Assembling	  the	  iPSC	  Research	  
Platform	  
 
 
The remarkable discovery of iPSCs by Takahashi and Yamanaka may be the molecular 
equivalent of the discovery of antibiotics and vaccines in the last century. 
Wu and Hochedlinger, Nature Cell Biology 2011 
 
I think it’s the whole field of stem cells to be accelerated at a tremendous speed. 1998: 
hESCs. 2006: iPSCs. 2007: human iPSCs. Six years later Yamanaka wins the Nobel Prize… 
Well, it gave everyone the idea that ‘bang bang’, in a couple of years we’ll be way forward… 
Everyone wants to be the first, to be the first to produce the first tangible results. 
Interview with stem cell scientist 
 
 
As attested by the Nobel Assembly in their October 2012 press release announcing the 
award of the Nobel Prize to Shinya Yamanaka, whilst straddling research-oriented and 
application-driven (Carrier and Nordmann 2011) epistemic cultures (Saha and Hurlbut 
2011), the field of iPSC research has built momentum, and fuelled expectations, in 
anticipating the realization of its clinical potential. In a field catalyzed by the therapeutic 
promise, iPSCs have been heralded as the "holy grail" of stem cell technologies, endowed 
with the capacity to finally deliver the latter’s as yet mostly unfulfilled promise (Wu and 
Hochedlinger 2011; Hauskeller and Weber 2011). For this reason, iPSC–based 
technologies have been swiftly adopted for widespread translational efforts, in the distinct, 
yet interlinked areas of disease modeling, drug discovery and regenerative medicine.  
How these developments have occurred, on the backdrop of a widespread thrust in 
biomedicine towards the acceleration of clinical translation, analyzed in the previous 
chapter, is what I am going to expound in this chapter of the dissertation. More to the 
point, I will proceed as follows.  
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First, in section (2.1) I sketch the core features of the iPSC research platform (Keating 
and Cambrosio 2003), and trace the key junctures of the iPSC developmental trajectory. In 
doing so, I provide a brief overview of some key issues that had - and in some respects still 
have - to be confronted by stem cell laboratories worldwide to tame the unruliness of these 
novel biomedical entities and standardize accordingly their material ontology. Next 
(section 2.2), I analyze the main epistemic tenets of iPSC–based disease modeling, and 
highlight how the former are brought to bear on the letter's translational deployment. Then, 
in section (2.3) I reconstruct the narratives and expectations around iPSCs’ therapeutic 
potential. Finally, in section (2.4) I provide a closer look at the use of iPSCs in clinical 
research. In particular, rather than focusing on their development as therapeutic products 
for regenerative purposes, I mainly devote my attention to their usage as translational tools 
in drug discovery, i.e. as models for testing for new compounds. This choice is motivated 
by the fact that the platforms whose analysis constitutes the core of this dissertation are, in 
various degrees, similarly geared to the development of iPSC–derived (pharmaceutical) 
treatments, rather than iPSC–based (regenerative) therapies.  
As its overarching aim, this chapters intends to provide an overview of the iPSC 
research landscape, so as to acquaint the reader with the jargon, concepts and practices of 
iPSC research, thus laying the groundwork for the empirical analysis conducted in the 
following parts of this dissertation. 
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2.1 Assembling the “core” of the iPSC research platform. 
 
Figure	  4.	  The	  iPSC	  research	  “pipeline”.	  From	  Bellin	  et	  al.,	  Nat	  Rev	  Mol	  Cell	  Biol	  2012	  
Figure 1 provides a synopsis of the different “steps” of the iPSC research “pipeline”, 
that constitute the core of the iPSC research platform (Keating and Cambrosio 2003). 
Schematically put, it can be described as follows. Following obtainment of informed 
consent from donors, somatic cells (typically skin or, since more recently, blood cells (Loh 
et al. 2010)) are harvested through a biopsy or blood procurement from patients and 
healthy “controls”. Then, through a variety of methods, they are “reprogrammed” into 
iPSCs, expanded, and then differentiated into the relevant cell types (sometimes, as in the 
case of neurons, otherwise experimentally inaccessible), carrying the precise genetic 
mutation(s) of pathological relevance. 
Differentiated cells, along with iPSCs themselves, are then used as in vitro models to 
provide insights into the molecular mechanisms underpinning disease. They can also be 
employed to conduct screenings for new compounds, while also allowing toxicity testing 
in a physiologically–relevant context. Differentiated cells can also potentially be used as 
cell–based therapeutics for regenerative purposes, through the replacement of affected cell 
types. 
 
The assemblage of the iPSC research platform, described here in its essential features, 
has required significant “investments in form” (Thévenot 1984) from the part of different 
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biomedical communities. As iPSCs burst onto the biomedical scene, a number of issues 
pertaining to their standardization had to be confronted to turn them into a viable 
translational technology. In what follows, I account for some of the most relevant among 
them. Purpose of this brief review is not to provide an exhaustive analysis of iPSCs 
standardization, but rather to bring to the fore some of the issues that, at some key 
junctures of their standardization trajectories, had to be confronted by iPSC research 
platforms worldwide. 
 
(i) Tissue samples procurement: 
The standardization of the “upstream part” of iPSCs research has increasingly been 
perceived as an important goal for the stabilization of the field. In particular, it becomes an 
essential requirement for translating iPSCs into commercializable therapies (Grskovic et al. 
2011).  
A first important step in this regard concerns the recruitment of patients. Access to a 
broad patient population has been seen as a major, and at times indispensable, asset for 
pursuing research with iPSCs. In particular, large academic institutions with affiliated 
hospitals, with an institutional review board (IRB) process in place for collecting patient 
samples, are deemed as having a “strategic advantage” in collecting tissues and producing 
iPSCs (Grskovic et al. 2011). Accordingly, emphasis – especially from commercial actors 
– has been put in establishing linkages with such organizations, patient advocacy groups, 
academic clinicians and clinics that treat such patients, as well as in developing 
participatory platforms to enroll patients (REF.). The narrative revolving around the 
“moral duty” (Caplan 1984; Harris 2005) or the incentives to participate in research, either 
for altruistic reasons or purported personal benefits, has played a significant part in 
mobilizing the patients’ broad endorsement and participation in iPSCs research (Dasgupta 
et al. 2014). 
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In the second place, especially following the entrance into the field of pharmaceutical 
corporations, worried about potential hindrances to the commercialization of research 
findings, the importance of standardizing consenting procedure has risen to the fore. As a 
the CEO of a company involved in iPSCs research noted: 
At the moment, the problem is not making iPSC, it is the procurement. The delays 
are upstream. You do the collaboration, you work on the cell lines, get some nice 
things, then go out to the OTT, and you discover that the initial consent is not in 
line with the commercialization! That's why pharma […] is very interested in 
standardizing the upstream part. 
Interview with CEO of an iPSC research company 
To this end, a number of different consenting strategies, geared to ensure the streamlined 
circulation of research findings, have been developed, from “broad, one–time consents”, to 
consent templates reflecting “an intention for sustained interactions with participants in 
select circumstances about the ongoing uses of their coded specimens” (Lowenthal et al. 
2012). 
 
(ii) Reprogramming methods: 
Standardization of reprogramming technologies has been one of the single most 
important aspects concerning the stabilization of iPSC research practices. The development 
of improved reprogramming technologies, initially consisting in retroviral transduction of 
the reprogramming factors, has proceeded at a steady pace, programmatically driven by the 
intent to accelerate the clinical translation of iPSCs. In 2009, Jamie Thomson’s group at 
the University of Wisconsin reported the successful reprogramming of human fibroblasts 
by a single transfection with episomal vectors (Yu et al. 2009), a technology later 
improved by Yamanaka’s lab (Okita et al. 2011); the same year, Japanese researchers 
devised a reprogramming method based on the usage of Sendai virus (Fusaki et al. 2009); 
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while, a year later, Derrick Rossi’s group at the Harvard Stem Cell Institute reported the 
conception of a reprogramming technology based on synthetic modified mRNA (Warren et 
al. 2010).  
While taking different approaches, these methods were similarly geared to maximize 
the efficiency (i.e. the number of iPSCs generated per somatic input cell), and success rate 
(i.e. the percentage of samples for which iPSCs emerged) of reprogramming – in order to 
increase its yield – as well as to ensure the non–integration of reprogramming genes in the 
host genome, so as to avoid the risk of tumorigenicity upon injection of iPSC–derived cells 
into the human body.  
Having being commercialized worldwide through readily available and widely used 
reagents and kits, these methods have rapidly become the mainstays of reprogramming 
technologies, whose choice of usage, as highlighted by a recent comparative study 
(Schlaeger et al. 2014), hinges on each platform’s particular requirements (such as 
reliability in iPSCs derivation, need to reduce workload of generating iPSCs, amenability 
to automation, employment in GMP facilities).  
 
(iii) Pluripotency assessment and iPSCs characterization: 
Another key aspect concerning the standardization of iPSC research practice revolves 
around the development of techniques for the assessment of the defining feature of this 
entire field of research, i.e. the pluripotency of reprogrammed stem cell lines. More to the 
point, a general trend in the field has been to move from qualitative to quantitative and 
digitized assays, which in turn are meant to facilitate the development of, and their 
integration into, automated robotic technologies. 
A first important evolution – still very much underway at the time of writing – has 
occurred in the practices and techniques of pluripotent stem cells’ selection. Fully 
reprogrammed (and hence bona fide pluripotent) stem cells are typically grown in a 
colony–like shape, visually evaluated by experienced scientists, and manually “picked” in 
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order to be expanded (while non–reprogrammed, non pluripotent cells are discarded). As 
one scientific publication describes the procedure (Muller et al.2012): 
"Visual inspection and manual selection of “good” from “ugly” looking colonies 
probably remains the most under-appreciated yet most important control 
instrument for pluripotent quality assessment, used every day in hPSC labs 
worldwide. Development of the expertise to decide which colonies to pick and 
which to discard requires apprenticeship with experienced researchers and is 
difficult to operationalize. 
	  
Figure	  5.	  Colonies	  of	  iPSCs	  (photo	  by	  LM) 
In fact, under the thrust to increase the throughput of cell lines (the biologists’ jargon 
used to define productivity), the last few years have witnessed the progressive introduction 
of bio–imaging technologies that perform the digitization of the visually–assessed 
morphological parameters defining pluripotency (e.g., the shape of colonies, their growth 
rate, their rate of shape-changing) through their quantification into a discreet, binary signal 
(whereby the presence/absence of a single biomarker readout is taken as proxy for 
pluripotency, see e.g. Paull et al. 2015)1. Aimed at "flushing out" tacit knowledge (Keating 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 The term digital is used here in a twofold connotation. First, as a datum amenable to be processed 
by means of bio-informatic technologies. Second, as a binary category (yes/no), and thus opposed 
to analog, i.e. something that allows for indefinite gradation (e.g. degrees of) . As noted by 
Germain (2013): “A digital watch, for instance, tells us the time in a single and definite way: there 
are not different ways of reading the watch to learn about the time, and one will not get more 
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et al. 1999) from the process of pluripotent colony selection, these novel technologies – an 
account of which constitute salient parts of chapters 4 and 5 – are envisioned to enable the 
scale up from experimental systems to systems suitable for industrial production, i.e. “from 
systems that are still returning knowledge through their instability and need for skill, to 
reliable, highly quality–controlled processes” (Fisher 2012). 
For the same reasons – streamlining the process of iPSC derivation, and enabling a 
marked and otherwise unattainable increase in the yield of cell lines, in order to enroll 
iPSCs in circuits of higher curative and economic return, such as pharmaceutical research 
– the methods of iPSCs characterization2 have themselves undergone a processes of 
quantification. 
Since very early on in the experimental life of iPSCs, a major issue that had to be 
confronted was the comparability with hESCs, whereby, note Christine Hauskeller and 
Susanne Weber (2011), “the pluripotency of iPS cells need[ed] to be checked against the 
“normal” pluripotency of hES cells”. Quite rapidly, the equal potency of hESC and hiPSC 
was established by striking “a balance between feasibility and epistemic power” (Germain 
2013), and resorting to what was considered, at the time, “the most robust and ethically 
permissible standard” (Lensch et al. 2007) for pluripotency assessment, namely the 
formation of teratomas (usually benign tumours displaying tissues of the three germ layers) 
in immunodeficient experimental rodents (Park et al. 2008). 
However, in spite of its status as the “gold standard” for pluripotency assessment (Park 
et al. 2008; ISCBI 2009), the teratoma assay presents some notable pitfalls, being hardly 
standardizable, expensive and time-consuming (Gropp et al. 2012). For these reasons, calls 
within the scientific community have gradually mounted (see e.g. Buta et al. 2013) for its 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
information by looking at it more closely. In other words, it is straightforward to say whether two 
watches are giving the same time. A gauge, by contrast, is analog (between any two points on the 
gauge is always another one), and in practice there is no saying that two measurements are the 
same (would they still be the same under a magnifier?).” 
2 Explain Marti and colleagues (2013): “Characterization of pluripotent stem cells is required for 
the registration of stem cell lines and allows for an impartial and objective comparison of the 
results obtained when generating multiple lines. It is therefore crucial to establish specific, fast and 
reliable protocols to detect the hallmarks of pluripotency”. 
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replacement with quantified in vitro assays, that measure relevant DNA methylation 
profiles and gene expression levels. Insofar as they provide a remedy to these 
shortcomings, new technologies, such as recently developed ‘PluriTest’ (Müller et al. 
2011) or ‘Scorecard’ (Bock et al. 2011), ,have been progressively adopted by laboratories 
worldwide and have been increasingly replacing the standard teratoma assay. Establishing 
a standard reference map for pluripotency assessment, an assay like the Scorecard presents 
the added advantage of predicting the differentiation potential of iPSC lines (i.e., their 
amenability to differentiation into a specific lineage), thus providing the level of specificity 
and detail – unattainable through the qualitative teratoma assay – that supports its 
application in a wide range of experimental procedures (Bock et al. 2011). 	  
	  
Figure	  6:	  Scorecard.	  Quantitative	  differentiation	  assay	  measuring	  cell-­line-­specific	  differentiation	  
propensity	  	  
2.2 Constructing iPSCs as Translational Devices. 
The above described procedures constitute the “core” of the iPSC research platform, 
around which a number of interlocking features conjured up to trigger and solidify visions 
of soon-to-be reaped clinical opportunities for iPSCs. 
Bypassing embryos as a source of pluripotent stem cells, laboratory and clinical 
research with iPSCs - albeit not devoid of ethical quandaries of their own (Testa 2009; 
Zarzeczny et al. 2009; Blasimme and Dröcher 2011; Cattaneo et al. 2013) – have been 
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framed and constructed, from the very beginning (Takahashi and Yamanaka 2006; Yu et 
al. 2007; Takahashi et al. 2007), as a more viable and less regulation-hindered alternative 
(Hauskeller and Weber 2011) to the ethically-contested and politically-charged research 
involving human embryonic stem cells (hESC). For instance, Takahashi and Yamanaka’s 
seminal 2007 paper explicitly refers to “ethical difficulties regarding the use of human 
embryos” as an incentivizing factor for the envisioned generation of pluripotent cells 
directly from the patients’ own somatic cells.  
At the same time, iPSC-based technologies have consistently navigated a more 
accessible and academy-driven patent landscape (Roberts et al. 2014, field notes 2015) 
compared to that of hESCs, that has been largely dominated by both moral objections and 
legal restrictions to the allocation of property rights on embryo-derived cell lines, as well 
as the monopolistic scope of the Wisconsin Research Alumni Foundation (WARF) patents 
(Bahadur and Morrison 2010). As a representative from a company involved in iPSC 
research observed: 
The patent situation for hESCs was much more complicated vis-à-vis iPSCs, when it 
is much clearer that, to work with iPSCs, you need to get a license from Japan. 
Moreover, in the EU you can’t patent hESCs, and in the US those who held the patents 
were really strict, whereas in Japan they are much more research friendly, and willing 
to let you go along with your research. 
Interview with representative of company involved in iPSC research 
 Taken together, these distinct tenets have greatly streamlined a vast amount of 
cognitive, material and financial resources - by public agencies as well as re-incentivized 
private investors alike - towards the rapid development of iPSC-based technologies. 
Moreover, the relative ease of procurement of the primary material (typically skin or 
blood cells), and of transcription factor-induced reprogramming per se, provided a major 
facilitation vis-à-vis the socio-technically laborious (Waldby and Mitchell 2005), low-
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yielding - and as of 2013 yet elusive, with regard to karyotype normality (Tachibana et al. 
2013) - process of deriving human pluripotent stem cells by means of somatic sell nuclear 
transfer (SCNT). Whereas in fact therapeutic cloning can be seen as a technically “dirty 
and time–consuming process” (Germain 2013), also requiring the disentanglement (Callon 
1998) of a socially and ethically valuable entity, such as an oocyte or an embryo, “from the 
networks of embodied social relations in which [it] originate[s]”, in order to position it as 
“a technical entity whose productivity is at the disposal of the laboratory” (Waldby and 
Mitchell 2005), iPSCs require a much more straightforward procedure. Insofar as skin 
samples can not only be easily procured and reprogrammed into stem cells, but are also 
commonly associated with a category of waste, i.e. as something possessing no value or 
interest for the person from whom it originates (Waldby and Mitchell 2005)3, they are 
much more easily mobilized in research practice, thus allowing the streamlined derivation 
of a vast number of pluripotent stem cell lines. 
This very ease was in turn pivotal for the main aspect that sets iPSCs apart from their 
embryonically-derived counterparts in terms of translational potential, namely their 
patient- and disease-specificity. Precisely insofar as they could be easily derived from 
patients, and provide experimental accessibility to previously inaccessible cell types (such 
as neurons), iPSCs allow the generation of more faithful, less-mediated models of human 
disease compared to hESCs or animal models4. As such, they are seen as “invaluable tools 
for understanding disease mechanisms", a feature that in turn is geared to provide "new 
opportunities to develop medical therapies" (Nobel Assembly 2012). 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 Not only defined in terms of its value (the “zero degree of value”), “waste”, note Waldby and 
Mitchell drawing from cultural critic Walter Moser, implies a certain relationship between 
fragment and totality. As Moser (2002, quoted in Waldby and Mitchell 2005) writes:  “Waste is 
often fragmentary, partial, residual in relation to a totality that would have pre–existed it. The 
French déchet – singular, nominative – conveys this sense better perhaps. The separation of the part 
from whole is usually one of the genetic pre–conditions for the existence of waste… waste is that 
part which has been actively detached (torn, ejected, expelled) from a whole and subsequently cast 
off and excluded: refuse” 
4 For an in-depth epistemological discussion on iPSC-based modeling, something that is beyond 
the aim of this thesis, see Germain (2013). 
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2.2.1 iPSC–based disease modeling: translating diseases in space and time. 
As noted by Merkle and Eggan (2013), in vitro disease modeling with hPSCs has 
significantly benefited from the confluence of three technologies: the torrent of genomic 
data associating genetic variants to disease phenotypes, the ability to generate patient-
specific iPSCs and differentiate them into cell types affected in disease, and powerful new 
tools for the manipulation of the human genome (allowing what Adamo, Atashpaz, 
Germain et al. (2015) define the “functional annotation of human genomes”). 
Through this technological convergence, iPSC–based models provide a molecular 
translation of disease within an in vitro system through the (not so trivial, see Germain 
2013) task of identifying, by means of comparison (i.e. looking for differences) between 
control- and patient-derived cells, an in vitro phenotype that “recapitulates” (Grskovic et 
al. 2011) the clinical condition of experimental interest.  
In their research practice, scientists have thus increasingly employed iPSC–based 
models in order to create spaces of representation, i.e. models established for “engendering 
things that otherwise cannot be grasped as objects of epistemic action” (Rheinberger 
1997), that allow to align genetic lesions to data obtained from the clinical history of the 
patient, or, as some proponents of the technology belonging to my group have stated, to 
“bridge” the patients' genotype to clinical phenotype in developmentally relevant human 
cell lineages (Cattaneo et al. 2013; Adamo, Atashpaz, Germain et al. 2015). This 
“bridging” – which could be easily characterized in terms borrowed from semiotics as the 
establishment of a signifying relationship in which the genotype of the patient stands for 
its clinical phenotype, and viceversa5 – opens up a twofold important experimental 
possibility. 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5 In particolar, drawing from Peircean semiotics, we could define the “bridging” occurring through 
the establishment of the in vitro phenotype as the establishment of a signifying relationship of 
indexical nature.  
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In the first place, described as experimentally fungible diseased "avatars" (see, e.g. 
Solomon 2012), iPSCs promise to make the impact of individual genetic variation on 
health and disease experimentally tractable (Adamo, Atashpaz, Germain et al. 2015). Put 
otherwise, in their guise of cellular models genetically matched to the patient - a feature 
which have prompted some practitioners to refer to them as to "the new patient" (Bellin et 
al. 2012; see also Goldstein 2012), thus assuming a reductionist stance which 
problematically gets rid of the normativity inherent to the lived experience of disease 
(Canguilhem 1978; Saha and Hurlbut 2011) – iPSC–based models enable to probe 
experimentally, for the first time in the history of medicine, the molecular contribution to 
disease in different genetic backgrounds, in a way conducive to the obtainment of more 
robust results across the broader patient population and the pursuit of promising lines of 
enquiry within the framework of personalized medicine6.  
 
In the second place, other than translating disease in space, by recreating in vitro the 
affected cell or tissue type(s), as well as reproducing the cell–context interaction (Mariani 
et al. 2012, Lancaster et al. 2013), iPSCs can be said to translate disease in time, by 
providing a developmental replay of its symptomatic as well as pre-symptomatic phases. 
Indeed, the transition from a pluripotent to differentiated state is not only meant to 
provide differentiated cell lines to be probed experimentally for the disease of interest, but 
can also be, in itself, the focus of research (Germain 2013). For, in vitro differentiation is 
intended to replicate, or “mimic”, in vivo development and hence to “recapitulate” disease 
onset and progression. Thus, iPSC–based models allow to track the 'history' of disease as it 
affects early developmental lineages (and even the pluripotent stage itself, see e.g. Adamo, 
Atashpaz, Germain et al. 2015) which can be of potentially high informative value about 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
6 This feature has prompted a possibly far-fetched visions pointing to a future in which "it will 
become routine not only to access the complete genetic information of a patient but to directly 
probe the patient’s own iPSC-derived tissues for a broad range of medical questions.” (Lee and 
Studer 2010). 
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the disease-relevant pathways affected by genetic mutations; in turn, they can be valuable 
to provide insights into the pathophysiology of disease and the discovery of new 
prognostic biomarkers whereby, for many diseases, “subclinical developments” (i.e. the 
pre–symptomatic phase of disease)  may occur earlier than disease onset, while 
maintaining a causative relationship with the latter (Colman and Dreesen 2009).  
Thus, as one scientist has put it, iPSC disease modeling (what some proponents of the 
technology have called the 'disease-in-a-dish' approach (Unternaehrer and Daley 2011)) is 
a key tool for "drilling down" to fundamental disease mechanisms that are neither 
immediately evident nor accessible to study in the clinical presentation of the disease 
(iPSC scientist, quoted in Saha and Hurlbut 2011). 
 
Experimentally, in virtue of the genotype-phenotype alignment, iPSCs offer a 
bidirectional and iterative road between clinical care and experimentation - a feature that, 
as we observed in the previous chapter, is seen by advocates of translational research as 
one of its enabling asset to repair the lag in the clinical application of biological 
discoveries. 
 As extensively described by Germain (2013) in his study of iPSC–based modeling, the 
clinical phenotype serves as the basis for the discovery of the in vitro phenotype of the 
disease, whose 'rescue' by means of either gene editing technologies or a tested compound, 
can, in turn, generate findings to predict clinical outcomes in patients (Grskovic et al 
2011). In more applied lines of research (see below), such as drug discovery, this bi-
directionality manifests itself in the fact that “iPS cells can be generated from any human 
who is taking a medicine. Thus, any effect or lack of effect of a particular drug that is 
detected during clinical treatment can be re-analysed using iPS cells from patients.” 
(Nishikawa et al. 2008). 
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For all of the above, iPSCs offer a crucial translational advantage with regard to hESCs 
models. Whilst - other than limitations owing to its yield, and leaving aside the regulatory 
hindrances that have surrounded the hESC technology in many countries worldwide - it is 
in principle possible to obtain disease-specific pluripotent cells from embryos, either 
through genetic modification of existing hESCs, or the generation of new hESCs from 
embryos carrying simple, monogenic diseases detectable via preimplantation genetic 
diagnosis (PGD), some insuperable epistemic hurdles persist with regard to hESC disease 
modeling.  
Notably, insofar as defected embryos are typically discarded, one cannot observe how 
the given genetic lesions affect the patient's clinical phenotype in the course of its lifespan, 
thus depriving pluripotent stem cell modeling of its very richness (i.e., the bi–directionality 
from clinical observation to molecular characterization, and back), and thus significantly 
hampering its heuristic power7.  
As a leading Harvard stem cell scientist - who took part from very early on in the 
process of hESCs derivation, and is now spearheading research with iPSCs - summed up 
the major experimental advance represented by iPSCs with respect to hESCs: 
You use iPSCs because you want to understand the disease, and iPSCs are 
associated with the person, who has a lot of clinical information. hESCs never had that, 
it is not related to the disease, and you don't have those information. You may have 
some inborn genetic variations or errors, but you never know what the consequences of 
the variations might have been in the development of the organism. So, once you have 
made 30, 40, or 50 hESC lines, you don't have a need to make any more. I even asked 
that question myself [...]. We made 64 hESC lines, and I'll be honest, out of these, my 
lab used only between 4 and 6. 
(Interview with Harvard stem cell scientist) 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
7 As noted by Colman and Dreesen (2009) to explain this point: “Many genetic diseases display 
variable penetrance and severity of clinical symptoms from patient to patient. This lack of 
consistency is due to the complex interactions of genetic background and environment and may 
extend to the properties of derived pluripotent stem cells.” 
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2.3. Constructing narratives and expectations around iPSCs’ therapeutic 
potential. 
In light of these features, reprogramming technologies have been widely adopted by 
laboratories worldwide, and have played an enabling role in spawning new avenues of 
clinical and pharmaceutical research. On one side, iPSC-based technologies have raised 
prospects for drug discovery. On the other side, albeit most likely in a longer timeframe 
and through a more tortuous translational trajectory, iPSCs-derived cells are predicted to 
become powerful translational objects themselves in the treatment of degenerative 
diseases, through the autologous replacement of affected cell types (Bellin et al. 2012; 
Cyranowski 2014).  
 
Interesting to point out, in this regard, is how the ‘mobilization of hope’ (Kitzinger and 
Williams 2005), that constitutes an important component of the translational narrative 
revolving around iPSCs, shifted from an initial focus on the employment of iPSCs in 
regenerative applications to their usage in the drug discovery process. 
Since Yamanaka’s discovery in 2006, the “naïve expectations” (interview with UK stem 
cell scientist) that mobilized the imagination of scientific and policy communities, thus 
helping to gather and consolidate interest and resources in the field, as well as to provide 
legitimacy to it, were that iPSCs would have provided a catalysis for cell therapy8, and 
hence enable a quantum leap in the realization of the promethean – and as yet mostly 
elusive – promise of an entire field of research (Hauskeller and Weber 2011; Thompson 
2013; field notes 2015). 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
8 Not only were indeed iPSCs to bypass the need for human embryos, but also greatly reduce the 
risk of immune rejection derived from the usage of hESC lines not matched genetically to the 
patient. 
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In the introduction of their landmark 2006 paper reporting the reprogramming of mouse 
fibroblasts, Takahashi and Yamanaka already presented the envisioned usage of iPSCs for 
cell therapy as one – and possibly the – main motivation for their work (Takahashi and 
Yamanaka 2006; see also Germain 2013). As they introduce the new technology, they 
explicitly frame iPSCs as a technical and ethical advancement vis–à–vis hESC–based 
regenerative therapies: 
Human ES cells might be used to treat a host of diseases, such as Parkinson’s 
disease, spinal cord injury, and diabetes (Thomson et al., 1998). However, there are 
ethical difficulties regarding the use of human embryos, as well as the problem of tissue 
rejection following transplantation in patients. One way to circumvent these issues is 
the generation of pluripotent cells directly from the patients’ own cells. 
Similarly, in the first paper providing proof–of–principle of the therapeutic potential of 
iPSCs, published in Science in 2007 by Rudi Jaenisch’s group at the Whitehead Institute 
(MIT), Jacob Hanna and colleagues argued that “the ethical debate over ‘therapeutic 
cloning,’ as well as the technical difficulty and inefficiency of the process, has spurred the 
quest to achieve reprogramming of somatic cells by defined factors” (Hanna et al. 2007). 
And as Yamanaka himself, in a 2007 paper on Cell Stem Cell, reviewed the different 
techniques for deriving patient–specific pluripotent stem cells, he explicitly positioned 
reprogramming technologies as means to achieve, through the generation of pluripotent 
stem cells directly from cells obtained from patients, one the “ultimate goals in 
regenerative medicine”. 
However, even though the promethean ideal of replacing damaged body parts 
constituted an enticing reservoir off which to feed the translational imaginary for the iPSC 
research community, resources in the field – with some notable exceptions – were for the 
most part funneled in a different direction, namely towards the establishment of robust 
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protocols of iPSC–based models of diseases, that served then as the basis for the 
development of assays for drug discovery.  
Many scientists and investors were in fact quick to realize a simple thing. Namely that 
clinical translation of iPSCs – whose narrative, as I have expounded in the previous 
chapter, hinges on a rhetoric of acceleration that dictates the rapid achievement of tangible 
outcomes – would have been more easily pursued through the streamlined path of drug 
discovery, rather than the lengthier and more rugged route of regenerative therapies. 
Observed a US stem cell scientist: 
The impact from modeling and drug testing will be in a much shorter timeframe than 
therapeutics (cell therapy). The process is challenging, managing risk, getting the right 
cells, having the cells go to the right place... And there’s also another limiting factor: if 
you don't know how to do something, you don't know if you are 1 year or 10 years 
away. That’s why people have mostly taken the quicker road of modeling and drug 
testing… 
(Interview with US stem cell scientist) 
Moreover, cell therapy has been perceived as a financially riskier endeavor, for it 
requires a higher level of investment for an uncertain return, with companies adopting a 
rather cautious approach to pour resources in the area (McKernan et al. 2010; Webster 
2013).  
The standardization of the field, a necessary prerequisite to ensure the mobility of cell–
based therapeutics across different institutional and jurisdictional places (Webster 2013), 
and thus their commercialization, presents indeed several layers of complexity. First, it 
requires the establishment of an as yet largely non–existent experimental infrastructure 
(consisting of GMP facilities, in vivo cell tracking technologies, ‘clinical grade’ culture 
media, etc.); second, the identification and dissemination of defined standards to reduce 
variability across labs (such as the definition of Standard Operating Procedures, and 
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‘defined media’ to help the reproducibility of cell batches); third, the standardization of the 
material nature of the cells themselves (Webster 2013), to turn them into easily 
marketizable commodities. In addition, other than these technical issues, the consolidation 
of the regenerative medicine field for iPSCs requires the establishment of a “non existent” 
“commercialization space” (GEN 2014)9. As the director of an iPSC laboratory in a 
Harvard–affiliated institution in Boston argued:  
[iPSC–based cell therapy] is high risk, and it is very expensive, we are talking in most 
cases about individualized medicine, it is not an off–the–shelf product, it’s not going to 
be a huge money–maker, it will take a lot of time for development. It is more 
comparable to a surgery than to a blockbuster drug, right? So, […] it is very risky for 
companies to pursue this, and the few that do obviously focus on off–the–shelf–like 
products, like oligodendrocytes cells, the Geron trials, pancreatic beta cells […]. 
(Interview with director of stem cell lab, Harvard–affiliated institution, Boston) 
At the same time, advancing a new field of research involves the managing of 
expectations, which actively contribute to its consolidation (Brown, Rappert and Webster 
2000). Sociologists of expectations have long since highlighted the performative role 
played by the latter in stabilizing new fields of research. As, for instance, Jenny Kitzinger 
(2008) notes: “expectations are performative, they help to set priorities and attract 
investment, and hence stabilize future scripts and increase the likelihood of a particular 
future being bought into being”. At the same time, however, mismanagement of 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
9 As attested by a GEN market analysis of the “iPSC commercialization space”, as of 2014 the 
market for iPSC research has mainly consisted in the commercialization of technologies for the 
“life sciences research space”, and an “expanding” market segment in the utilization of iPSCs and 
iPSC–derived cells in drug development activities, whereas the third market segment of iPSC for 
cell therapies is deemed as “non existent at the moment”. 
Furthermore, the stabilization of the regenerative medicine field for has required the mobilization 
of ontological politics (Mol 1999) and the co–construction (Faulkner 2012) of an ad hoc regulatory 
landscape for their accelerated clinical deployment, as attested by the creation of Advanced 
Therapy and Medicinal Products (ATMP) regulation in the EU, and the Amendment to the Drugs 
and Medical Devices Law in Japan. In the paradigmatic case of the ATMP regulation in the EU, for 
instance, ontological politics was required to tame the unruliness of these novel biomedical entities 
and fitting them into a well determined ontological and regulatory category in order to accelerate 
their clinical deployment. 
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expectations can also generate setbacks, thus hampering the effective consolidation of the 
field. As remarked by the aforementioned director of an iPSC laboratory in a Harvard–
affiliated institution in Boston: 
 
Also, I think there are expectations... Because there has been a lot of hype around stem 
cells... You want to find the balance, you don't want to feed into that hype, you don't 
want to jump ahead too much, but you also want to avoid what happened with gene 
therapy, there was first hype, then setbacks, and now in the view of the general public, 
when the field is maturing and there are good procedures, is not a big thing... It can be 
a death sentence if something takes too long, and funds dry out. Or, if you are moving 
ahead too fast, you can have bad outcomes...and just a bad outcome in the news can be 
a death sentence for a company and the field for the funding situation. 
Interview with director of stem cell lab, Harvard–affiliated institution, Boston 
 
2.4. Translating iPSCs in Drug Discovery. 
For all these reasons, with the most notable exception of Japan10, which has devoted a 
substantial amount of resources to develop platforms for iPSC cell therapy in order to 
affirm its primacy in the field, the translational component of the stem cell field has 
revolved around the development of assays for drug discovery 
Through increased efforts at maximizing yield and standardization (Unternaehrer and 
Daley 2011, McKernan and Watt 2013), iPSC-based technologies have been incrementally 
deployed as translational tools in the drug discovery process, where they are deemed to 
play a significant role in the conjoined efforts of public and private actors at halting the 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
10 Exploring regenerative medicine and stem cell policy in Japan, Mikami (2014) introduces the 
idea that sociotechnical imaginaries can cause a lock-in effect on national science policy. In the 
context of Japan and stem cells, imaginary lock-in means there is an undesirable level of 
inflexibility, resulting from the state’s early commitment informed by its vision of the nation’s 
future. The situation of lock-in in Japanese science policy has, according to Mikami, emerged 
alongside governmental agencies’ explicit announcements that the country aims to win the 
international competition in stem cell science. 	  
	   65	  
purported productivity crisis in pharmaceutical RandD (Booth and Zemmel 2004; Paul et 
al. 2010; Pammolli et al. 2011; Light and Warburton 2011).  
More to the point, by allowing testing for drug efficacy and toxicity in a disease- and 
patient-relevant context (Engle and Puppala 2013; Tang et al. 2015), iPSCs are geared to a 
twofold advance in the quest for innovative therapeutic compounds. 
In the first place, they promise to effectively address what has been portrayed as a 
significant contributing factor in the high attrition rate in the development of first–in–class 
drugs, namely the molecular reductionism inherent to the target-based approach to drug 
discovery (Sams-Dodd 2005; Nolan 2007; Swinney and Anthony 2011; Scannel et al. 
2012; Swinney 2013). Contextually, they are geared to open up new possibilities for drug 
screening programs based on phenotypic assays (Engle and Puppala 2013; Tang et al. 
2015). 
Starting to be widely adopted within the pharmaceutical industry since the dawn of the 
genomic era in the 1990s, following the commercial success of the cancer drug imatinib 
(Gleevec) (Keating and Cambrosio 2011), target-based drug discovery requires the 
formulation of a specific molecular hypothesis concerning the drug-target interaction, 
which is then tested, usually with biochemical assays, by measuring the effect of the 
compound against a single, well-defined target (such as a purified protein). On the 
contrary, the phenotypic-based approach requires minimal prior assumptions regarding a 
tested compound's molecular mechanism of action, and can also better address the 
complexity found in vivo by measuring the induced effects of new compounds in cells, 
tissues or whole organisms (rather than in 'idealized' setting such as a purified target 
protein), and then observing their phenotypic alterations.  
In recent years, on the backdrop of the purported lack of efficiency (Paul et al. 2010) of 
the (predominant) target-based strategy for the discovery of first-in-class drugs (Swinney 
and Anthony 2011), owing to the little relationship occurring between in vitro assays and 
in vivo clinical responses, and the difficulties in rationally identifying, from all of the 
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potential molecular interactions, the specific ones that will contribute to an optimal 
pharmacological design (see, e.g. Nolan 2007), emphasis has been increasingly shifting 
towards a different approach to drug discovery, geared to include phenotypic-based assays 
in a more prominent way (Nolan 2007; Swinney and Anthony 2011). As Nolan (2007) has 
wryly noted to underscore the urgency of this shift in paradigm: “We don’t make drugs to 
save the lives of cell lines or to better the existence of bacterial extracts filled with 
overexpressed kinases!”. 
In this scenario, the use of iPSC-derived cells in phenotypic-based assays is predicted to 
substantially improve their effectiveness, and thus increasing the likelihood of successfully 
translating preclinical discoveries to the clinic (Engle and Puppala 2013). In particular, 
while providing a physiologically relevant context in which to carry out drug testing, 
iPSC-derived cells are seen as effectively addressing some issues inherent to the so far 
standard use of directly isolated primary cells in these kinds of assays. Not only, as noted 
above, can iPSCs provide access to previously inaccessible cell types, such as neurons. In 
parallel with unlimited proliferation capacity, they also maintain a more stable phenotype 
in long-term culture vis-à-vis primary cells, thus being scalable and amenable to 
automation; and they allow to test multiple cell types from the same patient, so as to 
measure compound toxicity in different cellular settings (Engle and Puppala 2013).  
Morevoer, patient- and disease-specific cells are predicted to conduct the so-called 'in 
vitro clinical trials', in which iPSCs derived from a wide variety of individuals could be 
used to predict patients’ response to a drug, while also allowing for direct testing of 
potential new drugs in samples from target populations, thus directly supporting initiatives 
in precision medicine (Engle and Puppala 2013). As attested by a prominent Harvard stem 
cell scientist:  
That's the idea, that you are going to use the exact same cells to make 
cardiomyocites, liver cells - the two most reasonable cells in terms of toxicity -, and see 
how they are affected. People have talked about it a lot, none has done it yet. Kevin 
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[Eggan] is on the path of doing it, and this could revolutionize the way we think about 
clinical trials and drug development. 
Interview with Harvard stem cell scientist 
 
2.5. Conclusions. 
This chapter has served the purpose of providing an eagle eye view of the iPSC research 
landscape. From the standardization of research practices, to the constructions of narratives 
and expectations around the therapeutic potential of iPSCs, to their deployment in 
pharmaceutical research practice, I have here accounted for the multiple, intertwined ways 
in which iPSCs have been constructed as prominent translational devices.  
Invested with high hopes and expectations within what Charis Thompson (2013) has 
aptly defined a pro–cures–as–innovation framework, in which its translational potential is 
intimately tied to a rhetoric of innovation, iPSC research has progressively positioned itself 
as a mainstay of advanced as well as developing stem cell-based bioeconomies and 
knowledge-based societies worldwide. Governmental agencies and private investors, in 
Western and Asian countries alike, have mobilized a large amount of material, financial 
and cognitive resources geared to the establishment of state-of-the-art biomedical 
platforms (Keating and Cambrosio 2003), as well as bio-networks (Patra and Sleeboom-
Faulkner 2009; Sleeboom-Faulkner and Patra 2011) operating on iPSC at the transnational 
scale (e.g. Mikami 2014; Sleeboom-Faulkner and Hwang 2012; Thompson 2010, 2013; 
Zhang 2011). While the Japanese case stands out owing to sustained state-led efforts at 
primacy in the field (Mikami 2014), iPSC research platforms worldwide both collaborate 
and compete in standardization practices aimed at stabilizing the field (Webster and 
Eriksson 2008; Webster 2013). In parallel, they strive to develop models of governance 
that could successfully advance desired framings of iPSC-based innovation, so as to gain 
competitive advantage in the distinct yet interlinking markets of scientific credibility, 
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intellectual property rights, biomedical commodities and socio-political prestige (Salter 
2013). 
Against this backdrop, an important point should be clarified in conclusion. The 
topography of the field of somatic cell reprogramming that I provide in this chapter may 
run the risk  – given the inevitable generalizations warranted by such a rapid overview – of 
projecting an essentialized image of iPSCs research, as a well–defined landscape defined 
by immovable signposts, in which the standardization and innovation paths follow a linear 
and uniform trajectory. 
On the contrary, I would like to argue, the stabilization of the iPSC research field does 
not follow a linear trajectory, but develops along different, heterogeneous and sometimes 
competing pathways that involve a broad array of actors and practices (cf. Webster 2013). 
Thus, novel biomedical entities like iPSCs should not be understood as fixed substances 
defined by immutable properties, but rather as "informed material", as "entities whose 
shifting ontology depends on relations that can or cannot be established with other 
substances and practices" (Cambrosio et al. 2009). Put otherwise, the pluri–potency of 
iPSCs is not only brought to bear onto their material differentiation into different lineages, 
but also onto their openness to a multiplicity of standardization pathways and socio–
technical futures. As the empirical chapters of this dissertation will show, depending on the 
different ‘social matrix’ in which they are made to attach, as they circulate across different 
platforms in distinct socio–political contexts, iPSCs are enrolled in distinctive innovation 
journeys (Van de Ven et al. 1999), where, at stake, is the co–construction of the material 
and the social (Webster 2007).  
How these co–productive processes take place in American and European platforms is 
what I aim to expound, after a necessary methodological detour, in the following chapters 
of this dissertation. 
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Chapter	  3.	  Theories	  and	  Methods.	  
 
 
As I observed in the concluding remarks of the previous chapter, and as decades of STS 
and social sciences scholarship have long since shown, innovation in science and 
technology has a strong normative component embedded into it. Far from being the mere 
realization of affordances stemming from techno-scientific breakthroughs, as the so called, 
much-hyped, and widely criticized (see e.g. Godin 2006; Felt and Wynne 2007) linear 
model portrays it (Bush 1945; Nelson 1959), innovation is as much a statement about 
epistemic and technical ingenuity as it is an assertion of the norms, interests and values 
that enable it and underpin its circulation. 
The interwoven nature of the normative and the technical within the fabric of 
innovation has been brought to the fore through distinct, but in fact convergent, analytic 
paths. On the one hand, work in STS has done much to illuminate the role played by 
normative commitments and complex socio-cultural dynamics in shaping the products of 
techno-scientific systems. On the other hand, an equally significant body of STS 
scholarship has coalesced around a broad understanding of innovation, which is framed as 
encompassing not only its technological yield, but also the societal (re)configurations 
required to both foster and accommodate the presence and circulation of novel material 
artifacts and technologies, in a process of reciprocal adaptation entailing the mutual 
constitution of techno–scientific and normative orders (Jasanoff 2004).  
In line with the overall aim of this project to provide a yet unattempted cartography of 
iPSC-based innovation, and drawing from the latter strand of STS scholarship, which 
mostly owes, for its systematization, to the scholarship of Harvard professor Sheila 
Jasanoff and her work on the notion of co–production (Jasanoff 2004), in this chapter I aim 
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to lay bare, and critically dissect, the methodological toolkit that I will then deploy, in 
chapters 4, 5, and 6, in order to wade through my empirical case studies.  
Consistent with the etymological polysemy of the word 'methods' (from the ancient 
Greek metá–hodós) – that bears reference to both the spatial dimension (the ‘where’) of a 
journey and the modality (the ‘how’) through which to undertake it – in the subsequent 
sections I will proceed as follows. 
First, I review the salient features of the notion of biomedical platforms, as articulated 
by Peter Keating and Alberto Cambrosio, thus accounting for my choice of identifying 
leading iPSC research organizations as privileged sites for empirical analysis of iPSC–
based innovation. A fundamental assumption underpinning this dissertation is indeed that, 
as argued in the introduction, it is the meso–scale of leading research platforms that 
represents the perfect analytic viewpoint for tracing the innovation trajectory of iPSCs 
(differently from the case of hESC research, which greatly owes for its innovation 
dynamics to the macro–scale represented by different national styles of regulation and 
civic epistemologies (Jasanoff 2005)). 
Next, I refine and expound my analytic approach, geared to deploy the notion of 
biomedical platforms within Sheila Jasanoff's co-productionist framework (Jasanoff 2004) 
to build up the analysis of my empirical case studies. As I do so, and drawing from other 
theoretical approaches, I highlight what – at least for the purposes of this dissertation – are 
some of the analytic pitfalls of the scholarship revolving around the notion of platforms, 
namely its neglect of the ways in which the broader socio–political context in which 
platforms are situated affects their innovation dynamics. To address this shortcoming, I 
trace the distinction between an endogenous and exogenous form of co–production, and 
contend that both kinds of co–productionist accounts are needed in order to capture the 
dynamics of innovation in contemporary biomedical research. 
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3.1 ‘Platforms’ as widespread actors’ category. 
In their in-depth, sociologically-informed work spanning a good part of the last 15 
years, Alberto Cambrosio and Peter Keating have advanced the notion of biomedical 
platforms, aimed at providing both a far-reaching theorization and a thorough empirical 
account of the dynamics of contemporary biomedical innovation (Keating and Cambrosio 
2000, 2003; Cambrosio et al. 2009). Heuristically powerful, semantically flexible, as well 
as descriptively rich, the notion of biomedical platforms constitutes an important 
theoretical backbone upon which the present work is built, and thus no doubt deserves its 
fair share of analytic scrutiny. 
 
For those immersed in the field of biomedicine, as either analysts or practitioners, the 
notion of 'platform' is not an unfamiliar one. From 'genomic platforms' arising in a broad 
array of research institutions all over the world, to 'stem cell platforms' established within 
major pharmaceutical companies, to platforms developing around technologies such as 
microarrays or mass spectrometry, to public initiatives such as the 'UK Regenerative 
Medicine Platform' - to recall but a few instantiations of the term - the landscape of the 
biosciences is dominated by the ubiquitous presence of such multifarious 'platforms'.  
As Cambrosio and colleagues note accordingly, “while social scientists are still likely to 
wonder about the meaning of ‘platforms’, this term is now commonly used and understood 
by natural scientists and clinicians” (Cambrosio et al. 2009) – and at an ever increasing 
rate since the beginning of the new century. A search for its occurrence in the title of 
articles listed in PubMed shows indeed that while the term 'platform(s)' was found on 
average in 27 titles/year during the 1990s, this average rose to 574/year during the 15-years 
period 2000-2014, with a staggering 1133 results/year in the last 5 years (2010-2014). 
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Table	  1.	  PubMed	  Research	  of	  the	  term(s)	  ‘platform*’	  in	  ‘titles’.	  
	  
Not just a mere resultant of the analyst's propensity to abstraction, the notion of 
platform is thus a widely circulating category, employed by actors themselves in reference 
to a broad range of practices, programs, technologies. 
In particular, in its 'common sense'/'native' meaning (i.e., as an actor category), the 
notion of 'platform' revolves around three main usages. First, platforms refers to sets of 
techniques and technologies mobilized by research domains increasingly reliant on the use 
of complex instruments that often combine biological reagents and digital equipment, with 
the varied -omics technologies being a conspicuous case in point (Cambrosio et. al 2009). 
In a similar fashion, the term is also used as a synonym of, or in relation to, core facilities, 
namely, a combination of laboratory instrumentation and associated skills shared by 
researchers from one or more institutions, to streamline what are considered routine 
experimental practices, but which are generally too expensive, complex or specialized to 
be sustained by a single laboratory or small group of researchers themselves (Cambrosio 
et. al 2009; Ernst and Young 2012; see also chapter 5). Third, 'platform' often maintains an 
institutional connotation, whereby it replaces notions such as ‘initiative’, ‘program’ or 
‘network' in reference to publicly-supported and often interdisciplinary endeavors aimed at 
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tackling scientifically as well as socially relevant issues, by means of collaborations among 
a typically broad variety of actors (SAHN 2014). 
 
3.2 The performative hybridity of biomedical platforms. 
The semantic amplitude of the term, that bears reference to experimental and 
technological arrangements, as well as institutional configurations, is maintained, and in 
fact harnessed, by the analytic rendering proposed by Cambrosio and colleagues.  
The notion of biomedical platforms set out to “draw together, within a single category, 
biomedical instruments and programs and related patterns of cooperation between 
biologists, clinicians, and companies that produce reagents and equipments” (Keating and 
Cambrosio 2003). Analytically, it thus serves the purpose of capturing, and making 
amenable to thorough empirical investigation, a defining feature of contemporary 
biomedical research, namely its increasing reliance on hybrid forms of inter–disciplinary 
and inter–institutional collectives1. 
 
The concept of hybridity, in particular, maintains a key saliency for Keating and 
Cambrosio’s characterization of biomedical platforms.  
At a first, and coarse-grained, level of analysis, a platform's hybridity can be 
characterized - in a way reminiscent of Latour's own definition of networks as 
amalgamations of social and natural constituents (Latour 2012) - as the establishment of 
linkages among a broad array of actors and technologies, operating within different 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  More extensively, biomedical platforms can be defined as “stabilized interconnections between 
new biomedical entities (e.g., genes and mutations, existing as both material and representational 
entities), the sets of technologies (equipment, related reagents, etc.) necessary for their 
manipulation and representation, and the regulations (standards, nomenclature, quality norms) that 
are constitutive of their proper use in clinical and laboratory settings, and in particular at the 
laboratory-clinical interface” (Cambrosio et al 2009). According to other definitions provided by 
the authors, the notion of ‘biomedical platforms’ designates “Specific combinations of techniques, 
instruments, reagents, skills, constituent entities (morphologies, cell-surface markers, genes), 
spaces of representations, diagnostic, prognostic, and therapeutic indications, and related etiologic 
accounts.” Furthermore, platforms are “material and discursive arrangements that act as the bench 
upon which conventions concerning the biological or the normal are connected with conventions 
regarding the medical or pathological.”	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disciplinary contexts while often belonging to distinct institutional backgrounds, spanning 
from the scientific to the industrial, from the governmental to the non-profit sector.  
Indeed, at both the micro- and meso-level of individual labs and research organizations, 
the dominant epistemic culture (Knorr-Cetina 1999) in contemporary biomedicine builds 
on, and is shaped by, the alignment of a broad array of actors embodying a distributed 
form of cognition and scientific expertise (Giere 2002); the recourse to varied sets of 
complex instrumentations (Keating et al. 1999), requiring dedicated (and often tacit) skills 
for their functioning (Polanyi 1958; Knorr-Cetina 1999); the contribution, and close-hand 
involvement, of equipment and reagents providers, oftentimes performing an indispensable 
ancillary role in the set-up phase of experimental systems and standardization 
technologies.  
Similarly, at its macro–level, the institutional configuration of biomedical research is 
increasingly reliant on the establishment of large, trans–institutional research consortia. 
Andrew Webster (2015) notes that 
A significant characteristic of the science system today is the growth of large-scale 
'platforms' that support and align national and international networks, and might be 
seen as the defining feature of contemporary ‘research infrastructures’. 
Hence, while collaborative research is in itself nothing new, contemporary 
developments in the life sciences, especially since their post–genomic translational turn, 
reveal a "qualitative shift" in the way in which epistemic communities and their networks 
are configured (Webster 2015): from the ample diffusion of interdisciplinary and trans-
institutional collaborations; to their ‘projectification’ (Vermeulen 2015), through the 
institutionalization of practices of coordination among actors (Webster (2015) cites the 
advent of ubiquitous 'work-packages' and associated ‘deliverables’ as a prime example of 
management strategies meant to ensure "that research can be managed across diverse 
groups and interests [...], while each retains a specific, discrete responsibility and 
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intellectual home in which they feel comfortable”); to the increased relevance of practices 
of standardization, aimed at both establishing consensus between different laboratories 
(Cambrosio et al. 2006) and patrolling the boundaries and entrance gates of emerging 
fields of research (Webster and Eriksson 2008; Busch 2013). 
In a first sense, the notion of platforms thus points to a marked increase in complexity 
in the configuration of biomedical research, on the backdrop of which, so the argument 
goes, it would be impossible to account for innovation in the field of biomedicine without 
referring to the heterogeneous, multi-disciplinary and cooperative nature of its current 
practices.  
 
Secondly, at a more fine-grained level of analysis, the notion of hybridity refers to the 
development of new interactions, dependencies and arrangements resulting from the 
blurring of organizational and knowledge boundaries along public-private and laboratory-
clinical gradients. Similarly to the rise of a 'hybrid culture' out of a new articulation - rather 
than the juxtaposition - of different practices of knowledge-making described by Strasser 
(2011), and the process of hybridization that bring together “things whose articulation, 
amalgamation or even blending was not assumed to lie in the nature of the things so 
brought together”, theorized by Rheinberger (1997), the consolidation of platforms propels 
the reconfiguration of contemporary biomedical practices and the creation of new hybrid 
collectives and modes of practice. In other words, rather than interfacing well-defined, 
self-contained actors and organizations, each pursuing different aims according to distinct 
systems of incentives (Aggeri et al. 2007; Cambrosio et al. 2009), platforms promote the 
re-articulation of heterogeneous and distributed forms of expertise and the realignment of 
distinct (commercial, academic, non-profit) goals. Insofar as they enact a major form of 
coordination among actors, each bearer of its own disciplinary expertise, style of practice 
(Keating and Cambrosio 2011), as well as interests and aims, these hybrid formations bring 
about a profound reconfiguration of the institutional space underpinning biomedical 
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practice, in a twofold movement that, while it feeds off the actors' own actions to create a 
new field of practice, at the same time, and recursively, significantly redefines the actors’ 
identity, agency, and goals (Latour 2005). 
 
These two sets of converging features bring in turn to the fore a salient characteristic of 
platforms, namely their performativity in both defying, and reconfiguring, entrenched 
organizational and knowledge boundaries, and recasting the identities, actions and 
normative commitments of a broad variety of actors. 
Through their performing hybridity, platforms both disrupt and stabilize, enabling the 
emergence of new organizational models, that in turn stabilize novel biomedical 
technologies, entities and practices with their attending epistemologies (Cambrosio et al. 
2006; Keating et al. 1999) – all features of intuitive and immediate appeal for a technology 
such as iPSCs that is explicitly invested with the mission of forging a new alignment 
between biology and the clinic (see chapter 2).   
Furthermore, and precisely through their hybrid performativity, biomedical platforms 
represent an important site of value–articulation, underpinning the making of "what comes 
to count as a relevant order of value in given situations, practices, socio-technical systems, 
institutions, and professional cultures" (Dussauge et al. 2015). In other words, I take 
platforms not as mere intermediaries (Latour 2005) for the reproduction, or rehearsal (Felt 
2015), of widely held commitments, expectations and imaginaries, but rather as mediators 
(Latour 2005) that re-articulate them in novel ways, with outcomes that can span the entire 
stabilization-disruption range, from the reinforcement of entrenched sociotechnical 
imaginaries (Jasanoff and Kim 2009, 2015) to their challenge through the projection of 
alternative framings and vanguard visions (Hilgartner 2015). 
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3.3 Accounting for the performativity of platforms: the endogenous co–product ion  
of scientific and governance innovation. 
The hybrid performativity and flexibility at re-articulating, that characterize biomedical 
platforms, offer, in turn, the docking site for confronting the broader implications of iPSC 
research arrangements in terms of co-production (Jasanoff 2004).  
In light of the above, a primary aim of the second part of this dissertation will be to 
investigate how, through the assemblage of a broad array of actors, technologies and 
practices, the three iPSC research platforms analyzed in this work perform, in their 
endeavors, the constitution of epistemic as well as normative orders, each underwriting the 
other’s existence and consolidation.  
In particular, consistent with the manifold articulations of the discourse and imaginary 
revolving around clinical translation (see chapter 1), I intend to analyze, comparatively2, 
how the three iPSC research platforms re–articulate translation in a variety of different 
ways, producing distinct framings of the translational lag narrative, and materializing, 
through the enactment of specific modes of iPSC research practice, distinctive normative 
stances concerning social order and the collective good. Drawing from the approach 
recently proposed by Dussauge and colleagues (2015), I thus aim to craft an empirically 
sensitive account that, rather than treating the values and expectations underpinning 
translational iPSC research as something stable and predefined, as given entities endowed 
with explanatory powers, looks at how they are enacted, and co-produced (Jasanoff 2004), 
within and along with concrete epistemic practices3.  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	   The importance of comparison for the outcomes of the present work should not be 
underestimated. Comparison, notes Sheila Jasanoff (2005), is a powerful way to problematize the 
assumption of notions such as ‘science’, ‘state’, or ‘society’ as stable units of analysis, and “should 
be seen as a means of investigating the interactions between science and politics, with far reaching 
implications for governance in advanced industrial democracies”. 
In the case of three iPSC research platforms, thaty I analyze in this dissertation, they lend 
themselves well to comparative analysis by being different enough to present interesting contrasts, 
but similar enough for the variations to be disciplined (Jasanoff 2005). For this reason, they can be 
fruitfully employed as mutual "controls" in assessing their respective specificities. 3	  More to the point, write Dussauge and colleagues (2015), empirically sensitive accounts of this 
kind are particularly suitable to probe sets of questions concerning: (i) the co-production of the 
normative and the epistemic in scientific practice (how is knowledge produced, and produced as 
valuable?); (ii) the definition of matters of concern (which kind of knowledge is considered 
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More to the point, on the basis of the results presented in the empirical chapters of the 
dissertation, I identify two different ways of applying the co-productionist lens to the 
analysis of biomedical platforms, and I thereby propose a multi-scalar approach geared to 
analyze empirical evidence at different levels of interpretive relevance. 
In the first place, building on Jasanoff’s contention that “knowledge making is 
incorporated into practices of state–making, or of governance more broadly, and in reverse, 
practices of governance influence the making and use of knowledge” (Jasanoff 2004), I 
argue that biomedical platforms propel what I term the endogenous co-production (Marelli 
and Testa forthcoming) of scientific innovation and regimes of governance, through the 
adoption of mutually constitutive standardization and governance practices. For, as 
particular sociotechnical articulations of the translational visions are formed and tried into 
practice, they gain material currency in the establishment of specific practices and 
technologies of iPSC standardization, and the contextual implementation of distinctive 
regimes of governance (Hilgartner 2012, 2013).  
Accordingly, the (endogenous) co–productionist account that I propose in this work is 
aimed at symmetrically probing: (i) how, by resorting to different strategies of 
standardization, that establish specific iPSC research technologies and infrastructures, and 
shape the material ontology of these emerging biomedical entities in distinctive ways, 
those iPSC research platforms pursue different paths to iPSC–based innovation; and (ii) 
how, by adopting specific regimes of governance that allocate agency and power among 
actors, define specific modes of accountability and steering mechanisms – thereby 
establishing a significant part of the constituency claiming jurisdiction in this domain of 
biomedicine – they uphold and give material instantiation to distinct socio–political 
expectations, interests and normative commitments. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
valuable and worth attaining? What comes to count as valuable, desirable, or otherwise worth 
caring for?) iii) the interrelations (alignments and tensions) among multiplicities of values (how are 
hierarchies among values established? How are boundaries and links made between notions of 
economic, epistemic, and cultural values?). 
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In proposing the notion of endogenous co–production, I draw on a number of studies 
that have investigated and brought to the fore the mutually constitutive relationship 
between scientific and governance innovation.  
 
In particular, in his analysis of the establishment of the Human Genome Project (HGP), 
Stephen Hilgartner (2013) shows how, contextually to a substantial reconfiguration of the 
practices of genomic research, the HGP required, for its successful implementation, the 
creation of a new regime of governance establishing “control relationships” for allocating 
control among agents and specific “governing frames” that “provide an interpretive 
schema for identifying relevant agents, spaces, objects and actions, and promote an official 
view of how they are supposed to interact – for example, by defining rights and modes of 
accountability”. In doing so, he crafts an ethnography–based account of the genome 
mapping and sequencing community in biomedicine that brings to the fore the “process of 
coproduction that constituted a new category of science – ‘large-scale biology’ – and the 
sociotechnical machinery for governing it” (Hilgartner 2013). 
Adopting a political economy perspective, Brian Salter (2013) has instead more 
explicitly called attention to the innovative potential of the process of knowledge–
production related to governance. The production process from scientific idea to 
marketable product, he argues, is long and tortuous, and requires more than just the 
scientific knowledge needed to conceive and develop products. What becomes crucial is 
also the production of new forms of governance knowledge that could help resolving the 
potential tensions of which the trajectory of innovation is rife with. Thus, governance 
becomes a site of innovation in its own right, and is to be co–produced with science. As he 
notes, "the production of governance knowledge takes place in parallel to the production of 
scientific knowledge: both are necessary if the progress of a concept from a scientific idea 
to marketable product is to occur” (Salter 2013). 
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Furthermore, in their study on the evolution of diagnostic and therapeutic practices in 
the field of medical oncology in the last 50 years, Alberto Cambrosio and colleagues 
(2014) have proposed the notion of regimen as an heuristic concept able to capture the 
mutually constitutive character of scientific knowledge and organizational and governance 
structures of clinical research (or, in other words, the co-production of oncology's 
epistemic content and institutional arrangements). As they write, this notion describes "the 
growing isomorphism between new objects in cancer research and the quest for 
organizational arrangements that could allow to change approach in a domain 
characterized by the increasing production of data produced by means of post–genomic 
technologies” (Cambrosio et al. 2014). 
Tracing the development of clinical assays and protocols (whose staple came to be the 
distinction in "phases" (Phase I, II, III) within cancer clinical trials), they show how the 
new “stile of practice” (Keating and Cambrosio 2012) inaugurated by the assays 
represented, at the same time, as much an epistemic advance (insofar as it provided a 
renewed understanding of cancer and its potential therapies), as well as an innovation in 
the organization of cancer research (since it propelled the institutionalization of Cancer 
Cooperative Groups, that were then themselves responsible for the widespread introduction 
of the assays within clinical routine). What is more, they also show how, from the middle 
of the 1990s, the discovery of new targeted therapies (that act on specific molecular targets 
associated with cancer, rather than on whole subpopulations of cells) prompted not only a 
process of reconfiguration of clinical trials (introduction of Phase 0, 'hybridization' of 
Phase I and II, etc.) and the introduction of new kinds of assays (such as the neo-adjuvant 
approach, aimed at reducing the size of cancer, through chemotherapy, before surgical 
intervention), but also a profound reorganization of the governance structures of cancer 
research itself, which led to the demise of Cooperative Groups and the emergence of more 
flexible Cancer Consortia. 
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Drawing from all of the above, it is thus possible to elaborate a first set of questions that 
guide the analysis of the three case studies that I conduct in the empirical chapters of this 
dissertation. Hinging on the methodological approach that I have just proposed I will 
address these related sets of issues:  
(i) Which norms and values are distinctively enacted and upheld by different 
platforms? How are the very notions of stem cell translational research and translational 
science policy being redefined, and differently performed, through such endeavors? 
(ii) How, in the three different platforms under scrutiny, are different conceptions of 
what is valuable translational iPSC science being articulated, prompting the design of 
different iPSC-based research programs and technologies, alongside the implementation 
of distinct regimes of governance, modes of accountability, and steering structures?  
 (iii) Through which mechanisms, programs and practices do the governance and 
standardization practices being enacted on each platform come to sustain and reinforce 
each other?  
  
3.4 Platforms–in–context. For a critical appraisal of Keating and Cambrosio's 
analytic framework.  
These prior methodological observations represent an indispensible background to 
make sense of the structuring and functioning of the three iPSC platforms on which the 
present dissertation focuses.  
At the same time, what ought to be recognized is how the endogenous dynamics 
underpinning the constitution of platforms, such as the ones I have so far accounted for in 
discussing the establishment of hybrid regimes of coordination among different actors, are 
not alone in shaping the organizational structure of the platforms, as well as their epistemic 
and normative performativity. The way in which platforms emerge and consolidate as 
specific socio-technical configurations, enact specific tropes of values and generate new 
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biomedical knowledge, is indeed something which is also heavily reliant - although not 
stricto sensu dependent, as posited by neo-institutionalist accounts (Powell and Di Maggio 
1991; see also Bonazzi 2007) - on the exogenous conditions in which they find themselves 
to operate, or, in other words, on the relations that they establish with their outer socio-
political context.  
Put otherwise, politics writ large, other than endogenous regulation, plays a first-hand 
role in the assemblage of platforms, as it pre-structures the space that they are bound to 
inhabit (Powell and Di Maggio 1991), thus providing the epistemic, normative, and 
material resources and affordances that enable, as well as constrain, their developmental 
trajectory. 
 
While not escaping the attention of Cambrosio and colleagues (see, for instance, 
Cambrosio et al. 2006; 2014), their scholarship remains in many ways unsatisfactorily 
muted towards this aspect. In a way reminiscent of a Derridean post-structuralist stance, 
and the contention that there is no external referent upon which any system of signification 
would be founded ("il n'y a pas de hors-texte", Derrida 2013), they maintain that no 
relation among actors exists independently of the very act of establishing it, and no such 
act is performed by an actor external to the platform, for “[a platform] has no outside” 
(Keating and Cambrosio 2003). Theorizing the self-contained dimension of platforms4, 
their analytic framework set out accordingly to explore endogenous regulatory practices 
resulting in the definition of concerted programs of collective action and the establishment 
of consensus among actors within a given platform (producing what they term as a 
regulatory form of objectivity, see Cambrosio et al. 2006, 2009). In so doing, it lends itself 
to foreground processes of meaning- and value-making taking place within a given 
platform, while implicitly, if not programmatically, losing sight of the exogenous and 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  4	  Keating and Cambrosio (2003) assert that “while medical and lay actors position themselves vis-
à-vis a given platform, contributing, for instance, […] to its further entrenchment, they cannot 
operate 'off' the platform".	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contextual forms of coordination that equally contribute to a platform entrenchment and 
stabilization. Notably, their scholarship tends to dispense with a close engagement with the 
contingent norms and values, the broader political cultures and civic epistemologies 
(Jasanoff 2005), as well as the historically-situated market configurations or bioeconomies 
(Goven and Pavone 2014) that underpin, drive, and validate processes of knowledge-
generation in the life sciences.  
In reason of that, such internalist perspective5 maintains what is, for the purposes of this 
work, a twofold shortcoming. In the first place, it omits from its topography the landscapes 
of power and normativity which represent, at the same time, the context of and the conditio 
sine qua non for the assemblage of biomedical platforms, thus remaining completely silent 
as to why these novel configurations are established in the first place. Second, while the 
'platform' axiomatic (which maintains a family resemblance with that of the 'network', as 
conceptualized by ANT6) represents a potent analytic tool to account for how ontological 
orderings are enacted in relation to emerging techno-scientific practices, through the 
concerted efforts of a broad array of (human and non-human) actors, it seems less suited to 
address the normative and political questions of social macro-order to which major 
research programs in the life sciences inevitably lead7. Thence, while it makes possible to 
appreciate the socio-technical complexity that underpins the constitution of novel 
biomedical technologies, it has less to say on how these emerging configurations of 
techno-scientific knowledge are brought to bear on the configurations of political systems, 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5 For the purpose of the present discussion, I define as an internalist approach one foregrounding 
questions about the processes and negotiations through which knowledge is produced, whereas I 
define as an externalist approach one that takes scientific and technological practices as windows 
onto wider society and its ordering macro-structures of politics, law, and economics. Hence, I take 
a different approach from the one proposed by Steve Shapin (1992). For him, an internalist account 
of a particolar techno-scientific phenomenon focuses on the domain of theories and ideas, whereas 
an externalist account relates the emergence of certain teories or ideas to events that were going on 
in social and political culture at the time and place of discovery. As noted by Charis Thompson 
(2005) in expounding Shapin’s perspective: “An externalist account of Newton’s science would 
examine why he chose certain problems and certain resources in terms of the political context at 
the time. Materialist factors, such as the economy, rather than ideas, become the well- springs of 
change.” 
6 For a critique of the ANT approach, see Jasanoff 2012 and Jasanoff and Kim 2015. 
7 For a compelling review of different approaches and strands of analysis in STS, see Thompson 
2005.	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thus not addressing the rather relevant issue of their socio-political implications. Against 
these deficiencies, a broader, contextualized view of the functioning of platforms, that 
takes into consideration its normative dimension as well, is thus required. 
 
A fruitful approach geared to address these shortcomings is the one proposed by 
Sleboom-Faulkner and Patra (2009, 2011). Their work, much in Cambrosio and colleagues' 
vein, set out to explore the rapid expansion of collaborative endeavors in the life sciences, 
focusing in particular on the development of experimental stem cell therapies platforms in 
India and Japan. Differently from Cambrosio and colleagues' approach, however, their 
research program aims at generating a contextualized understanding of the rise of these 
stem cell platforms, as they reach beyond local spheres to facilitate interactions across 
national scales, and to this aim they elaborate the notion of bionetworking. According to 
their definition (Sleebom-Faulkner and Patra 2011): 
Bionetworking is a social entrepreneurial network activity involving biomedical 
research and healthcare organizations that thrive under conditions of health 
inequality (Patra and Sleeboom-Faulkner, 2009). A bionetwork consists of a 
plurality of actors engaged in ‘biotechnical ventures’ (Waldby and Mitchell, 2007) 
working across geographical spaces, regulatory regimes and social institutions. A 
bionetwork exploits differences and similarities in the provision of healthcare, 
levels of wealth, standards of scientific development, and research regulatory 
regimes and their implementation. 
Differently from the notion of platform, that of bionetworking, rather than bracketing or 
explaining away the social and political context(s) in which platforms operate, zeros in on 
it so as to explain their functioning. In particular, differences and asymmetries in standards 
of scientific developments, regulatory conditions, healthcare access, political regimes and 
socio-cultural backgrounds are seen as powerful explanatory resources to make sense of 
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the configuration of collaborations on a transnational scale. A bionetwork, for instance, 
emerges out of connections created across two countries, such as India and Japan, in which 
discrepancies in healthcare coverage and regulatory standards allows for the provision of 
Japanese research grade stem cell technologies as therapeutic products within the Indian 
setting (Sleeboom-Faulkner and Patra 2011). 
However, insofar as it focuses on discrepancies arising at a transnational scale, this 
approach can hardly be employed to account for differences in the configuration of 
platforms operating within the same political and regulatory context, or in different 
contexts characterized by evenly balanced, rather than lopsided, interdependencies. 
Furthermore, whilst conducive to account for the socio-political situatedeness of 
biomedical platforms, it seems less suited to address the symmetrical question of how 
emerging networks and collaborations, while feeding off a certain socio-political milieu, 
are also endowed with the capacity to reinforce (or challenge) their underpinning socio-
political order. Indeed, insofar as this approach takes such underlying social asymmetries 
as an explanans for the configuration of emerging collaborative endeavors, it falls short in 
the scope of accounting for the mutual articulation (alignments and tensions) between 
research platforms and the broader societal landscape in which they are situated8. 
 
A thoroughly symmetrical approach accounting for both bottom-up (i.e., platform–
driven) and top-down (i.e., context–dependent) dynamics in technological innovation is the 
one advanced within the so-called Strategic Niche Management research (henceforth: 
SNM). A key critical objective of this strand of scholarship is a technologically 
deterministic view of innovation, that – much in the vain of the aforementioned linear 
model – erects a clear-cut divide between object and context of innovation, and 
conceptualizes the creation and survival of technological novelty as a dynamic solely 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
8 At the same time, this approach suggests a series of interesting research questions, such as: how 
are national boundaries transgressed and interconnections established in transnational 
collaborations? Which dynamics are in play in constituting biomedicine as a global enterprise? 
How do geopolitical asymmetries affect the emergence of new field of research? 
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inherent to intrinsic features of the former. In line with other strands of STS scholarship 
(see above), SNM scholars recognize instead that the stabilization of emerging 
technologies requires interrelated social and technological changes (Schot and Geels 
2008). Sustainability of novel technologies, in other words, hinges on the alignment, or co-
construction, of technology and society, that which leads to the establishment of 
technological and innovation niches (ibid.). 
Particularly apt for the purpose of explaining the socio-economic entrenchment of 
radical technological novelties, such as disruptive types of technologies (Christensen 1997) 
or socially desirable innovations serving long-term societal goals (such as ecological 
sustainability) - both of which face a mismatch and misalignment with regard to existing 
infrastructures, regulations, and practices - the notion of technological niche refers to a 
"protected space that nurtures a specific set of interactions" (Schot and Geels 2008; see 
also Rip and Kemp 1998; Law and Callon 1988) and allows for the "experimentation with 
the co-evolution of technology, user practices, and regulatory structures" (Schot and Geels 
2008), in a way conducive to making a technology and society mutually acceptable (Schot 
and Geels 2007). In other words, innovation niches are constructed spaces, sheltered from 
mainstream competition while different in shapes and sizes9, where the (technical) content 
and the (societal) context of innovation can be reciprocally adapted, thus reinforcing the 
consolidation trajectory of innovative technologies and practices10. As such, the notion of 
niche allows for the development of an analytic perspective attentive to both the role 
played by the context in influencing the dynamics or 'journeys' (Van den Ven et al 1999) of 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
9 An example of niche could be the test lab for new products, functioning as a domesticated 
selection environment, where the risks of selection occur in private (see Rip 2012). 
10 More in detail, SNM scholars (cf. Schot and Geels 2008) have argued that, within technological 
niches, novelties emerge through internal, bottom-up processes (akin to inner-platform dynamics) 
revolving around: (i) the articulation of expectations and visions, providing direction and guidance 
to the development of niches, and (ii) the construction of a robust social network, that creates a 
constituency behind the new technology by facilitating the enrollment and mobilization (Callon 
1986) of relevant stakeholders, while fostering learning processes at multiple dimensions 
(concerning the technical design of the technology, users preferences, the regulatory landscape, 
etc.). 
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innovation, and the way in which, conversely, emerging innovations lead to changes in 
their underlying social context. 
 
At the same time, however, inasmuch as it maintains a narrow focus on small-scale 
networks and socio-technical configurations being molded around specific emerging 
technologies, the notion of niche is unable to capture the "general patterns and structures in 
the context, relevant to innovation dynamics, over and above the specific constellation of 
actors and framework conditions at play in the particular innovation journey that is 
considered." (Rip 2012). In other words, identification of relevant niche-internal processes 
is not enough to fully tease out the manifold forms of mutual interactions in play between 
the content and context of innovation. As Schot and Geels (2008) observe, building on this 
line of analysis: 
it is clear that internal niche developments are not the only important factor. 
External factors also play a crucial role. Niche innovations are rarely able to bring 
about […] transformation without the help of broader forces and processes. This 
conclusion led to a search for conceptualizations that linked niche internal and 
external processes. This search was done under the heading of the multi-level 
perspective. 
Accordingly, this analytic perspective, mostly owing to the work of Arie Rip, René 
Kemp and Johan Schot (Rip 1992; Rip and Kemp 1998; Kemp, Rip and Schot 2001), has 
developed a multi-level model of innovation, focusing on both internal processes 
propelling the expansion of technological niches, as well as external processes that 
contribute to the broader societal diffusion of niche innovations. More to the point, this 
analytic framework operates a three-layered partition of the "space" of innovation, 
distinguishing between the macro-level of the socio-technical landscape, the meso-level of 
the socio-technical regime and the micro-level of the technological niche. The 
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technological niche, whose tenets I have briefly expounded above, is where radical 
novelties emerge. The socio-technical regime carries and stores rules (both cognitive 
routines and belief systems, as well as regulative rules and normative roles) for how to 
produce, use, and regulate specific technologies (Schot and Geels 2007, 2008); as such, it 
accounts for the stability of existing technological systems – which, in turn, could make 
innovation difficult to introduce. The socio-technical landscape, "the slowly changing 
backdrop against which interactions are played out" (Rip 2012), represents the exogenous 
environment, in both a literal (the surrounding space) as well as metaphorical sense – a 
repertoire (Gilbert and Mulkay 1984) of norms and values (Rip and Kemp 1998); it 
comprises those elements beyond the direct influence of niche and regime actors, such as 
deep cultural patterns, political and macro-economic developments, institutional 
configurations. 
Building on this analytic partition, the multi-level perspective on technological change 
emphasizes how interactions and alignments between processes at different levels are 
needed to bring about transition: not only do technological niches exert pressure "from 
below" on established socio-technical regimes; changes at the landscape level create 
pressures on regimes as well, thus creating "windows of opportunities" for niche 
innovations to emerge and consolidate themselves. This process of mutual interactions 
could be eventually conducive to adjustments, or even reconfigurations, at the regime 
level, something that could then exert influence on the landscape itself in a recursive 
dynamic. 
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Figure	  7:	  Multi–level	  perspective	  on	  technological	  change	  (adapted	  from	  Figure	  5	  Schot	  and	  
Geels	  2008) 
 
The key idea in play here, in other words, is that technological change takes place 
through processes of "co-evolution and mutual adaptation within and between these layers" 
(Rip and Kemp 1998). Therefore, rather than bestowing explanatory power to either niche, 
regime or landscape configurations, this analytic framework identifies mutually-sustaining 
interactions and tensions occurring at the niche-regime-landscape interface as the 
privileged site of analysis to account for both the exogenous and contextual forms of 
influences that contribute to a technology stabilization, and its performativity in the 
broader socio-political landscape (i.e., how niche-dependent innovations either manage to 
successfully challenge established socio-technical regimes; or become incorporated and 
normalized (May and Finch 2009) into existing regimes; or, again, set in motion a series of 
developments that result in changes to the landscape itself). 
546 J. Schot and F.W. Geels
Figure 4. Multiple levels as a nested hierarchy (Geels 2002, 1261).
Figure 5. Multi-level perspective on transitions (adapted from Geels 2002, 1263).
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3.5 Probing platforms in context. The exogenous co–product ion  of networks of 
knowledge and socio–political orders. 
While not exhaustive of the hefty literature on SNM and the multi-level model, these 
remarks can serve well as analytic pointers to be used in order to shed light on some of the 
(under theorized) ‘exogenous’ dynamics occurring at the platform-context interface, and 
can be thus be brought to the task of analyzing the emergence and consolidation of 
platforms, as well as the performative role they play within their underlying socio-political 
context. 
In particular, they point to how the entrenchment of platforms is heavily reliant on the 
relations they entertain with the outer context (that provides both resources and constraints 
for their development), i.e. the broader socio-technical landscape comprising the national 
political cultures (Jasanoff 2005) with their institutions; the national and global bio–
economies and market configurations; the international regulatory spaces created within 
specific technological zones (Barry 2006); the adoption spaces11 (Ulucanlar et al. 2013) in 
which technologies are mobilized, while also being framed in a particular way that define 
how they are perceived by users and the public (as being, for example, ‘novel’, 
‘revolutionary’, ‘prestigious’, or ‘difficult to implement’, ‘risky’ and so on). 
Drawing from this perspective, I am thus able to identify, in conclusion, a second way 
in which the co–productionist framework can be deployed in relation to the notion of 
biomedical platforms to account for the mutual constitution of epistemic and normative 
orders. Accordingly, I argue, that reprogramming-based platforms are conspicuous 
examples of a higher, meta-level of ‘reprogramming’, through which platforms are 
sculpted by and in turn re-shape their broader socio-political context, and that I propose as 
an exogenous form of co-production. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
11 Ulucanlar and colleagues (2013) define the adoption space as the context "where attitudes, 
practices, interactions and events, together with the technology’s material features, shape 
technology perceptions in ways that are instrumental in decisions about its use." 
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On the one hand, translation–oriented biomedical platforms are an important vehicle to 
advance and materialize visions of desirable futures and normative stances, concerning 
social order and the collective good (see chapter 1), in ways that will be empirically probed 
in the following chapters of this dissertation. For instance, as the paradigmatic case study 
of the European Bank for induced Pluripotent Stem Cells (EBiSC), analyzed in chapter 6, 
vividly attests, they not only encode and reinforce (Jasanoff and Kim 2009) particular 
conceptions of what a (supra)national entity, such as the European Union, stands for; but 
also, in the context of contemporary knowledge–based societies, where human cells have 
been increasingly replacing coal and steel as the main threads in the fabric of economic 
development and political integration, they are enrolled in projects of (supra)nation–
building, thus representing privileged means deployed by institutional actors for forging 
new economic and political identities. 
At the same time, as most clearly elucidated by the two American case studies of 
NYSCF and HSCI, analyzed in chapters 4 and 5, the emergence of innovative platforms 
navigating an enticing scientific field does not simply fall along established socio-political 
boundaries but redraw them in significant ways, in what Ruha Benjamin has aptly called 
the “co–emergence of cellular and civic configurations” (Benjamin 2003). For, while 
operating in the same scientific field within the same socio–political context, NYSCF and 
HSCI uphold distinct framings of the constitutional position of science in society (Jasanoff 
2012), thus contributing, through their endeavors, to the emergence and reinforcement of 
distinct, and in many ways competing, socio–political orders. Sheila Jasanoff (2012), in 
one of the most poignant pieces of her scholarship, argued that: 
Networks of new knowledge and its material embodiments are helping to frame and 
stabilize some of the basic elements of a global political system, such as the rights, 
privileges, and identities of the world's citizens and the powers of major global actors. I 
have argued that the totality of these changes is constitutional in scope, both enabling 
and constraining new political formations. Through science and technology, seen as 
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profoundly social institutions, many parts of the world today are engaging in what 
amounts to a tacit constitutional convention. On the table are the nature of the human 
self, the relations of consumers and corporations, and the certification of knowledge in 
the conduct of global politics.  
How the emergence of innovative iPSC research platforms, coalescing around specific 
configurations of actors advancing distinctive normative agendas, is brought to bear on the 
broader socio–political landscape they inhabit, is thus another major theme that I seek to 
address in the following chapters of this dissertation.  
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Chapter	  4.	  The	  New	  York	  Stem	  Cell	  Foundation.	  
	  	  
4.1 From federal politics to stem cell research platforms. 
As Herbert Gottweis has poignantly observed, “from a discourse-analytical perspective 
one important aspect of policymaking is the fact that it is always a performative process 
that uses and mobilizes complex and often heterogeneous systems of representation to fix 
the meaning of transient events” (Gottweis 2002). As such, policymaking performs a 
fundamental signifying and ordering function, insofar as it does not simply react to the 
emergence of novel biomedical entities, technologies, and research practices assumed as 
“objective data” (ibid.) for regulatory decision making, but rather, it actively inscribes the 
normative stances it advances into their textures, thus constructing, as well as controlling, 
the latter’s material and socio–political ontology (Jasanoff 2005). 
As the case of NYSCF and HSCI vividly attests, the stabilization of the stem cell 
research field in the United States owes indeed, in large part, to well-known and widely 
debated developments in the recent past of that country’s politics. NYSCF and HSCI were 
established as paradigmatic - yet distinctive - byproducts of a broader process of boundary 
work (Gieryn 1999) by the federal science policy that, at the onset of the 21st Century, set 
and stabilized new boundaries between stem cell science and the polity, while decisively 
contributing to the shaping of the nascent field of human pluripotent stem cell research.  
The stabilization of the scientific-political domain of stem cell research, in particular, 
was strongly influenced by the “mobilization of historical narratives” (Gottweis 2002) 
derived from past struggles over embryo and fetal research1, in which the latter, far from 
just being matters for concern per se, or insofar as they could foster ancillary and possibly 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Notes Gottweis (2002) that “central in these debates was the question of what constitutes an 
embryo and a fetus and thus – implicitly –  at which point in the reproductive development “life” 
comes into existence. Also important were the potential socio–cultural and moral implications of 
fetal and embryo research and the role of the law and the state in the “protection” of embryos and 
fetuses.” 
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morally repugnant practices, such as abortion or selective breeding of embryos for research 
and therapeutic purposes (Jasanoff 2005), were, “from the start, a salvo in national and 
international political debates about innovation, abortion, and competition in ways that 
were over-determined and under-situated, with bioethics as a lingua franca zone of 
contestation” (Thompson 2013). 
 
In what follows, I thus aim to carry out a twofold task, reviewing the most salient 
junctures in science policy leading to the current configuration of the stem cell research 
field in the United States, while also sketching out some of the underlying political 
narratives attending to its stabilization. As a word of warning, such brief review, as any 
genealogical reconstruction, is partial and situated. Rather than aiming to attain a supposed 
objectivity, something that both philosophers of history and STS scholars have long since 
recognized as an elusive feat (Derrida 2013; Haraway 1988), I intend to chart some of the 
milestones underpinning the consolidation trajectory of the field of stem cell research, thus 
providing a socio–political contextualization for the establishment of the stem research 
platforms I analyze in the subsequent part of the dissertation. 
 
4.1.1 The Clinton years. 
Arguably, a good starting point to map out the evolution of the science policy landscape 
concerning embryo and stem cell research in the US political context can be dated back to 
the dawn of the Clinton Administration. In 1993, with the NIH Revitalization Act (NIH 
1993), Congress and President Clinton devolved to the NIH, for the first time, direct 
authority to fund human embryo research. In practice, the Act abolished the need for such 
a research to be approved by the NIH's Ethics Advisory Board, as required by the Federal 
Policy for the Protection of Human Subjects enacted in 1977. As such, it reversed what, if 
not de iure, at least de facto, represented a ban on the federal funding of embryo research: 
as it went, when the Ethics Advisory Board charter expired in 1980, no renewal or 
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replacement body was put in place by Congress, so that research proposal had nowhere to 
go for review, and no federally funded research could hence have been made possible 
(Salter, Gottweiss, Waldby 2009). Meanwhile, in the same years, privately funded embryo 
research was left relatively unencumbered (Kinner 2000), in a way that established a 
“clearly drawn boundary” (Gottweiss 2002) between public and private research for the 
emerging space of embryo and fetal research2. 
In 1995, however, Republican-controlled Congress reversed that position and approved 
what came to be known as the Dickey-Wicker Amendment to the appropriations bills for 
the Departments of Health and Human Services, Labor, and Education for Fiscal Year 
1996. An important and perduring piece of legislation, having being renewed each year 
through Fiscal Year 2009, the Amendment dictates that US Government funds cannot be 
given to research that “directly makes, destroys, discards or harms any living human 
embryos” (P.L. 104-99). It hence erects barriers to using federal funds for research that 
included creating stem cell lines from embryos and embryo-like organisms.  
The Clinton administration's pushback arrived in August 2000 when the NIH published 
new guidelines, following the first derivation of hESC lines by Jamie Thompson’s 
laboratory in 1998, and the mobilization of ontological politics (Mol 1999) in the form of a 
legal opinion issued by the Department of Health and Human Services, creating a line of 
demarcation between hESC lines and embryos by stating that the former "are not a human 
embryo within the statutory definition" (DHHS 2000, quoted in Saul 1999). Against this 
backdrop, the new NIH guidelines forbid the use of federal funds to destroy human 
embryos to derive stem cells (in line with the provisions of the Dickey-Wicker 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 In parallel, it should be noted how, on the contrary, ex utero fetal tissue (from aborted fetuses) has 
been the subject of research since the 1930s (Kinner 2000b), with NIH funding being made 
available since the 1950s, a decision being reversed in 1988 by the Reagan administration. As 
noted by Gottweis (2002), “the central argument of the critics of fetal research in the Reagan and 
Bush administrations was that research needed to be terminated. Otherwise, there could be a 
chance that women might feel encouraged to have abortions because they might see a chance that 
their abortions could be useful to tissue recipients”. 
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Amendment), but permitted research with stem cell lines derived from IVF spare embryos 
slated for being discarded at fertility clinics. 
 
4.1.2 The Bush years. 
On the backdrop of a controversial electoral victory that enabled the advancement of a 
'compassionate conservatism' agenda in many respects aligned with that of the religious 
right, in August 2001 the Bush Administration enacted policy, "expeditiously 
implement[ed]" by the NIH (NIH 2001), that brought the federal funding of human 
embryonic stem cell research to a virtual standstill3. The Bush administration's policy 
required indeed that federal funding for hESC research should be restricted to research 
using stem cell lines that met a number of criteria (stemcells.nih.org): (i) the derivation 
process (beginning with the “destruction” of the embryo) had to be initiated prior to 
August 9, 2001; (ii) the stem cells must have been derived from an embryo that was 
created for reproductive purposes and was no longer needed; (iii) donation of the embryo 
must not have involved financial inducements, and informed consent must have been 
obtained. 71 lines from 14 laboratories worldwide (the so called 'presidential lines' 
established within the NIH registry soon thereafter) met Bush's eligibility criteria, although 
only 21 lines were deemed experimentally viable by the scientific community (Murugan 
2009).  
Yet, while restricting federal funding, the Bush policy still adhered to a well-rehearsed 
libertarian policy script, dating back to the 1970s (Khushf 1997), that no overall, tout-court 
ban on research practices involving embryos or fetuses be imposed (Salter, Gottweiss, 
Waldby 2009). The rationale underpinning the Bush administration's ruling - in many ways 
consistent with the previous policy of the Clinton Administration, in that combined support 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3 Noted for instance a HSCI scientist involved in hESC research at the time (Lensch 2008), that 
“the current policy demands that when working stem cell lines created after August 9, 2001 (2), I 
cannot use existing (and often expensive) equipment that was purchased using NIH money for 
what otherwise may be identical work. This means that I have to have separate centrifuges and 
microscopes for cell A versus cell B, different pipettes for culturing cell A versus cell B, and even 
a different pencil for taking notes on cell A versus cell B, thus wasting money, space, and time.” 
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for research with elements of restriction (Salter, Gottweiss, Waldby 2009) - was influenced 
considerably by the longstanding “right-focused discourse” about the regulation and public 
funding of non-therapeutics abortions in the US (Gottweiss 2002). The absence of public 
consensus regarding the moral status of the (pre)embryo, so the reasoning went, argued 
against both the development of regulations constraining research and the use of public 
funding to support it, as “the liberty or resources of some individuals would [have been] 
inappropriately constrained or co–opted to pursue ends that they would explicitly eschew” 
(Khushf 1997).  
Hence, as the ruling did not affect private investors and individual states alike, a 
twofold boundary was created and enacted (Thompson 2013), demarcating the public from 
the private, and states from the nation, as a source of funding, steering and governance for 
hESC research – with wide–range implication for the configuration of American stem cell 
research that reverberate well into the present decade (see below).  
 
4.1.3 The Obama years. 
During the Bush presidency, the ban on the federal funding of hESC research was 
repeatedly challenged by both Republicans and Democrats, in line with growing popular 
support for such kind of research (Thompson 2013). In 2005 and 2006, similar bills that 
would have made federal funds available for hESC research on “leftover” embryos, 
following appropriate consent by donors (i.e. the Stem Cell Research Enhancement Act of 
2005, H.R. 810), were approved in the House and the Senate, only to be vetoed by 
President Bush. Furthermore, on June 20, 2007, following another presidential veto of 
measures lifting restrictions on human embryonic stem cell experimentation (i.e., the Stem 
Cell Research Enhancement Act of 2007, H.R. 3) (Stolberg 2007) - the third of his 
presidency and the second on the topic of stem cell research - President Bush issued 
	   98	  
Executive Order 13435 that, while making significant rhetorical changes4 (Thompson 
2013), de facto upheld the 2001 federal funding ban. 
Similarly to the importance attributed to the issue by his predecessor, who devoted to 
stem cell research his first Presidential Address to the nation from his ranch in Crawford, 
Texas, on August 9, 2001, one of the first pieces of legislation crafted by newly appointed 
President Obama was the promulgation, on March 9, 2009, of Executive Order 13505. 
Titled “Removing Barriers to Responsible Scientific Research Involving Human Stem 
Cells”, the executive order revoked the Bush–era policy of August 9, 2001, Executive 
Order 13435 of 2007, and charged the NIH with the task of developing guidelines for the 
funding of human pluripotent stem cell research (Thompson 2013). In summary, the main 
change was to permit the use of federal tax dollars for research on hESC lines that had 
been derived from leftover IVF embryos, whether or not they had been derived before 
August 9, 2001. 
 
With the advent of the Obama presidency, and the contextual emergence and 
consolidation of iPSC research (the first human iPSC lines were derived at the end of 
2007), the field of stem cell research underwent a rapid process of consolidation. Whilst 
conducive to the normalization of relationship between stem cell science and the American 
polity, this process brought about a twofold relevant implication. 
On the one hand, it made more difficult, for research organizations that grew 
accustomed to rely on private funding as their main form of sustenance, to tap into the 
same wealth of resources that were in fact previously mobilized, other than for support of 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4 As Noted by Thompson (2013), “first, the NIH’s registry of stem cell lines eligible for federal 
research funds, formerly known as the Human Embryonic Stem Cell Registry, was renamed the 
Human Pluripotent Stem Cell Registry. Second, the order articulated Bush’s deontological 
principle in a clearer way, refusing the sacrifice of one life for the medical benefit of another […]. 
Additionally, the order linked Bush’s positions on embryo destruction to concerns about the 
commodification of humans – a less partisan issue because of its appeal to many progressives and 
many religiously motivated voters – by defining embryos as part of the human species[.]” 
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stem cell research itself, as political statements against the policies of the Bush 
administration. Noted the CEO of a major American stem cell research organization that, 
At the beginning, it was a lot easier to raise funding, when people during the federal 
ban wanted to support work that wouldn't have been supported otherwise. […] 
Moreover, at the very beginning, I would say a lot of people were angry at the 
President, and at the politics. And in fact, that was a bit of a challenge for us because 
when we didn't have a bad guy any more, it was like “wait a minute, why am I still 
supporting [the organization]?” 
Interview with CEO, stem cell research organization 
On the other hand, and most relevantly, such normalization diminished the level of 
public attention, political scrutiny, and ethical oversight devoted to the field of human 
pluripotent stem cell research – a field and a science that, precisely because of such 
inseparable entwinement of the technical and the normative underpinning their 
standardization, was accustomed, in the words of Charis Thompson (2013), to “have 
ethics”5. For instance, notes Thompson (ibid.) with regard to the case of the California 
Institute for Regenerative Medicine (CIRM), “everyone was working to remove the use of 
somatic cells for iPS experiments from high levels of scrutiny. Now iPS research required 
SCRO notification only if using identifiable cells, and the lowest level of oversight (a 
statement compliance) if using de–identified cells, even if they came from fetal tissue”. In 
a way, I contend drawing from Thompson (2013), these developments not only contributed 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
5 Thompson (2013) writes: “I use the word ‘ethics’ in this book to refer to the wide-ranging 
activities including formal bioethics policymaking, in which various actors engaged during my 
research (myself included) to advocate for some ways of proceeding with pluripotent stem cell 
research over others on the ground that they would be better for some people or things in some 
ways. As such, ethics is an overarching normative term for me, ranging in its application from 
political contests over funding, rhetoric, and institution building to matters of personal belief and 
normative arguments made by scholars and activists mailing from a range of disciplines and social 
locations. […] The ethics of sciences that ‘have ethics’ can be contrasted with a more conventional 
view of the ethics of science made up of a professional code of conduct (don’t fake your results, 
don’t steal my reagent) and possible downstream ethical, legal, or social implications (after the 
science is over, are the results used for good or ill?)”. 
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to overshadowing other relevant biopolitical issues related to stem cell research6, but also 
reinforced the consolidation of privatized regimes of innovation (analyzed below in 
relation to NYSCF and HSCI’s endeavors), whose emergence owes, in the first place, to 
the enactment of President Bush’s 2001 federal ban. 
 
4.2 Narratives and policies. 
Among all the twists and turns, some consistent “discursive codes” (Gottweis 1998) and 
narratives shaped the consolidation of the science policy context underpinning the 
establishment of the stem cell research platforms analyzed in this dissertation. 
As a legitimacy strategy meant to both elicit and justify support for a high controversial 
field of research, and counterbalance pro–life objections to it, the narratives of both the 
Clinton and the Obama administrations, as well as of the wide plethora of actors supportive 
of stem cell research, mobilized two core elements of the US political identity, American 
health and American scientific and technological leadership, and tightly linked them to 
hESC research policy (Gottweis, Salter and Waldby 2009). Stem cell research thus became 
a proxy of, and an “extended promise” (ibid.) for, the future of both the well–being of 
citizens, medical research, and the technological primacy of the US on the world’s stage. 
As, for instance, President Obama remarked in his signature rhetorical fashion in his 
March 2009 speech, preceding the promulgation of his Executive Order:  
This Order is an important step in advancing the cause of science in America. [...] 
By doing this, we will ensure America’s continued global leadership in scientific 
discoveries and technological breakthroughs. That is essential not only for our 
economic prosperity, but for the progress of all humanity. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
6 Following Thompson (2013), I use the term ‘biopolitics’ in the broad sense as encompassing 
questions about “who lives at whose expense through which technics”. Marginalized biopolitical 
questions of such kind thus concerned the relation between the funding of stem cell research and 
issues of inequalities in healthcare access; the tensions between the emphasis on technological 
innovation and other aspects of disability justice; the research subjects and the donors of tissue 
samples; the ‘dual use’ of stem cell technologies in military research (see ibid.). 
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As Charis Thompson has poignantly observed (2013), stem cell research in the US 
context has thus been propelled and supported by a pro-cures-as-innovation vision, i.e. a 
rhetoric that bundles together “the fundamental ethical imperative to save and improve 
lives” and biotechnological innovation. Put otherwise, the legitimacy strategy of those 
who, moving at different scales (from federal to state politics, to single research 
organizations), sought to articulate the normative commitment to advance stem cell 
research against ethical, religious, and political objections, hinged heavily on the 
mobilization of the translational narrative (analyzed in chapter 1) revolving around the 
twofold curative and economic potential that stem cells would hold, in healing the wounds 
of the diseased patients as well as those of an ailing post-fordist economy. Observes 
Thompson (2013), with specific regard to the case of California and the state–funded 
CIRM (but her observation can be easily generalized):  
To make plausible this ethical claim that the point of research was cures, the 
research had to be shown to be concerned with the entire innovation trajectory, all the 
way from as–yet–undone basic science to clinically valid treatments. The bench–to–
bedside commitment also lent itself to being read as a commitment to funding a new 
field of innovation, putting California out ahead of the rest of the US and even the 
world. State investment in this “next Silicon Valley” had the potential to reinvigorate 
California’s economy; the research might also dramatically cut medical costs currently 
incurred by dealing with chronic conditions that might be cured with stem cell research. 
 
Secondly, while the Clinton, Bush and Obama administrations’ policies varied with 
regard to their practical outcomes, as well as the framing of both the ontological status of 
embryos and the ethical implications of hESC research – according to the distinct meta-
ethical positions and political worldviews they upheld – they nevertheless adhered to the 
longstanding libertarian stance concerning the regulation and public funding of non-
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therapeutics abortions, whose central argument was that the absence of public consensus 
regarding the moral status of the pre-embryo excluded both the development of regulations 
constraining embryo–based research and the use of public funding to support it. 
As noted above, such stance played a critical role in enacting and legitimizing the 
creation of a boundary between the private and public in the field of embryo research  – in 
stark contrast to developments occurring in other political contexts, where the demarcation 
between allowed and forbidden research was traced along different lines, such as the 
embryo’s country of origin7, its development stage8, or its derivation methods9 (see e.g., 
EuroStemCell.org, Jasanoff 2005, Metzler 2011, Testa 2011).  
On the backdrop of these developments, the growth in significance of constituencies not 
accustomed to be science policy leaders in the US (Thompson 2013) triggered significant 
experimentation in science policy: those empty spaces opened up by the retreat of the 
federal government from a key area of biomedical innovation had to be filled by innovative 
and more flexible regimes of governance (Nowotny and Testa 2011), advanced by new 
biomedical collectives tinkering with new norms, standards and forms of regulation. 
As a new socio-political geography of biomedical research was established, the pressing 
issue that had to be confronted by these emerging collectives - notably, among them, 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
7 In Germany, in line with the provision enacted by a 2008 amendment to the 2002 Stem Cell Act 
(Stammzellgesetz), the derivation of embryonic stem cells is banned, but embryonic stem cell lines 
can be imported specifically for research if the line was generated before the cut-off date of May 1, 
2007 (the date originally defined by the 2002 act was January 1, 2002).  
8 In the UK, research on human embryos is regulated by the Human Fertilisation and Embryology 
Act (1990) and the subsequent Human Fertilisation and Embryology (Research Purposes) 
Regulations 2001, and can only take place on embryos up to 14 days. 
9 In Italy, the Dulbecco Committee set up by then Health Minister Umberto Veronesi in 2000 stated 
that stem cell lines could be derived from SCNT–derived clones, but not from IVF–derived 
embryos. As poignantly observed by Giuseppe Testa (2011), the provision of the committee 
represented an “ontological exercise in kind–making”, for it was the first time that a political body 
framed “clones as distinct from embryos”. The words of the Dulbecco Report, whose provisions 
were overturned by the subsequent approval of Law 40 in 2004, are surely worth reporting: “An 
enucleated oocyte reconstructed with an adult somatic cell nucleous cannot be considered as a 
classical zygote, because it does not derive from the union of two gametes. This is proven by the 
fact that such a reconstructed oocyte does not develop spontaneously into an embryo, and this 
happens only following artificial stimulations that force it to develop into a blastocyst. Only few of 
these blastocysts possess the effective capacity of forming an embryo, and hence a fetus, once 
transferred into the uterus. […] Finally, the oocyte reconstructed with a somatic cell nucleus is 
much more similar to a potential form of asexual cellular expansion of the patient, in analogy to 
what is currently practiced when skin biopsies are amplified in vitro” (DC 2000). 
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academic centers established at elite universities such as Harvard, MIT, Stanford; non-
profit organizations such as NYSCF; state-sponsored agencies and funding programs such 
as the California Institute for Regenerative Medicine (CIRM) - was to carve out their own 
space of public legitimacy. To this end, they engaged in a comprehensive process of 
framing (Jasanoff 2005), mobilizing narratives supporting the distinctive models of 
innovation being designed and implemented, while recasting competing visions of the 
scope and aims of 'good' stem cell science (e.g., the way stem cell research operates, under 
whose responsibility, and towards what ends; how agency and resources are allocated 
among actors; how epistemic and financial risk, as well as ethical controversies inherent to 
lines of research being pursued, are assessed and managed).	  
In this context, the subsequent advent of iPSCs has reinforced, rather than challenged, 
the governance models initially developed by these stem cell platforms around hESC (and, 
to a lesser extent, SCNT) technologies. In what follows, I thus move in medias res and 
investigate how, through the establishment of distinct regimes of governance and 
innovation strategies, HSCI and NYSCF – the two American stem cell organizations I 
analyze in this dissertation – distinctively reproduce and recast the commitment to advance 
translational stem cell research, while insulating it from “unwanted” political pressures. 
 
4.3 A "New Research Model" to Accelerate Translational Stem Cell Research: 
The New York Stem Cell Foundation. 	  
I was asked whether I wanted to participate in writing about The New York Stem Cell 
Foundation as a case study... Can this model be exported on a broader level? I think it's a 
good idea, and it can, and it should. It's because the independence, the integrity of the 
entrepreneurial engine... it's really a pure model, because to be able to do the best work 
with the best people, and not have to pay the piper of a study section, or a commercial 
interest, is what has allowed us to have I think eight of the major innovations in the entire 
field, and we have only been around for nine years! There is definitely something in the air, 
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a sort of secret sauce, and you see it when you come to the lab - it's like a parallel 
universe, everyone is really happy! 
Interview with CEO, NYSCF 
 
The origin of the New York Stem Cell Foundation as a "parallel universe", in the 
poignant words of its co-founder and CEO, dates back to the Summer of 2005 and owes 
mostly to the charismatic leadership of Susan L. Solomon, a former attorney, venture 
capitalist and entrepreneur–turned–patient advocate following her son’s type I diabetes 
diagnosis.  
In the political climate of the time, and following in the footsteps of early pace-setters 
such as Harvard University (see chapter 5) and the State of California, which established 
the $ 3 billion-funded California Institute for Regenerative Medicine (CIRM) in 2004 
(Hayden 2008; Benjamin 2013; Thompson 2013), Solomon started engaging in 
conversations with fellow patients advocates and leading figures in biomedical research, 
such as Harold Varmus (former director of NIH under President Clinton) and Nobel Prize 
laureate Paul Nurse, with the intent of setting up a stem cell program in New York City. 
Tapping into her extended advocacy and business network, she soon accrued an initial 
capital of $ 1.7 million (which rose to more than $ 120 million by 2014 (Solomon 2012a, 
2012b; field notes 2014)) and set up a non–profit organization from scratch, operating at 
first from the living room of her luxurious Upper West Side apartment in New York City – 
thus adding a little twist to a well–worn cliché of American innovation – before moving, in 
2006, to the premises NYSCF currently occupies in the same district of the city (field notes 
2015). 
Therefore, similarly to other endeavors driven by the thrust of single, or a small group 
of typically wealthy and well–connected individuals (see e.g., for the case of the CIRM, 
Thompson 2013; Benjamin 2013), the biographical and political elements knitted together 
to propel the establishment of the organization. If the diagnosis of her son with juvenile 
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diabetes represented, for NYSCF’s CEO, “an unwanted visitor in your home” giving “a 
personal sense of urgency” to her advocacy (Solomon 2012; interview with CEO, 
NYSCF), the Bush administration policies were equally perceived as an unwarranted 
hindrance – both of them prompting action to “move ahead as quickly as possible [to] put 
together a private organization supported by philanthropy” (interview with CEO, NYSCF). 
 
4.3.1 The beginnings. 
The decision to establish NYSCF hinged on two aspects perceived as equally crucial by 
Susan Solomon and the small group of philanthropists and patient advocates involved in 
the first steps of the organization, namely the lack of government support for embryonic 
stem cell research, and the perceived lag in the commercialization of academic research 
findings. Therefore, since its inception, NYSCF moved swiftly in order to pursue two key 
objectives.  
The first priority was to support the hESC field, deemed in danger of not surviving its 
infancy due not only to lack of funding at a critical stage of its development, but also to the 
threat of promising researchers being “scared away towards safer havens” by regulatory 
burden (interview with CEO, NYSCF). Recalled the CEO of the organization that “one 
clear problem was that because of funding policies in the USA at the time, young 
researchers were discouraged from going into the field. So we thought it was very 
important to establish a well-supported community, as quickly as we could. We wanted to 
help early post-doctoral researchers: fund them, give them ways to collaborate, and support 
from top people in the field, so that they could be encouraged to go into the field” 
(Solomon 2012b). 
Accordingly, NYSCF set out to establish an extramural research granting program, 
aimed at providing funds for cutting–edge research conducted by (early career) 
investigators all over the US, as well as to host a major translational stem cell conference 
in Manhattan, with the intent of “bang[ing] a drum loudly” (Solomon 2012), raising 
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awareness for stem cells and hence funnelling public support and resources towards this 
emerging field of research and the organization itself. As explained by the CEO: 
we needed to wake people up: this was a very exciting, emerging field, and they need 
to take time off their busy schedule and pay attention. The ‘they’ were researchers, 
clinicians, and opinion leaders of all sorts. So it was decided that we would have had a 
major annual conference (that we hoped would have become a leading conference), and 
for the last nine years we held a big, annual translational stem cell meeting.  
Interview with CEO, NYSCF 
Notably, other than to report NYSCF–sponsored scientific breakthroughs and promising 
lines of research to the broad scientific community, the launch of the annual conference – 
with its well–attended, close–door gala dinner, which gathers, among the invited guests, 
many top Wall Street executives (Gordon 2015) – was also aimed at showcasing the 
organization to potential donors, thus fuelling a “celebratory culture” – out of which 
NYSCF thrives – which is “functional to the raise of funding in competition with other 
major stem cell organizations” (interview with NYSCF investigator). 
 
Figure	  8.	  Photo	  taken	  at	  NYSCF’s	  9th	  annual	  Translational	  Stem	  Cell	  Conference,	  held	  at	  
Rockefeller	  University,	  October	  22–23,	  2014. 
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As a means to further support promising, albeit hindered, lines of research, in 2006 
NYSCF decided to set up its own research facility in Manhattan’s Washington Heights, a 
site that has meanwhile grown more then tenfold since its inception, and now employs over 
45 researchers. Conceived as a “safe haven laboratory”, the facility was intended to 
insulate stem cell research from fluctuations in political support and federal funding, so as 
to enable its unrestrained pursuit. In the words of the CEO, 
we felt it was really critical […] to have a place where the work could happen and 
you could check the politics at the door. And we still think that this is really, really 
important.  
Interview with CEO, NYSCF 
Curiously, the prompt for establishing the laboratory did not come from hESC research 
itself, but rather from an equally contested, albeit less developed, line of research, that on 
SCNT. Recalled the director of scientific programs and the chief of staff of the 
organization (field notes 2014 and 2015) that, in 2006, scientists in two leading East Coast 
universities, Harvard and Columbia, were intending to set up a collaboration on a line of 
research involving the derivation of patient–specific stem cell lines by means of SCNT 
from diabetes patients, with the primary goal of better understanding the biology 
underpinning the disease, and the longer–term aim of possibly developing cell–based 
therapies. Since, however, the Bush administration’s policy prevented SCNT research to 
be conducted within federally–funded premises, thus severely hindering the development 
of this line of research, scientists at the two organizations soon realized that they needed a 
shortcut, and reached out to NYSCF in order to get out of the impasse. As remarked by the 
director of scientific programs: 
None of the universities were basically able to do this within their campuses. They 
needed a safe haven lab, and asked Susan if she was able to set it up, and she did. It 
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started with a room where all they did was SCNT. Over time other people wanted to 
access a safe heaven-type of laboratory, and it started to evolve a bit. 
Interview with director of scientific programs, NYSCF 
 
 
Figure	  9.	  NYSCF’s	  research	  facility	  in	  Manhattan’s	  Washington	  Heights. 
 
4.3.2 Bridging research and cures. 
Other than supporting hESC and SCNT research, the second, equally critical objective 
pursued by the organization was to enable a distinctively translational research pipeline. 
Accordingly, since its inception – and even more so after the derivation of human iPSCs in 
2007 – NYSCF’s organizational culture (Schein 1984) was based on a translation–oriented 
approach, one in which the creation of a shared professional identity among members of 
the organization (i.e., its internal integration) and the definition of the tasks to be 
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accomplished, and the methods to reach the goals (i.e., its external adaptation), proceed 
from the translational mandate.  
In particular, consistent with its ambition to "accelerate cures for the major diseases of 
our time through stem cell research” (mission statement), NYSCF implemented a specific 
organizational gearshift revolving around two mutually-sustaining pillars. First, in setting 
forth its research objectives, NYSCF marked an explicit departure from academic 
orthodoxy, foregrounding therapeutic innovation over traditional peer recognition. As a 
staff scientist explained: 
We don't care much about the papers that come out of our lab, as the process of 
obtaining enough data on a drug to move into the clinic is very different from 
generating enough data to publish a Nature paper, and what we are focused on here is 
to take one of our discoveries and get funding for it to move it fast along the 
translational pipeline. 
Interview with staff scientist, NYSCF 
Furthermore, in devising its organizational model and establishing its experimental 
infrastructure, NYSCF set out to target and address a perceived major impediment to the 
effective translation of biomedical research, namely the “giant gap between the work being 
done at academic institutions, and the delivery of pills and treatments on the commercial 
side” (Solomon 2012b). In particular, in order to accelerate access across academic and 
private sector parties, the leadership of the organization sought to carve out for NYSCF the 
role of the (gap-remedying) mediator (Latour 2005), one that could streamline the 
transmission of scientific knowledge from academia to the industry by attending to its 
quintessentially material transformation - i.e., translation - into fungible, clinically 
actionable products. In the words of NYSCF’s director of scientific programs: 
We try to see ourselves as a translational component in between academia and 
biotech or pharmaceutical companies, some sort of an accelerator. […] In fact, in one 
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aspect, we already are one of the biggest players in the field, not the largest stem cell 
lab, but we are the most focused on translation and scale up of any group in the world 
in stem cell research. 
Interview with director of scientific programs, NYSCF 
	  
Figure	  10:	  NYSCF's	  	  self-­portrayed	  role	  as	  translational	  component	  in	  between	  academia	  and	  
pharmaceutical	  companies	  (photo	  taken	  at	  NYSCF	  laboratory	  by	  LM)	  
 
More to the point, vis–à–vis the purported chasm disconnecting ‘research’ from ‘cures 
and treatments’ (as for NYSCF’s own rendering of the ‘valley of death’ metaphor, see 
Figure 3), NYSCF adopted a centralization strategy aimed at establishing, within its own 
research laboratory, those translation-grade infrastructures that the field was deemed to be 
lacking in order to create efficient synergies and linkages between academic and 
pharmaceutical research centers. Most notably, as described in detail below, NYSCF 
devoted a significant amount of time as well as cognitive and material resources towards 
designing and establishing the largest robotic device for iPSCs derivation, culture and 
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differentiation in the US, which came to represent the cornerstone of its translational 
pursuit, as well as the organization’s poster child for its aggressive marketing strategy with 
potential donors. Less glamorous but equally relevant, it also devised a consenting form, 
“which now is widely used by the entire field” (interview with CEO, NYSCF), geared to 
ensure the streamlined circulation of iPSC research findings among academic and, 
especially, commercial constituencies (Lowenthal et al. 2012; see chapter 2).  
By means of this process of capacity–building, NYSCF sought to position itself as a 
translational hub (Fishburn 2012), situated at the core of a vast network of academic and 
clinical centers, advocacy organizations, biotech and pharmaceutical companies. By 
establishing internally the cognitive and material infrastructure purportedly needed to 
connect these different kinds of organizations, each focused on a specific aspect of stem 
cell research, it thus aggressively pursued the final aim of facilitating the uptake of 
academic research by clinical, biotech and pharmaceutical organizations.  
 
 
Figure	  4:	  NYSCF	  as	  translational	  incubator	  at	  the	  core	  of	  an	  integrated	  discovery	  nexus. 
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4.3.3 A new model of governance: venture philanthropy. 
We thus see at work, in NYSCF translational pursuit, a twofold reconfiguration of stem 
cell research: a spatial insulation from political hindrances coupled to a temporal 
acceleration over traditional modes of scientific scrutiny. Essential to this reconfiguration 
was the development of an innovative regime of governance, which represents a distinctive 
trait of NYSCF’s endeavor in the stem cell field. 
For one thing, insulation from the federal political environment was achieved through 
the almost exclusive reliance on private funding. A skilled, well–connected fundraiser, 
NYSCF’s CEO was able to mobilize a large wealth of resources, provided by patient 
advocacy and charitable foundations – such as the Helmsley trust and the Michael J. Fox 
Foundation for Parkinson’s Research – as well as affluent philanthropists from the New 
York City’s financial élite. The latter set of people, in particular, played a key role for the 
scale up of NYSCF’s operations. If the first donation received by the organization 
amounted to 100,000 USD, provided by a fellow member of a distinguished urban research 
and advocacy organization, the Regional Plan Association, in whose board Susan Solomon 
has served for many years (interview with chief of staff, NYSCF), the involvement of 
major hedge fund executives greatly augmented the flow of resources available to NYSCF. 
By tapping into the wealth of Wall Street billionaires such as Julian Robertson (manager of 
the Tiger fund) or Stanley Druckenmiller (former manager of George Soros' renowned 
Quantum fund) – who became prominent funders of the organization – NYSCF was able to 
both set up enticing funding schemes for investigators all over the US, and establish its 
own high–tech, high–cost research infrastructure.   
 
Moreover, other than with respect to its funding strategy, NYSCF’s ‘New York City 
dimension’ – as one of my interviewees defined the close–knit link that ties NYSCF to its 
geographical location at the epicenter of the world’s financial industry (field notes 2015) – 
is brought to bear on the governance structure being implemented by the leadership of the 
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organization. Backed by private philanthropists’ money, NYSCF adopted – unique in the 
whole stem cell field worldwide – a venture philanthropy regime of governance, one that 
was meant to greatly enhance the translational capability of the organization. 
 
Articulating a new model for philanthropic funding, venture philanthropy rose to 
prominence in the mid–1990s10, around the time of the dot–com boom, borrowing 
concepts and practices from venture capital funding (which was widely used in the ‘new 
economy’ to start up businesses and support their capacity–building process), and 
deploying them for innovation-oriented organizations in the non-profit sector (Grossman et 
al. 2013). Drawing moral legitimacy and resonance by appealing to pro-business values 
and a pro–market ideology that fits with an "MBA-type of thinking" typical of potential 
donors (Moody 2008), venture philanthropy also resonated with a pragmatist sensibility 
that values things "because they work" (Dart 2004) - all pervasive elements within the 
American civic epistemology (Jasanoff 2005) and socio-political culture. As sociologist 
Michael P. Moody (2008) observes, “it appears there was this sort of natural fit between 
venture philanthropy and the existing venture capitalist-oriented ways of thinking and 
acting that prevailed among many of the newly wealthy individuals at this time, many of 
whom were either the beneficiaries of venture capital funding or the venture capitalists 
themselves.” 
Having thus rapidly developed into a “‘new’ organizational field” and “‘new’ 
professional culture” (Moody 2008), the venture philanthropy model has aimed to mark a 
departure from traditional models of philanthropic giving, through the adoption of an 
outcome-driven, evidence-based approach. In particular, by employing methods derived 
from venture capital, such as due diligence and risk and performance management 
(Grossman et al. 2013), venture philanthropy–backed organizations are meant to achieve a 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
10 More precisely, venture philanthropy was first introduced as a concept, to articulate a new model 
for philanthropic funding, in an influential 1997 Harvard Business Review article that, however, 
did not even contain such wording (Letts et al. 1997). 
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twofold objective: first, to defy the inefficiencies and “the internal bureaucracy typical of 
large organizations” (interview with CEO, NYSCF); second, to implement, quickly and 
effectively, the purpose for which philanthropic money is allocated11. As explained by the 
chief of staff of the organization, 
Our model of governance is a venture philanthropy, accelerated model, and this is 
what sets us apart from other research institutions. We don't have to rely on federal 
funding, and we are able to take fast decisions - much faster than academic 
organizations with large bureaucracies. We are quick to identify where investments 
should be made, and then embark in that very quickly. And this is key to bring us faster 
to new treatments. 
Interview with Chief of staff, NYSCF 
 
Drawing from this template, NYSCF designed its governance structure accordingly. For 
one thing, building on the venture capital expertise of its CEO, it set out to maximize the 
effectiveness of its management strategies, and adopted a marked outcome–driven 
approach. The CEO claimed that: 
I try to keep things as flat as I can, organizationally […] First of all, it's just facts. 
90% of our money is used for direct programs, 10% to keep the lights on. That is pretty 
extraordinary… And people who are more in the professional philanthropy business, 
have said that they feel NYSCF is giving them the best return on any philanthropic 
investment that they have made. So, we are very results oriented… 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
11 Grossman and colleagues (2013) explain: “In 2011, non-religious philanthropy in the U.S. 
totaled $202.54 billion. Trillions of additional dollars have been given to nonprofit organizations 
over past decades. Yet philanthropists are increasingly frustrated that their goals of improving 
public education, reducing homelessness, or increasing job readiness still seem elusive. Despite 
conventional wisdom, the dearth of philanthropic results may be less a function of the total amount 
spent and more a product of the way money is traditionally given to nonprofit organizations. For 
the most part, philanthropy is distributed for specific programs, for relatively short periods of time, 
and with little accountability for results. Even when a nonprofit can prove its effectiveness, donors 
rarely provide enough growth capital to enable organizations to impact a societal problem at scale. 
[…] Venture philanthropy takes a different approach.” 
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Interview with CEO, NYSCF 
Second, and most relevantly, it bestowed agenda setting prerogatives to a composite set 
of philanthropists and patient advocates – thus empowering them as the privileged 
constituency the organization is meant to serve – and set accordingly its own criteria of 
accountability. More to the point, in charge of maintaining fiduciary responsibility for the 
organization is a varied board of directors which comprises patient advocates, top Wall 
Street executives, leading clinicians and scientists and even a Pulitzer laureate for 
distinguished architecture criticism (i.e. Susan Solomon’s own husband) – “people who 
care about the issue and are supporters of the organization, who Susan knew, who are well 
established and respected, and could bring responsible governance and different trains of 
thoughts to the organization” (interview with chief of staff, NYSCF). Furthermore, the 
board of directors is where CEO Susan Solomon, who is “in charge of everything” 
(interview with chief of staff, NYSCF) reports and is held accountable; it acts as trait–
d’union between the donors (some of whom sit on NYSCF’s board) and the organization 
itself; and also, by ensuring that primary responsibility for research oversight is retained 
within the organization – something that, in spite of potential criticism, is hailed as 
“critical” by NYSCF’s CEO (interview with CEO, NYSCF) – it is also meant to construct, 
and preserve, the “integrity” of “NYSCF’s own view” on stem cell research (interview 
with CEO, NYSCF).  
The predominant role played by philanthropists and patient advocates within the 
organization also influenced NYSCF’s ethical oversight strategy. The chair of NYSCF’s 
SCRO committee notes in vivid words that: 
The biggest difference of our SCRO committee is that the membership is spread out 
all across the country. Other SCRO committee have all local members. We are a sort of 
“virtual reality SCRO”, we meet by teleconference. I think this is interesting if you think 
about deliberation: what happens if we have to deliberate on something controversial 
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and we don't meet face-to-face? The other difference is that NYSCF’s SCRO committee 
is tilted a little bit more heavily towards community members. If you look at the eight of 
us, there are two scientists, bioethicist, one of the legal guys is also a patient advocate. 
So, roughly half of them are patient advocates, which is significantly more than e.g. the 
[other] SCRO committee, where we have one community member. […] Furthermore, I 
think people see the SCRO has being very friendly towards NYSCF, that's my 
impression. Everyone has got a very favorable view of the organization, that's why the 
volunteered to be part of SCRO. 
Interview with chair of SCRO committee, NYSCF 
 
 
4.3.4 NYSCF as sociotechnical vanguard – Accelerating by disrupting. 
In light of the above, drawing from the cultural repertoire (Lamont and Thevenot 2000) 
of American (venture) philanthropic innovation, in which pro-market and pragmatist 
attitudes converge (Dart 2004; Moody 2008), NYSCF was thus able to carve for itself the 
role of what Hilgartner (2015) designates as a sociotechnical vanguard. Precisely as a 
private capital-backed organization adopting a venture philanthropy-based governance 
model, NYSCF could frame its endeavor as that of a visionary avant-garde, predicated on 
the virtue of unleashed scientific knowledge matched to equally unleashed means to 
translate it. 
Faithful to venture philanthropists' quest for innovative, disruptive advancements 
leading to "pattern-breaking social change" (Childress 2008), this convergent unleashing of 
knowledge and means was explicitly framed as the core of NYSCF's mission as a "game 
changer" promoting disruptive innovation in the stem cell field (Bower and Christensen 
1995; Christensen 1997)12. As most eloquently attested by the following interview excerpt, 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
12 Defined by influential Harvard Business School scholar Clayton Christensen as introducing "a 
very different package of attributes from the one mainstream customers historically value", and 
even performing "far worse along one or two dimensions that are particularly important to those 
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what NYSCF's vanguard vision (Hilgartner 2015) typically mobilizes is the pioneering 
role of the organization in driving a wave of change that is contrasted with a gloomy 
scenario of unfulfilled translational promises should a "business as usual" approach happen 
to prevail: 
The more I looked into the process of medical research, and what it could take 
to get the new field [of stem cell research] started, the more I felt I could make a 
contribution, as I have a background as a "change agent", I guess you could call it. 
I'm one of those people who could, I felt, also marshal others, who could look into 
new fields and look into the future, and see things that are not real today but can be 
real tomorrow, and this is not something that everyone can do… 
And then, looking around, and realizing that if we left it as business as usual... 
the analogy that I like to use is [with hurricane] Katrina, where everyone assumed 
that everybody else was bringing the ice, and nobody brought the ice to all these 
poor people stuck in the Dome. And I know that a lot of these people assumes that 
the system is taking care of things, but either it's not, or not in a reasonable amount 
of time... 
Interview with CEO, NYSCF 
Consistent with this disruptive ambition, "bringing the ice" to the stem cell field took 
the form of a specific organizational gearshift revolving around the implementation of a 
marked risk-prone approach to stem cell science that spanned from the financial resources 
all the way to the epistemic depth of technologies and machineries.  
As to the former, against the backdrop of risk-adverse funding agencies (Ledford 2012), 
increasing decommissioning of the pharmaceutical industry from early phase drug 
discovery (Bartek 2014) along with its reluctance to invest in a largely immature stem cell 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
customers" (Bower and Christensen 1995), disruptive technologies are those that "typically enable 
new markets to emerge" by "redefining established trajectories of product performance 
improvement" (Christensen 1997), that is, in other words, by defying, rather than meeting, the 
demands and expectations of the customer base.  
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field (see chapter 2), NYSCF’s strategy was to target financially "risk-taking, early stage 
work that is essential for translation" (interview with CEO, NYSCF), so as to de-risk 
downstream, industrial research and thereby accelerate commercial development. For 
instance, since the establishment of its robotic platform in 2013 (see below), a major aim 
of the organization has been to pursue the scale up of iPSC research, so as to establish the 
proof–of–principle that academic research findings obtained on a small numbers of cell 
lines could in fact be robustly replicated on a large number of samples within an industry–
compatible infrastructure. As NYSCF's director of scientific programs explained in that 
regard:  
When people put commercial dollar into something, they trust that the results 
they are going to get are what they want...and that it's a good investment. And right 
now the stem cell field is not a good investment. That's why we are a non-profit 
company. We know how to make it a good investment, but we just need to get over 
that hurdle so to get people trust it. And once we're there, we're going to have 
personalized medicine, cheaper clinical trials, we're really going to change the face 
of the health care system..." 
Interview with director of scientific programs, NYSCF 
Not only meant to accelerate the commercialization of research findings, NYSCF’s 
engagement with high–risk research was also intended to sustain the completion of 
research projects filled with uncertainty – also by devising accordingly its IP strategy. 
Whereas venture capital–backed start–up companies are in fact typically oriented towards 
an early out–licensing of their findings to major pharmaceutical corporations for further 
product development (Mazzucato 2013), NYSCF set out to retain the long–term 
intellectual property of its research findings, so as to make sure that the out–licensing 
doesn’t occur too early into a compound’s translational trajectory, that which could entail 
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its death sentence. “We are not in the fashion business, we are in the patient business”, 
argued the CEO of NYSCF. Before explaining further that: 
at the typical, major stem cell program in the university the work is really not 
translational, in the sense that it is done at a small scale, and the incentives are either 
aligned for tenure and publication, and getting more grants, or to commercialize, to 
license patents to drug companies that have their own challenges – and you are then at 
the mercy of the fashion business, whether you are going to move ahead or not, because 
one minute they want to be in the pain business, the next decide no, no, no, they want to 
be in the Alzheimer business. There are no incentives, you are not rewarded for ongoing 
risk-taking… 
Interview with CEO, NYSCF 
Moreover, consistent with its 'safe haven lab' approach, NYSCF has constantly engaged 
in ethically or politically controversial kinds of research. For instance, owing to its 
insulation from the federal political environment, as well as to its location in New York 
State, which allows compensation to women for oocytes provision, NYSCF has for many 
years spearheaded research on SCNT (see e.g. Chan et al. 2012; Yamada et al. 2014). As 
the chair of NYSCF SCRO explains: 
They definitely have as a central part of their mission to fund research that maybe 
wouldn't be easily fundable through other sources. SCNT is a proper example for 
that. I am sure they view themselves as facilitating research otherwise difficult for 
political reasons or pressure... With the ethically controversial SCNT, for example, 
they are much more willing to facilitate that kind of research: it's part of their self-
identity, their are the ones who really try to push forward every aspect of research 
(and SCNT is just an aspect of this). 
Interview with chair of SCRO Committee, NYSCF 
	   120	  
Finally, as far as the epistemic dimension of risk-taking is concerned, it took the form of  
"something so new as to be absolutely unique" (interview with investigator, NYSCF): the 
Global Stem Cell Array (henceforth: GSCA).  
 
4.3.5 Epistemic reconfigurations. “Something so new as to be absolutely 
unique”. 
As shown by a large body of STS scholarship (see, e.g. Fujimura 1987; Scott 1988; 
Bowker and Starr 1999; Webster and Eriksson 2008; Timmermans and Almeling 2009; 
Nowotny and Testa 2011; Busch 2013), standardization practices and technologies are 
potent vehicles through which normative rationalities and visions acquire material 
currency.  
NYSCF's commitment to act as stem cell translation catalyst was epitomized in the 
implementation of the first fully automated, robotic system for the parallel derivation of 
hundreds of iPSC lines. Taking four years for completion, at an overall cost of over $35 
million, the GSCA (field notes 2014; Paull et al. 2015) became fully functional in 2015 to 
automate the derivation, culture and expansion of iPSC lines, as well as their 
differentiation into various lineages from all three embryonic germ layers, such as 
cardiomyocytes, midbrain-type dopaminergic neurons, hepatocytes, metanephric 
mesenchyme, and oligodendrocytes (Paull et al. 2015).  
In a matrioska-like arrangement, the GSCA represents a "central iPSC derivation hub" 
that enables "the seamless connection" (ibid.) between clinical donors, end user scientists 
as well as pharmaceutical companies, thus materializing into scientific practice NYSCF's 
organizational configuration as a translational hub. Furthermore, as a capital-intensive 
effort aimed at bringing technological closure to the standardization of human stem cell 
pluripotency, a field whose epistemology is still very much in flux, the GSCA plastically 
instantiates NYSCF's risk-prone approach to stem cell research. As recalled by a NYSCF 
Investigator during a visit to the facility that I conducted in April 2014: 
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The idea was, what could we do that is so large that nobody else would be able to 
realize, that the NIH won’t finance…? And this is how they came up with this project, 
which is such a high-risk project that we still don’t know whether it is going to be 
rewarding. I believe the idea was precisely to do something so new as to be absolutely 
unique. 
Interview with Investigator, NYSCF 
More specifically, by aiming at reducing biological and technical variability inherent to 
manual iPSC derivation and differentiation (Paull et al. 2015) - as well as greatly 
increasing their 'throughput' and scale -, the GSCA is geared to accomplish a threefold 
translational objective. First, it "enable[s] the application of iPSCs to population-scale 
biomedical problems" (Paull et al. 2015), providing "a platform for large-scale in vitro 
studies" (ibid.) such as the study of complex genetic diseases with modest effect size that 
require large cohorts of samples to probe the genetic contribution to phenotypic variation, 
thus corroborating the notion of iPSC-based functional annotation of human genomes 
pioneered in the work by Adamo, Atashpaz, Germain and colleagues (2015). Second, it 
underpins the creation of an iPSC repository (nyscf.org/repository), set up in collaboration 
with the Harvard Clinical and Translational Science Center (Harvard Catalyst), aimed at 
enhancing access by the scientific community to a vast panel of well-characterized iPSC 
lines from diverse populations of diseased patients. 
Third – and crucially – the GSCA is meant to facilitate the pharmaceutical development 
of iPSC-based technologies, in a twofold way. On the one hand, it represents an 
infrastructure well suited for high–throughput screenings of new compounds on iPSCs and 
iPSC–derived cells (see chapter 2). The novelty of the system, however, has been met with 
lukewarm reception from pharmaceutical companies. The head of the stem cell program at 
a leading pharmaceutical company explained for instance in May 2014 that: 
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We were in contact with NYSCF, I visited them one year ago, I mean... I am 
impressed by what they are doing, but currently it does not fulfill the needs of 
[COMPANY]. […] You know, there are huge costs, and finally for us, the quality of the 
cells is really crucial, and I think the science has to progress a little bit. We still clean 
the cells manually, we change the media every day, and we check the quality every 
couple of days, if there are cells that are starting differentiating we remove them 
manually. In a 96–wells plate you can't! If they loose a colony, they loose it and use 
another one... Maybe this is the way forward... For our logistic, the way we are doing, 
with a lot of manual steps, makes currently more sense... Only the media for iPSC, this 
will develop so fast, that in two or three years it becomes much easier, and then also 
automation really becomes feasible. 
Interview with head of stem cell program at multinational pharmaceutical company 
On the other hand, and in a much shorter timeframe, the GSCA is geared to establishing 
the proof-of-principle that discoveries made in academic laboratories, on a small number 
of iPSC lines, can be replicated, scaled up, and validated in a robust manner across a large 
number of cell lines. It thus provides the level of standardization required by large 
application-driven organizations so as to ensure, accordingly, the attainment of industry–
compatible standards. As explained by NYSCF's director of scientific programs:  
If you have projects that you think are relevant to identify a drug or something 
interesting about the disease and its biology, how do you get other people across taking 
it for real? And having a group validating it, scaling-up across a large number of 
samples and cell lines is really a critical component. Pharmaceutical companies are not 
trusting academic laboratories, but I think the partnership between us and the labs has 
got a lot of interest [from pharmaceutical companies]. When someone says they 
generate a kidney cell, can you really generate a kidney cell, does that protocol works 
across different samples, outside your lab? 
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Interview with director of scientific programs, NYSCF 
 
4.3.6 Reconfiguring the epistemology of iPSCs. 
The CEO of the organization recalled the decision to pursue the road of iPSC 
automation in the following terms – which point to the aim of transferring human skills to 
robotic machines: 
We looked at how stem cells were made and said: “look, this is terribly inefficient, 
it's super-slow, you can only make a few at a time, and you are doing by hand, and you 
are tying up really expensive talent seven days a week basically feeding pets! So, let's 
see if we can teach robots to do this… 
Interview with CEO, NYSCF 
However - as it is often the case in biomedicine (for instance, see Keating et al. 1999; 
Keating and Cambrosio 2003) -, the implementation of the robotic system did not consist 
in the replacement of human with non-human agency in order to (re)produce the same 
output. Rather, it triggered the development of a new protocol of iPSC derivation and 
differentiation that thoroughly reconfigures the ontological materiality of iPSC lines (Paull 
et al. 2015). In fact, automated reprogramming reconceptualizes the standard, "most under-
appreciated yet most important control instrument for pluripotent quality assessment" 
(Muller et al. 2012), namely the visual inspection and manual selection of "good looking" 
(i.e. fully reprogrammed) from "ugly looking" (i.e. partially reprogrammed) "colonies" of 
cells (see chapter 2). Optimized for the robotic practice and epistemology, the new 
protocol entails the disruption of the colony of cells into single cells, that are then 
individually sorted for pluripotency markers, and finally pooled together so as to have a 
mixed (polyclonal) population of cells purportedly displaying "less line-to-line variation 
than either manually produced lines or lines produced through automation followed by 
single-colony subcloning" (Paull et al. 2015).  
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Figure	  11:	  iPSC	  colonies	  vs	  single	  cells	  –	  workflow	  of	  the	  GSCA.	  
	  
Interestingly, the reason for adopting the new protocol was twofold, and it was dictated 
both by epistemic reasons (i.e., it introduces less variation) and as a consequence of the 
need to shift "from systems that are still returning knowledge through their instability and 
need for skill to reliable, highly quality-controlled processes" (Fisher 2012). The decision 
to opt for the cell sorting technique, rather than the standard colony picking procedure, was 
explained by the engineer in charge of devising the system in the following terms: 
If you want to do the picking, you need to localize the good colony in the well, where 
it is. And how do you do this in an automated fashion? Manually, if you look under the 
microscope you can pick and transfer colonies by hand; with automation how do you 
control the variation about where colonies could be popping up? It's possible to do that, 
you can do staining, imaging, etc., but it's more complicated, more time-consuming, and 
would be difficult to make that amenable to a large batch-factory type process. 
Whereas, if you remove everything from the well, and do cell sorting, etc, it's more 
amenable to a large-scale process. 
Interview with senior system architect, NYSCF 
Thus, through the automation of iPSC derivation, NYSCF's self-proclaimed disruptive 
approach gets translated into the very materiality of its own experimental practices. Not 
only does NYSCF aim at disrupting - figuratively - established scientific practices and 
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markets; in order to achieve this aim it takes the road of disrupting - literally – the 
epistemic and thus far nearly sacred unit of iPSC science, one that owed its value to the 
very care with which it was managed as a biological whole: the colony of pluripotent cells. 	  
In parallel, the translation-driven automation of iPSC derivation entails a further crucial 
reconfiguration, propelling the transformation of the GSCA-based experimental system 
into a system of production, "laden with connotations such as directivity, efficiency, 
quantitation of output" (Rheinberger 1997). Whereas scientific experimentation strives to 
engender new, unexpected events, the epistemic things that "give unknown answers to 
questions that experimenters themselves are not yet able clearly to ask" (Rheinberger 
1997), the GSCA turns iPSCs into technical objects (ibid.), devoid by intention of any 
epistemic uncertainty, and hence scientific interest, of their own. Indeed, while indeed the 
stem cell field still struggles creatively with the notion of pluripotency as a yet-to-be 
stabilized object of inquiry (see, e.g. Kalmar et al. 2009; Nichols and Smith 2009; Gafni et 
al. 2013; Obokata et al. 2014), automation requires that such uncertainty be tamed, the 
epistemic currency of such questions be devalued, and the search for "the better standard" 
come to a closure.  
As such, automation represents not only a key moment in the standardization trajectory 
of iPSCs, but also the moment in which "they almost leave the lab" (interview with iPSC 
scientist) and become akin to a commodity (Marx and Engels 1970): something that, in 
virtue of its highly standardized nature, severs the ties that bounds it to the (laboratory) 
context of its production, can circulate across different experimental settings, while being 
enrolled, as a consequence, in circuits of high return, be it experimental, curative or 
bioeconomic. As a prominent iPSC scientist put it, capturing by means of analogy the 
profound reconfiguration underwent by iPSCs through automation: 
The analogy which you have to make is with the Louis Vuitton hand bag: [...] it 
is handsome, hand-designed, there are only some that are made per year, etc, 
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whereas if you go to your regular department store, let's say Walmart, you'll have 
something that is mass-produced, there are millions of them, and it's a completely 
different thing. 
Interview with iPSC Scientist 
 
4.3.7 Conclusions. 
In this chapter, I have outlined the most significant junctures in the chain of events 
leading to the current policy configuration of the field of stem cell research, before moving 
to expound how they have been brought to bear on the configuration of a leading iPSC 
research institution in the US, the New York Stem Cell Foundation. 
NYSCF’s endeavor represents a unique case in the field of stem cell research, and in 
many respects a fascinating one. Propelled by the means of the sector with the highest 
return on capital in the world, the financial industry, it set out to programmatically 
accomplish a disruptive mode of scientific enquiry, supported by an equally innovative 
model of scientific governance, that of venture philanthropy. As its vanguard vision 
(Hilgartner 2015) finds material currency in the implementation of the first fully automated 
robotic system for iPSC derivation, expansion, and differentiation – a feat considered “so 
high risk that it is still not known if it is going to be rewarding” – it symmetrically 
empowers a small set of exceedingly wealthy and tech–savvy stakeholders, and frames 
them as those who are better positioned to advance translational stem cell science in the 
search of cures for the 21st Century. 
I will reflect more in depth on these aspects, and on what they do entail, at the end of 
the present dissertation. Before I do so, I travel the short distance that separates New York 
City from Cambridge and Boston, MA, to analyze, in the next chapter, the uptake of iPSC 
research in a bastion of academic research, Harvard University. 
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Chapter	  5.	  The	  Harvard	  Stem	  Cell	  Institute	  
 
 
The genealogy of the Harvard Stem Cell Institute – with more than a thousand affiliated 
researchers, the largest stem cell research organization in the world – owes in critical ways 
to its institutional affiliation at the core of America’s oldest and more prestigious academic 
institution, Harvard University. HSCI was established in 2004, out of privately-raised 
funds, as a "networked organization" (field notes 2015) connecting several institutions, 
schools and affiliated hospitals within Harvard, with the goal of leveraging these resources 
to advance stem cell science and its clinical application. In particular, internal academic as 
well as broader political motives synergistically propelled the creation of the new institute.  
 
For one thing, since the beginning of the new century, and the appointment of 
economist Larry Summers – a former chief economist of the World Bank and Secretary of 
the Treasury in the Clinton administration – as its 27th President, Harvard University has 
decisively pursued a path of heavy investment in the biosciences, with stem cells figuring 
prominently among them. “I am convinced that the next Silicon Valley… will happen in 
the biomedical area, will happen in the technology and in the products that relate to 
extending and improving the quality of human life”, declared Harvard president Larry 
Summer in November 2001, a month into its tenure (Schlesinger 2005).  
Attesting to the significance of Harvard’s endeavor in the area, largely fueled by its 
massive endowment, which in 2004 totaled 22 billion USD, were initiatives such as the 
creation of the Broad Institute (a 200 million USD joint venture with MIT to find clinical 
applications of the human genome), or the completion of the 260 million USD New 
Research Building at the Medical School (Schlesinger 2005). Most notably, contributing to 
the sense of transformation –made manifest through visible changes in the university’s 
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urban landscape  – was the projected creation of a new scientific hub resulting from the 
expansion of Harvard’s Allston campus, located south of the Charles river, and just half a 
mile away from Harvard’s main campus in Cambridge, MA – an area already home to the 
university’s Business School and its main sporting facilities. At the core of the new 
projected Allston Science Complex – meant for completion in 2010 (Lok 2007), before 
plans were scuppered due to the massive losses incurred by Harvard’s endowment fund 
following the 2007 financial crisis (Groopman 2009), and before they have been resumed 
for good in Spring 2014 – was to be the newly established Harvard Stem Cell Institute. 
There, researchers and professors from the faculty of Arts and Sciences, the Medical 
school, and the School of Public Health would have been “working days and nights 
unraveling the mysteries of the human cell” (Schlesinger 2005). Likewise, members of the 
Law School, the Business School, the Kennedy School of Government, and the Divinity 
School would have gathered so as to explore the ethical, business and social dimension of 
the new technology. 
 
Aside from Harvard’s long–term goal of enhancing its already world–renown capability 
and expertise in the life sciences, matters of current political affairs were at play in 
propelling the creation of the institute. HSCI set indeed out, in the words of then Harvard’s 
President Summers, to circumvent and compensate for the Bush Administration's “deeply 
misguided policy” on stem cells, which amounted to the "abdication of national 
responsibility” in the area (Harvard’s Office of the President 2004). Addressing a packed 
audience at the institute’s inaugural symposium in the Charles Hotel in Cambridge, on 
April 24, 2004, Democrat Summers revealed his well–honed “sense of the inherent powers 
of the Harvard presidency”, by “dar[ing] oppose”, in the quest for advances in the field, the 
university itself and the Republican federal government (Schlesinger 2005): 
That the federal government has withdrawn from funding so central a scientific area 
imposes, I believe, a great ethical obligation on the very, very small numbers of 
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institutions within our country that have the capacity to fill that gap […] Filling in a 
gap like this is the highest and best purpose for a university like ours (Harvard’s Office 
of the President 2004). 
Far from being a lonely, albeit powerful, voice, Summers’ words resonated with a 
widespread feeling within the Harvard community. As vehemently argued by prominent 
HSCI scientist George Daley, who was previously involved in planning the new initiative, 
no one was in doubt that "Harvard has the resources, Harvard has the breadth, and, frankly, 
Harvard has the responsibility to take up the slack that the government is leaving" (Vries 
2004).  
In his speech, Summers further added rhetorical momentum to his claims by “fearlessly 
amending” (Schlesinger 2005) Harvard’s famed rubric (“veritas”): “we value truth for its 
own sake, but we also value truth because understanding can make a profound difference 
in this world and a profound difference to millions of people's lives” (Harvard’s Office of 
the President 2004). 
Highlighting the curative promise entailed by the new technology, he also appealed to 
his own personal biography, and his healing from Hodgkin’s disease, a disturbance in the 
cells of the lymphatic system, which almost killed him as a young man, to justify sustained 
investment in a field whose fungible rewards lie intangibly far into the future. “Some 20 
years ago I spent no small amount of time in one of Harvard's great teaching hospitals, 
being treated, with the ultimate outcome in some doubt for a time. My treatment worked 
out very well”, he explained at the symposium. And continued: “And when that course of 
treatment ended, I asked a question. I asked: At what point in the development of science, 
what point in the development of the relevant research, had the discoveries been made that 
had made possible my treatment? The answer was, about 10 or 15 years before I was 
treated… And I thought to myself, wasn't I fortunate that that research program had been 
pursued as aggressively and as quickly as it had” (Harvard’s Office of the President 2004). 
 
	   130	  
Backed by Harvard’s most powerful figures, and driven by the aim of sustaining the 
promising, albeit hindered, hESC research, in Spring 2004, soon after Summers’ inaugural 
remarks, HSCI started its operations. In particular, making what, at the time, was a major 
statement of intent against the policy of the Bush Administration, it started deriving, and 
distributing to the broad scientific community worldwide, a large number of hESC lines, 
some of which have become among the most used in the field (Scott et al. 2009). The co–
director of the institute noted that: 
the first objectives were to create and distribute embryonic stem cells for researchers 
to try new things. That took a year or so and within the first year, I think, Harvard 
literally distributed thousands of cell lines for free to the world over. And I think this 
was the right thing to do, and I would do it again, because I don’t think we’re smart 
enough to know what people should do with this reagent, with this tool, and I like the 
idea that people anywhere could do this kind of work. I make a joke of it and say: my 
grandparents came from Bugnara, which is far in the East coast of Italy, in Abruzzi. 
There might be a researcher there who wants to do something, and I am not smart 
enough to tell them what to do, but they should be able to do whatever they want… 
Interview with co–director, HSCI 
 
5.1.1 “I f  you s tand alone i t ’ s  much harder than i f  you s tand toge ther”. A citadel of 
science against the President siege on stem cell research. 
 
Whereas NYSCF's endeavor owed in many respects to its geographical proximity to 
New York City's financial industry, HSCI significantly leveraged on its location at the 
heart of a world-renowned biotech hub in the Boston area, whose concentration of 
resources and expertise in the life sciences led former Harvard’s president Summers to a 
comparison to fifteenth–century Florence in the arts (Schlesinger 2005). Hence – to resort 
again to Summers’ arguably far–fetched metaphor – similarly to the affirmation of 
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humanism in the Italian Renaissance, which greatly owed to the gathering and exchanges 
of a broad array of intellectuals in city–states politically autonomous towards the imperial 
and religious powers (Garin 1969), Harvard’s stem cell pursuit draw strength from the 
establishment of dense connections among the Boston area’s many research institutions. 
As explained by the co-director of the institute: 
We felt – I think not unreasonably - that if we bended together all of the institutions 
in Boston that would make... you know, if you stand alone it’s much harder than if you 
stand together. I think that turned out to be true, all the hospitals and universities joined 
together, which gave them a lot of strength and a shield or protection against some of 
what I would consider to be the political non-sense and the legitimate religious 
questions.  
Interview with co-director, HSCI 
 
Figure	  12.	  Harvard–affiliated	  institutions:	  1a	  Harvard	  Medical	  School,	  1b	  Boston	  Children’s	  
Hospital	  (photo:	  LM) 
The words of HSCI’s co–director underscore a key point concerning the guiding 
principle underpinning the establishment of the new institute: the quest for protecting the 
autonomy of Harvard’s scientific community from what are referred to as “illogical 
political interferences” (field notes 2014). 
In order to achieve this aim, and set the new organization up and running, further steps 
were needed other than recruiting and assembling a broad network of researchers, in 
competition with other prominent research centers such as Rudi Jaenisch’s Whitehead 
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Institute at MIT, where many of HSCI’s newly acquired and soon–to–be–famed stem cell 
scientists headed from (Matlack 2009). 
The first objective was the creation of a new independent ‘institute’ within Harvard, so 
as to benefit from the university’s wealth of resources and expertise, while also 
maintaining a formal degree of independence from its (varied and complex) internal 
funding mechanisms, bureaucratic structures and academic politics – the latter centered on 
the powerful figures of the deans in charge of each school (Golub 2007; field notes 2014). 
Conceived as a “virtual company inside Harvard” (field notes 2014), HSCI’s institutional 
configuration as an independent entity gave it leeway in setting its own research agenda, 
raising its own funds, while also reaching out more easily to external companies. As 
recalled by the co–director of the institute, and a former HSCI investigator: 
The first steps were to get permission from university to start a group of people who 
would work together, and create an institute. And an institute is not a common word 
within the university, it’s not a department. A department has the ability to make faculty 
appointments, but we didn’t ask for that. We wanted to have the ability to raise funds, 
hold meetings and organize research. 
Interview with co–director, HSCI 
HSCI is able to do things because it is not a department. It has a discretionary 
nature over its budget, it can build partnerships with the private sector, in a much more 
seamless way… 
Interview with former HSCI investigator 
Accordingly, a second fundamental step to preserve the autonomy of the institute was to 
provide it with an adequate level of funding. Thus, aside from the financing coming from 
grants awarded to investigators by outside agencies, which amounts to around 80% of the 
available resources, HSCI was able to set up a yearly pool of around $20 million, 
stemming primarily from philanthropic sources (field notes 2014). Interestingly, whereas 
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NYSCF’s financing owes primarily to its outreach in the financial world, HSCI 
significantly leverages on Harvard’s name recognition and its broad network of alumni: 
The university’s development office has a lot of connections with our alumni. When 
these development officers meet with their philanthropists, philanthropists ask them 
what’s going on at Harvard and many of them will say one of the most exciting things is 
HSCI.  
Interview with co–director, HSCI 
Finally, a third key objective pursued by the nascent institute concerned the 
establishment of an appropriate steering and governance structure, one that could protect 
its scientific autonomy, while also enhancing the effective collaboration among 
researchers. To this end, HSCI resorted to the appointment of an executive committee, of 
around ten members, entirely composed of scientists and clinicians working in various 
Harvard departments and affiliated hospitals, in charge of the institute’s budget, as well as 
of the scientific review of its projects. As explained by the co–director of the institute: 
[Members of the committee] have different scientific expertise and come from 
different hospitals in the system – and it’s that group that decides funding, and reviews 
the projects. That group decides everything. So even though I am a director, I do not 
make many decisions on my own. 
Interview with co–director, HSCI 
Furthermore, as a mean to increase the institute’s management capacity, and expand its 
outreach towards biotech and pharmaceutical companies, in 2006 HSCI appointed an 
Executive Director, a former Harvard MBA with extensive experience in the private 
sector, one that could add robust administrative expertise to the leadership of the institute. 
In particular, among the “trickier issues” that needed to be dealt with appropriately were 
the negotiation of intellectual property rights, how to coordinate investments in ongoing 
stem cell research in the various institutions, and how to jointly market and profit from the 
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discoveries (Golub 2007). Reflecting on his own appointment, the executive director 
explained:  
Think about HSCI as a virtual company working like a venture capital group. There 
are multiple aspects to the business of HSCI: raising money, deciding where to put it, 
communicating about it to our donors, manage the projects, work with faculty to 
sponsor research with disease foundations and companies, in some cases helping 
license work to company, connect people with venture capital (when they want to 
launch start-up)… 
Interview with executive director, HSCI 
As a whole, these measures were geared to enhance the scientific autonomy of the 
institute, and facilitate the seamless integrations of its different research components. Put 
in different terms, the establishment of HSCI’s governance structure was driven by the 
attempt to resurrect, reproduce, and attune to the 21st Century the conceptual template of 
an ideal 'Republic of Science' (Polanyi 1962). In light of the perceived "Bush siege" on 
stem cell research, the response of the Harvard scientific community was to re-enact and 
fortify a self-governing 'citadel of science', with an executive committee representing the 
Harvard schools and teaching hospitals in charge of the steering and agenda-setting 
prerogatives, so as to ensure that the process of knowledge-production abides by science's 
inner professional standards and systems of incentives, and scientists are empowered to 
carry their own independent, self-coordinated initiatives, free from interference from the 
political authority (Polanyi 1962).  
 
5.1.2 "The first enterprise at Harvard that captured the whole of Harvard". 
Other than supporting hindered lines of research such as hESC research, as its 
underlying "primary goal" HSCI was meant to accomplish the distinctively translational 
task of advancing a "disease-focused science" (field notes 2015), harnessing basic 
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laboratory research in the biology of stem cells for the development of new clinical 
treatments. As observed by an HSCI scientist: "it is not enough to have the Nature paper. 
Ultimately, you want to impact the disease" (interview with HSCI scientist).  
Differently from NYSCF's all-out translational thrust, however, a key objective of the 
institute is to "strike the right balance between basic science and converting that science to 
clinical applications" (field notes 2015). A right balance that, owing to expectations related 
to Harvard's illustrious history as a source of cutting-edge discoveries, as well as to the fact 
that "the Harvard system, because of its name and its 'culture', is probably more 
conservative clinically that lot of other places" (interview with Executive director, HSCI), 
involves, alongside explicitly translational programs, preliminary significant investments 
in basic science: 
For us, the focus on basic research is huge, most of our research focus is on 
basic science, on how to understand mechanisms and solve fundamental problems. 
There are other non-profit organizations that are much more focused on 
translation...  
Interview with executive director, HSCI 
More in detail, HSCI set out to implement funding schemes aimed at accomplishing 
three complementary objectives: to support, through targeted seed grants, early stage 
projects, oftentimes setting out unproven paths of research (“when you have a crazy idea in 
the bathtub – argues HSCI’s co–director – and you want to try it, you’ll never get a grant 
for that idea. So we use our philanthropic money, […] to use the seed grants to start new 
projects and to get projects going”); to establish a small number of core facilities 
comprising shared equipment and skilled personnel that no single laboratory could support 
on its own; and to advance several disease projects focused on elucidating the molecular 
etiology of, and developing treatments for, diseases in areas ranging from cancer to 
cardiovascular to central nervous system diseases.  
	   136	  
 
To realize its translational vision, HSCI adopted an organizational strategy that could 
"tie together" research models of different types of institutions, ranging from academic 
departments to funding agencies and the commercial sector, thus leveraging on their 
respective strengths, while "bridging the gap, both financial and scientific, left by these 
groups" (field notes 2015). Most prominently, it aimed at developing an "interactive 
culture" among Harvard-affiliated researchers and institutions, one that could overcome 
the one lab "silo" approach that has been characteristic of traditional research arrangements 
in biology (see e.g. Knorr-Cetina 1999), and one that evolved to become "the first 
enterprise at Harvard that captured the whole of Harvard" (field notes 2015; interview with 
Director of HSCRB department, Harvard University). As a former HSCI affiliate, and now 
director of the department of Stem Cells and Regenerative Biology at Harvard, went on 
explaining:  
The days of the gentleman-scientist working in the basement and coming up with 
great discoveries are gone. Now it's about large teams requiring the expertise of many 
people, especially if you want to move into the clinic... So, the notion of collaborative 
research is not new, but I think the types of questions that are left have really pushed us 
towards thinking in different ways and engage in highly collaborative research. That's 
why the institute was put in place. 
Interview with director of HSCRB department, Harvard University 
 
Differently from NYSCF's centralized model, HSCI was thus conceived on the basis of 
a distributed innovation model hinging on the interaction of heterogeneous actors holding 
complementary pieces of knowledge (Felt and Wynne 2007). For one thing, in devising its 
steering structure (see section 5.1.1), the leadership of the institute paid special attention to 
the creation of mechanisms that could promote synergies among the institute’s vast 
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number of researchers, who possess distinct disciplinary expertise and belong to different 
institutions. As explained by HSCI’s co–director:    
When you get a grant from the National Institute of Health it may be for three or five 
years; at the end of that time you either published a paper or not. We set up a different 
program where we had milestones and productivity. And while we may commit for three 
to five years, if you haven’t made any progress in the first couple of years, then we say 
we are not funding you anymore. Frankly, this ended up selecting through a different 
kind of researcher. It selected through a researcher who was a little less concerned 
about getting all the credit for themselves, because they had to work on a team, a little 
less concerned about being able to make every decision on their own without any 
oversight. In general, I would say, selected through people who would like difficult 
projects, that individuals cannot solve by themselves. I think it’s a fuzzy distinction but 
it’s different from the way science is normally done. 
Interview with co–director, HSCI 
Furthermore, in establishing its experimental structures, the underlying vision was that 
the best way to advance the field was not – differently from NYSCF – to accrue agency 
within a centralized laboratory facility, but rather to empower (by providing the missing 
connections and funding) those research structures that were already in place within the 
broader Harvard community, so as to being able to draw on an already existent, but left 
idle, set of resources, skills and expertise. As noticed by HSCI's executive director and the 
director of the department of Stem Cell and Regenerative Biology: 
What is peculiar about HSCI is that we are a virtual research organization, an 
administrative team. We are set up without our own labs and infrastructure, but as a 
way of taking the stem cell perspective across the different Harvard-affiliated 
institutions. 
Interview with executive director, HSCI 
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NYSCF not only does a fundraise (primarily within influential people in NYC, Susan 
has a good network of people who are very passionate about this field), but also has its 
own lab. HSCI does not have its own lab. I think this is a very interesting approach: 
they have their own internal lab. HSCI does not have its own research lab. It has the 
iPS Core Facility, but I don't think a lot of research, discoveries, is happening there. It's 
production of quality control, and facilitating research because of the ability to make 
and engineer these different cell lines… 
Interview with director of SCRB department, Harvard University 
 
 
	  
Figure	  13:	  HSCI	  as	  a	  virtual	  research	  organization	  (HSCI	  logo). 
 
5.1.3 Sustaining innovation in standardization practices: the iPS Core Facility. 
Such configuration is consistent with, and shaped by, a sustaining (rather than 
disruptive) model of biomedical innovation (Bower and Christensen 1995; Christensen 
1997), one that is geared to the development of experimental practices and technologies 
that, whether radical or incremental in character, are meant to be integrated within - rather 
than disrupt - established experimental technologies and practices. Other than in its 
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organizational structure, HSCI's sustaining innovation approach lends itself well to 
analytic scrutiny in the standardization practices designed and implemented within the only 
iPSC laboratory infrastructure it directly oversees, the iPS Core Facility.  
Established in 2008, in order to have a small team of highly qualified iPSC scientists to 
master the rapidly evolving reprogramming technology, and adopting in 2011 a fee-for-
service model, the iPS Core has been constructed within a service-oriented framework, as a 
way to "speed up the work in the Harvard network" by streamlining the provision of iPSCs 
and hence "take the burden off individual researchers" (interview with Head, iPS Core 
Facility) in performing routinary tasks (such as iPSC derivation, expansion, distribution) 
pertaining to the realm of "basic innovation" (Webster and Eriksson 2008). As explained to 
me by the head of the Core: 
As reprogramming techniques became more standardized, people were interested in 
having these reprogrammed cells, but, first, why should every scientist learn how to do 
them on their own, spending unnecessary time reinventing the wheel in their own lab? – 
and second, some of the leading scientists we have here were not interested in making 
iPSCs, but rather in using them for their research. 
Interview with Head of iPS Core Facility 
	  Figure	  14.	  iPS	  Core	  Facility	  at	  HSCI	  (Photo:	  LM)	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More to the point, the core facility model (Ernst and Young 2012; Cambrosio et al. 
2009) maintains some distinctive features that set it apart from NYSCF's standardization 
strategy. 
In the first place, the Core aims at implementing a ‘standardization on a customized 
basis’ approach, aimed at maintaining flexibility in the adoption of reprogramming 
methods and iPSC culture protocols. Rather than focusing on the scale-up of one kind of 
(emerging, and not yet stabilized) technology (something which could lead to a detrimental 
lock-in effect), the iPS Core aims at being able "to react quickly when new technologies 
come out", in order to meet the requirements of its customer base composed of (mostly) 
Harvard and non-Harvard scientists. The rapid inclusion of the new CRISPR/Cas9 gene 
editing technology among the services it provides is arguably the best testament to this. As 
the executive director of the institute said: 
If the iPS Core were within a company, its job would be to say: 'how to make as 
many iPS cells, as cheaply, and efficiently, and effectively as possible...' The key would 
be repeatability, and scale, and costs. Because we are in the artisanal production mode 
- think about the small shoe factories in Northern Italy compared to the shoe factories 
in China -, the key is to say: 'look, we can make iPS with different techniques, that work 
best in different circumstances; we can knock a gene in/out, if you need that...' So it's 
standardization on a customized basis. 
Interview with Executive Director, HSCI 
 
Moreover, insofar as the routinary process of iPSC derivation is accompanied by the 
continuous tinkering with newly published protocols, in order to probe their potential 
adoption, iPSCs are maintained as epistemic things (Rheinberger 1997), whose epistemic 
currency as yet-to-be-stabilized research objects is still preserved intact. And finally, the 
Core maintains a risk-adverse approach with regard to the adoption of untested, unrobust 
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technologies. In that regard, rather than creators of innovation, core facilities can be more 
aptly described as "consumers of innovation" (interview with scientist, iPS Core Facility), 
lagging, and not leading, in the development of innovative technologies. Said the director 
of one Core Facility in New York City, capturing a widespread modus operandi among 
core facilities, and contrasting it to that of NYSCF: 
I think that for me the strategy has been to linger at the back, and to let those at the 
bleeding edge let me know how it goes... instead NYSCF is on its own world in going 
out there and doing the risky stuff... 
Interview with Core facility director 
 
5.2 Notes from the field: the automation project. 
Other than adopting a fee–for–service model for its reprogramming and gene editing 
services, the iPS Core also operates according to a collaborative model, as it engages in a 
wide spectrum of collaborations with different types of institutions. Whereas in the former 
case its agency is bound by the requirements of its customers, in the latter case the 
interaction takes the form of an interactive process, whereby iPS Core scientists, drawing 
from their expertise, actively contribute to shape the evolution of the project itself.  
In particular, during the course of my fieldwork at Harvard in 2013 and 2014, the Core 
had been involved in three different collaborative projects. First, a NIH–sponsored, multi 
hub project aimed at deriving over 2700 iPSC lines from individuals involved at various 
stages in the Framingham Heart Study, one of the best characterized longitudinal 
epidemiological study for cardiovascular diseases and associated risk factors (Mahmood 
2013). Second, a project sponsored by a major pharmaceutical corporation revolving 
around the molecular characterization of neurodegenerative conditions by means of iPSC–
based models. Third, a NIH–sponsored project for the development of software–based 
automation of the process of iPSC colony selection.  
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The automation project (henceforth: AP), in particular, was highly revealing of the 
distinctive way in which the iPS Core operates, as well as the main differences that 
separates it from NYSCF’s endeavor, for it can be fruitfully contrasted with NYSCF’s 
implementation of its own automated system, the GSCA. In what follows, drawing from 
attendance to the five close door project meetings that took place during October 2013 and 
October 2014, as well as interviews conducted with the main actors involved, I thus 
provide a contextualization of the project and highlight some of its most significant 
features for the scope of this dissertation. 
 
 
5.2.1 A SBIR–propelled project. 
The AP started in 2012, following a three–year grant awarded by the NIH as part of its 
Small Business Innovation Research (SBIR) funding scheme.  
Based on a National Science Foundation (NSF) pilot program, initiated during the 
Carter administration, the SBIR program was established in 1982, with the signing of the 
Small Business Innovation Development Act by President Reagan. The program requires 
government agencies with large research budgets, such as the NIH, to provide a fraction 
(originally 1.25 per cent) of their funding to support small enterprises (Mazzucato 2013), 
thus “encourag[ing] domestic small businesses to engage in Federal Research/Research 
and Development (R/RandD) that has the potential for commercialization” (sbir.gov). In 
particular, since its inception the program has aimed to foster interactions between 
academic research centers and small companies, in order to stimulate technological 
innovation and increase private-sector commercialization of innovations derived from 
federal research and development funding, while also encouraging “participation in 
innovation and entrepreneurship by socially and economically disadvantaged persons” 
(sbir.gov). As noted by Mazzucato, the SBIR program has represented an instrumental, 
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albeit low visible, part of the ‘entrepreneurial strategy’ of the US federal government, 
providing support to a vast number of high–tech start up firms: 
The SBIR program fulfils a unique role in this new innovation system, because it 
serves as the first place many entrepreneurs involved in technological innovation go to 
for funding. The program, which provides more than $2 billion per year in direct 
support to high-tech firms, has fostered development of new enterprises, and has guided 
the commercialization of hundreds of new technologies from the laboratory to the 
market (Mazzucato 2103). 
 
In the specific case of the AP, the SBIR grant propelled the establishment of a 
collaboration between the iPS Core, a small bio–imaging company from the North–West 
of the US involved in software development for image–based decision solutions, and a 
major Japanese multinational corporation, which became involved in the project because 
of its product–development capacity (for the SBIR grant mandates, as a main requirement, 
the development of a commercializable product)1.  
Overall objective of the AP was the development of a software–based, bio–imaging 
system that could support automation of the process of pluripotency assessment and iPS 
colonies selection (see chapter 2). More to the point, by capturing real–time images of the 
cells being reprogrammed at specific intervals during the first three weeks of the 
reprogramming process, the bio–imaging system was geared to accomplish a twofold task. 
First, to distinguish the fully reprogrammed colonies of iPSCs from those partially 
reprogrammed (which are thus not pluripotent). Second, to predict such outcome at an 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Notably, at the beginning of the project the Japanese corporation owned a 30% stake in the small 
company, and thus had close connections with it, and an inherent interest in the latter’s success in 
developing a marketable product. As the project evolved, however, the corporation decided to 
pursue a different path, and started, in parallel with the small company, the development of a 
competing technology of its own. 	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earlier time point than the standard time (one month) needed by scientists, thus allowing 
the anticipation of the colony selection procedure (see chapter 2).  
 
Figure	  15.	  Software–based	  pluripotency	  assessment. 
 
Furthermore, issues of consistency were also at stake, for the automated system was 
predicted to produce less line–to–line variation in expression of pluripotency markers, with 
respect to that entailed by the standard visual inspection and manual selection of colonies 
by experienced scientists. Consider for instance the following exchange occurring at a 
project meeting: 
iPS Core leader: you'll see how there is really much more difference among persons 
than with the machine. It's like having in one case one umpire calling the strikes, 
whereas if you have different umpires calling the strikes, you'll see how they tend to call 
the strikes in different ways. Even though it should be one strike zone, everyone has got 
its own strike zone. 
Harvard scientist: …exactly. The expert person cannot be everywhere, [the head of the 
Core] cannot be everywhere, and do all the reprogramming on her own, but the 
machine can in fact be everywhere! That's the difference. 
Moreover, the specific objectives for the different participants in the AP differed. From 
the perspective of the iPS Core, the reason for engaging in collaboration with the small 
bio–imaging company was to leverage on the latter’s expertise in order to develop an 
From manual to automated derivation of iPSCs"
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automated system, potentially suited for adoption by the Core in its daily operations. The 
rationale for undertaking the path of automation was twofold, and related to the need to 
decrease hands–on costs while increasing throughput, thus achieving an economy of scale 
(by the end of 2014 the Core was still being partially subsidized by HSCI funds), and to 
establish an experimental infrastructure geared to keep up with the large scale studies that 
increasingly dominate the landscape of iPSC research. In the words of the leader of the iPS 
Core: 
More and more groups are contemplating larger and larger studies, and if we don't 
have the capacity to engage them for those studies, then our Core will be left in sort of 
the Medieval time of iPSC production, we won't be a Core that front edge these things 
any more. 
When you automate and you have people that start to make a very consistent product 
like this, is not going to be cost-effective any more to do it in house, and you are usually 
producing something of usually substandard value. So because how cheap and easy is 
that someone else is making it, optimizing scale, if you doit manually  in your lab it 
would be like Stone Age, you know, trying to carve things with stones… So if you build 
a better automation, a better process, you are more efficient, you are going to increase 
the stream of revenue you generate, so that you can make over the course of a year 
5.000 cell lines, and then it turns to 10.000, and that increase the revenue […]. I think 
this is the main reason, driving down costs and increasing capacity. It's true for our 
Core, too.  
Interviews with iPS Core leader 
For the small company, and its Japanese partner, the goal of the project was, first, to 
establish links with a world–renown iPSC lab, Harvard’s iPS Core, thus being able to rely 
on SBIR grant money to test and develop one of their products. Explained in November 
2013 the main representative of the small company involved in the project that:  
	   146	  
So what's pushes the envelope... this collaboration was lubricated by NIH (through a 
SBIR grant), and we discovered from our business model that it is really an excellent 
way to do business, the RandD money gets us into top labs, when we get exposed to top 
companies, like [multinational corporation] and Millipore. We know how to write 
grants, we have collaboration with [multinational corporation], so now we are able to 
propose grants to the best academic labs in the country, and the money from the 
government facilitates this collaboration. 
Interview with vice president, small company 
The second objective of the small company was, consequently, to leverage on the iPS 
Core’s expertise in order to test for a new bio–imaging system to be commercialized 
among iPSC research laboratories worldwide. This product was envisioned as not only 
meeting the growing demand of a growing market, but also as facilitating the very 
consolidation of the market itself: 
In the future - and the future is now - people will need to create lot of cells lines. In 
the process of automating the cell line production, a high value step is the selection of 
the fully reprogrammed clones and the identification of those clones (it is the most 
technically challenging aspect of stem cell scientists). Then, colonies need to be 
characterized, which is extensive. So, rationale of the project is, what if we can tell 
through video image analysis which one to reprogram. If you have a computer which 
can tell this one is fully reprogrammed so you can pick it, it would be a much simpler 
process. 
[…] The reality is, it takes a lot of effort to make something work well. Now we want 
to get something that works really robustly and reliably, and this is something not 
trivial. What we are doing is paradigm changer. If we manage to get it, the whole field 
will shift and say yes, we want microscopy, and all of the sudden we'll have lot 
customers. We have proved the principle, now we have to prove the product. If it works 
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for Sendai...it won't be optimal product, but there will be customers, there will be lot of 
demand, people will take you seriously, and you'll have a business (now it's just 
research). 
Interview with vice president, small company 
 
5.2.2 The project inception: negotiating requirements. 
Differently from NYSCF, that in reason of its sheer financial capacity developed its 
own automated infrastructure internally, according to its own requirements (and by 
retaining the services of an engineer from the leading company in the field of cell–based 
automation, Hamilton Robotics, who, after extensive collaboration with NYSCF in the 
initial set–up phase of the GSCA, was hired by the organization in 2012), the way the AP 
evolved owed to its collaborative nature among different actors within the framework of 
the SBIR grant.  
 
For one thing, at the beginning of the AP, iPS Core scientists and representatives of the 
company had different ideas concerning the optimal project outcomes. Notably, two 
different approaches emerged with regard to the functions to be performed by the bio–
imaging software. For iPS Core scientists the usefulness of the new system relied, 
consistently with its standard experimental practice, on its ability to predict whether a cell 
colony in formation would have actually become a colony of pluripotent cells. For such 
purpose, a binary outcome was all that the system should have provided: 
Head of iPS Core: What you really want is [the] difference between pluripotent/not 
pluripotent cell, yes or no. Forget all the rest... 
For the small company, it was instead the system’s ability to predict the colony 
differentiation potential, i.e. its amenability to be differentiated into a specific cell type of 
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interest, that was seen as the main selling point to potential customers. As the company’s 
vice president explained to me: 
If you can understand things that humans cannot understand… that's nice if you are 
trying to sell something! Those guys can pick [colonies] very well at three weeks, but if 
all of a sudden I can tell them "if you use my software, I can give you the colonies that 
are a bit better in expansion... Given that these ten colonies are iPSCs, I can tell you 
which ones are gonna be better to be differentiated…” this type of things is not easy to 
see by eye, so it gives my software a good reason for someone to purchase it. 
Interview with vice president, small company 
These contrasting views about the issue surfaced repeatedly during project meetings. 
Consider for instance the following exchange: 
Head of iPS Core: we usually wait for picking until the end of the reprogramming, to be 
more sure, and we look at the morphology of the cells. But if the software can tell us 
that a colony is a good one after two weeks, we can pick the colony then! 
Company’s VP: In addition, we can also give you a scorecard. The idea is, with regard 
to the product we want to sell, other than say yes or no with regard to pluripotency, it 
can also tell us about how the cell will differentiate…  
Head of iPS Core: no, it must be yes or no! For the software, we just want to know the 
pluripotency, yes or no. 
Company’s VP: Right, but the score can tell us something more… 
Head of iPS Core: it must be yes or no! Here at the Core we do the differentiation into 
the three germ layers to assess pluripotency. Looking at the differentiation bias is a 
completely different thing, it could be useful for users, but it is not what we are 
interested here at the Core, it’s a different type of info… 
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Eventually, the issue was settled by opportunity and marketing considerations. Over the 
course of the project, representatives from the company and iPS Core scientists 
progressively converged on one point. The system had to meet two requirements. First, it 
should have been amenable to being commercialized to a wide variety of customers 
(mainly research labs); second, and consequently, it should have been something “radically 
simpler” (interview with head of iPS Core) than NYSCF’s GSCA – and that entailed 
dropping the differentiation prediction part, due to the burdensome data processing and 
dedicated equipment needed to make it workable for customers. In the words of the small 
company’s VP: 
Early automation systems, which you see at NYSCF, are fairly complicated - lot of 
handling of the cells, going from plaiting system to suspension to FACS sorting, using 
fluorescence markers… So, practically speaking, if we could tell what are the good 
colonies just by watching how they form, we will be able to engineer a much simpler 
automation system, which would not require specific equipment, could be a lot cheaper 
than the first generation system and be much more easily commercialized. It's a race! 
Interview with vice president, small company 
 
5.2.3 Building momentum in the project. 
Continuous references and comparisons with NYSCF’s GSCA were a constant 
throughout the project. In many significant respects, the automated system being 
developed differed considerably from that of NYSCF, and programmatically so. 
In the case of NYSCF, the automated system was the cornerstone of its centralization 
strategy, aimed at accruing agency within the organization. In light of its sheer complexity 
(e.g. the nine modules of the system occupy several rooms in NYSCF’s laboratory) and 
operating costs (all its components are customized), the GSCA was not meant to be 
integrated within standard experimental practices in the field of iPSC research. Rather, as 
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we have observed with regard to the introduction of a new protocol for iPSC derivation, 
the GSCA gives material currency to NYSCF’s disruptive innovation approach, for it 
introduces new experimental standards of its own. As remarked by the CEO of the 
organization: 
It is a huge amount of resources to do this, so what we don't want to do is to have 
something like VHS and Betamax, these competing platforms. What we would like to do 
is to have this automation be the automation that is used in the field. 
Interview with CEO, NYSCF 
On the contrary, integration was the keyword for participants in the AP, whereby the bio–
imaging system was being developed so as to meet a twofold requirement: the widespread 
commercialization of the bio–imaging software itself among iPSC research laboratories, 
and the consistency of the cell lines being reprogrammed by means of the bio–imaging 
technology with established standards in the field, in order to meet the requirements of the 
Core’s customer base, and thus allow its adoption by the Core in its routine operations. 
Notably, the latter requirement of integrating the automated system into the Core’s 
standard experimental practice led to the development of a bio–imaging software aimed at 
mimicking as closely as possible the operation of visual selection performed by skilled 
scientists. As iPS Core scientists argued in the following exchange: 
iPS Core scientist 1: If you have the software that can do what you can do with 
your eyes it would be great! 
iPS Core scientist 2: …The machine is a bit like us, hopefully better at recognizing 
earlier. 
Accordingly, whereas NYSCF’s approach resulted in the development of a magnetic 
cell sorting system, that disaggregates the colony of cells into single cells unit (see 
previous chapter), the bio–imaging software being developed in the AP relied on the 
quantification of morphological parameters typically assessed visually by scientists, such 
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as the density of cells, and the speed of cell growth, that could be predictive of pluripotent 
colonies formation.  
Furthermore, this translates, in experimental terms, with the preservation of the standard 
‘clonal’ reprogramming of colonies (whereby, to physically select iPSCs, suitable colonies 
are picked up with a pipette and transferred to a new culture well for subsequent culture 
expansion, in which the ‘progeny’ is derived from the same parental cell, and is thus 
clonally derived2). In the case of NYSCF’s GSCA, on the contrary, colonies are 
disaggregated, cells are individually sorted for pluripotency markers, and finally pooled 
together leading to a mixed (and thus polyclonal) population of cells (for ‘progeny cells’ 
are not derived from the same clone). Observed the leader of the iPS Core in the course of 
a project meeting: 
iPS Core leader: The main claim of NYSCF is standardization. But if it's full 
automation, you have to make concessions. Their population changes over time, 
because it's not clonal. Over time, once clones are stabilized, they are more stable, and 
that is because one clone grows a little bit faster, and after a while it takes over the 
whole population. If you go clonal, you already know that, that each clone is different, 
and that's why you compare more clones! NYSCF sold to half of the world that their 
platform is more consistent, but that's not really true. Hence: if you guys can manage to 
do this, your system would be definitely better. 
HSCI scientist: …this is what NYSCF says, that the robot is better than the experts at 
picking. 
iPS Core leader: The great pushback against NYSCF is that their system is non-clonal, 
and people don't like that… So there is also another possibility for the system you are 
developing, which is of selling it to them! [laughs] 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2 For a comparative analysis of clonal vs non clonal reprogramming, see Willmann et al. 2013. 
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 The Global Stem Cell Array 
(NYSCF) 
Bio–imaging software 
(Automation Project) 
System development Internal Collaboration within SBIR 
framework 
Automation of manual 
protocol 
Protocol reconfiguration 
(magnetic cell sorting) 
Mimicking visual assessment 
(morphology–based) 
Reprogramming type Single cell (non clonal) Colony of cells (clonal) 
End product(s) iPSCs and differentiated cells    – iPSCs 
   – Bio–imaging software 
Stages to be automated  Full automation (from iPSCs 
derivation to differentiation) 
Pluripotency assessment 
(iPSC colony selection) 
Table	  2.	  Main	  differences	  between	  NYSCF’s	  GSCA	  and	  automated	  system	  being	  developed	  in	  the	  
AP.	  	  
5.2.4 The end of the project. 
Table 1 provides a synoptic overview of the main differences between NYSCF’s GSCA 
and the system being developed in the AP. As we have observed, not only the developing 
process diverged in significant ways, entailing the involvement of different constituencies 
on an equal footing; but also, the need for participants to negotiate requirements was 
brought to bear on the project’s outcomes.  
Ironically, in the end, the two requirements of producing a widely commercializable 
system, and also one that could be easily integrated in standard scientific practice, thus 
meeting the needs of iPS Core scientists, proved to be conflicting. For the need to design a 
system simple enough to be amenable to widespread commercialization among iPSC 
scientists, was also the very reason that could potentially undermine adoption by the Core. 
Let me elucidate this point by means of comparison. 
The sheer complexity of NYSCF’s system, that which obviously hinders its 
commercialization as a product in se, was also what greatly enhanced its usability. Not 
only is GSCA’s cell sorting system able to predict iPSC’s differentiation propensity; also, 
it works in conjunction with a robotic handler that fully automates the whole operation, 
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without human intervention, thus greatly streamlining the process of iPSC derivation, 
expansion and differentiation. 
The system being developed in the AP, on the contrary, was not meant to predict iPSCs’ 
differentiation propensity, for this would have required ad hoc instrumentation, to perform 
the data analysis, that is not widely available in the standard iPSC research lab; also, it was 
not supposed to have a robotic machine for picking colonies, for this would have required 
integration with specific instrumentation similarly not available in iPSC labs. As a whole, 
while these two features were geared to facilitating its adoption by iPSC research labs, the 
latter in particular was, at the same time, causes of concerns for iPS Core scientists. 
Consider the following exchanges: 
iPS Core scientist 1: It took a very long time to do something that we do very quickly... 
without a robot for picking, this technology will be useless! 
iPS Core scientist 2: It took us a week, once we received the images of the colonies to 
pick from [the company], to… actually pick them! It is difficult, because you have to 
look at the image, then look for the colony in the Petri dish, but then during the time it 
takes for the software to do the analysis the colony has grown, it has moved… and then 
you have to find it… 
Head of the Core: it’s hours and hours to do what usually we do in two seconds! 
 
As of June 2015, participants to the project are confident of having obtained enough 
data to support the claim that the software being developed is able to predict iPS colony 
formation in advance than the standard month needed for reprogramming. Building on 
that, they are working on putting together a second grant application in order to further the 
development of their automated system into a viable product (field notes 2015). 
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5.3 Conclusions. 
In this chapter, I have attended to the progressive entrenchment of stem cell research at 
a bastion of American academic research, Harvard University, by focusing on the 
establishment of the Harvard Stem Cell Institute and the iPS Core facility. While similarly 
advancing a translational stem cell research agenda, HSCI and the iPS Core maintain in 
many significant respects a different approach from the one, outlined in the previous 
chapter, embodied by NYSCF. Whereas NYSCF, driven by philanthropic constituencies, 
set out to adopt a disruptive mode of innovation, HSCI’s endeavor, governed by some of 
the most prominent scientists in the field, is aimed at sustaining established research 
practices in the field of stem cell research. The two institutions’ different approaches to 
automation, I contend, nicely capture and epitomize these differences. 
I will reflect more in depth on these points of divergence – as well as some other points 
of convergence – in the concluding part of the dissertation. Before I do so, I shift from the 
American to the European context, and move to the third platform on which this 
dissertation focuses, the European Bank for induced Pluripotent Stem Cells. 
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Chapter	  6.	  The	  European	  Bank	  for	  induced	  
Pluripotent	  Stem	  Cells	  
 
 
The European Union is undergoing profound transitions. Strategic geopolitical 
challenges, ranging from the disputed trans–Atlantic trade agreement to the rise of intense 
political instability within and across its borders; grandiose yet seemingly ineffective 
programs to prop up its ailing economy vis–à–vis a largely self–inflicted and unrelenting 
crisis; and ongoing contestations about the lack of democratic credentials of its founding 
treaties and institutions: all these elements define the contours of a critical identity 
challenge.  
This appears to be especially true with regard to the current economic crisis, where a 
look at the statistics makes an uncomfortable reading. Unemployment rates within the 
European Union soared by more than 4% between 2008 and 2013 to reach the 11% 
threshold (12.1% in the eurozone), meaning that a staggering number of 26 million people 
are forcibly out of work in Europe at the moment (as of 2014). In countries like Spain, 
Croatia and Greece (with Italy and Portugal not far behind), more than half of the 
population under 25 is currently unemployed. As of 2011, one in four people in the EU 
experiences poverty or social exclusion, with persistent wide inequalities in the distribution 
of income across and within the member states (source: Eurostat). The economic crisis 
have made its toll felt on health, too: the strained Southern-European countries, Greece in 
particular, are witnessing outbreaks of HIV and infectious diseases (due to impaired access 
to care and prevention), and rise in prevalence of psychological problems and suicides 
rates (Karanikolos et al. 2013). Moreover, what numbers are not able to capture, and in fact 
	   156	  
often conceal under their detached objectivity, are the many disrupted lives, the nihilistic 
sense of unfulfillment, and the disbelief and anger pervading whole generations.  
Once a bastion of wealth and well-being, the European Union is now facing 
unprecedented struggles, threatening to turn it into a state of disarray. Most notably, what 
is evidently at stake, in the present situation, is not only its prosperity and global 
geopolitical role, but also, and more profoundly, the still unresolved issue concerning its 
identity as a supranational political entity: what does ‘Europe’ refer to, and what are the 
sources of ‘Europeness’? 
 
Unsurprisingly, especially for a continent that proclaims to embrace a knowledge-
driven economy (as for the ‘Lisbon Strategy’, 2004; and the ‘Europe2020 Strategy’, 2010), 
the ubiquitous presence of science and technology dominates the rugged landscape in 
which political agency is deployed, contested and renegotiated. Most notably, the life 
sciences and biotechnology, in reason of the innovation potential they entail, are 
increasingly being recruited to frame the basic elements of the supranational order–in–the–
making.  
In particular, both the intertwinement of biotechnology and capital that goes under the 
rubric of ‘bioeconomy’, and the push to the accelerated commercialization of laboratory 
breakthroughs (that represent, in many respects, two sides of the same coin), have emerged 
as linchpins around which the new supranational socio–political–economic order is 
imagined, negotiated and enacted. Conspicuous testament to this is the launch of the 
‘Bioeconomy for Europe’ strategy in 2012, which is geared to leverage the ”set of 
economic activities relating to the invention, development, production and use of 
biological products and processes” to “comprehensively address inter-connected societal 
challenges such as food security, natural resource scarcity, fossil resource dependence and 
climate change, while achieving sustainable economic growth” (European Commission 
2012); and – most prominently – the mobilization of health– and biotechnology–related 
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programs in the Horizon2020 funding scheme, which is a mainstay of the ‘Europe2020 
strategy’ (with nearly €80 billion of funding available over 7 years, from 2014 to 2020, of 
which the life sciences hold the lion share), aimed at fostering innovation, by “taking ideas 
from the lab to the market” (EC 2015), and thus securing Europe's global competitiveness.   
 
At the same time, while undoubtedly growing in relevance in recent times, the 
mobilization of biotechnology as an important component of the European institutional 
architecture has deeper-rooted origins. 
As argued by Gusmão (2001), the incremental process of European integration is 
strictly related to the construction of a ‘European research community’, through the 
progressive implementation of various structures and funding schemes that have propelled 
the emergence of research strategies that extend across national frontiers. While in fact, 
Aguilar and colleagues (2013) similarly observe, in the mid–1970s there was no such a 
thing as a common ‘research and innovation policy’ at the European level, efforts 
spearheaded by a relatively small number of individuals within the EU institutions led to 
the launch, in the early 1980s, of the ‘Biomolecular Engineering Program’ (1982–1986), 
which, in turn, paved the way to the consolidation of a ‘European supported 
Biotechnology’. In a similar vain, Sheila Jasanoff (2005) contended from an STS 
perspective that the contested consolidation of Europe as a unified political space (in spite 
of the opacity of most of its technocratic institutions and the lack of an 'imagined 
community' (Anderson 1983) of European citizens withstanding the efforts at integration) 
owed not only to major institutional developments, but also to the identification of 
biotechnology as a key area for policy intervention, and the contextual framing of a 
'European way’ to biotechnology. "Some twenty-five years of European biotechnology 
policies", wrote Jasanoff in 2005, should be seen "as both shaping and shaped by European 
politics". On the one hand, she argues, "like nineteenth-century nation-states, the EU has 
found it necessary to specify the problems it wanted to solve in order to consolidate and 
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legitimate its political existence", with those issues revolving around the regulation of 
biotechnology figuring prominently among them. Conversely, to address the “seemingly 
technical question” of the stabilization of biotechnology, ”it proved necessary to address 
what kind of union Europe was - or wanted to be - both in relation to its members states 
and as a player on the world stage“ (Jasanoff 2005).  
 
Against this backdrop, in this chapter I seek to provide an empirically sensitive account 
of how a specific instantiation of the push to biotechnology–driven innovation, namely 
translational induced Pluripotent Stem Cell research, is enrolled and mobilized in the 
current process of renegotiation of the ‘European’ socio–economic–political identity.  
In particular, I will focus on the revealing case study of the European Bank for induced 
Pluripotent Stem Cells (EBiSC), established in 2014 within the framework of the 
Innovative Medicines Initiative (IMI). Drawing from documentary sources and recent 
ethnographic fieldwork, I expound how, through the mobilization of an innovative 
biomedical platform, structured around a public–private partnership model of governance, 
the stabilization of a new and enticing field of research is co-produced along with the 
structuring of a significant portion of the European science policy. On this basis I then 
move to interrogate how the priorities of this program construe an envisioned European 
(public) good with its attending beneficiaries, through a distinctive choreography of actors 
and participatory resources. 
 
6.1 The Innovative Medicines Initiative. 
The European Bank for Induced Pluripotent Stem Cell was established, in 2014, within 
the framework of the Innovative Medicines Initiative (IMI). In many significant respects, 
the latter decisively influenced the development of the former, and thus deserves its fair 
share of analytic scrutiny. 
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IMI was established in 2008 as a public–private partnership (PPP) – the world’s largest 
in the life sciences – coupling the European Commission and the European Federation of 
Pharmaceutical Industries and Associations (EFPIA), the trade association of 
pharmaceutical corporations operating in Europe. By fostering collaborative endeavors 
between academia and the pharmaceutical industry, the fundamental aim pursued by IMI, 
very much in line with the core of the translational narrative, has been to "speed up the 
development of, and patient access to, innovative medicines, particularly in areas where 
there is an unmet medical or social need" (IMI 2015).  
IMI’s establishment owes to the legal act on IMI, adopted by the European Council in 
December 2007, and published in the Official Journal of the European Union in February 
2008 as a Council Regulation setting up the ‘Joint Undertaking for the Implementation of 
the Joint Technology Initiative on Innovative Medicines’ (EurLex 2008; Kamel et al. 
2008). In light of such provision, IMI was set up with its own legal entity based in 
Brussels, in premises situated within the Ixelles quarter, a stone’s throw from the offices of 
the European Commission. 
 
Figure	  16.	  IMI	  Headquarters,	  Ixelles,	  Brussels,	  Belgium. 
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Historically, the development of IMI is rooted in the European Technology Platforms 
(ETPs), launched within the 6th Framework Program (FP6, 2002–2006) of the EC, with the 
aim of establishing industry-led stakeholder fora that could devise and develop research 
and innovation agendas at EU and national level to be supported by both private and public 
funding (EC 2015a). A first step in the set up of collaborative endeavors between 
institutional and private actors, the ETPs further led to the establishment, within the 7th 
Framework Program (FP7, 2007–2013), of the Joint Technology Initiatives (JTIs). 
Cementing a more formal partnership between the EC and the industry of a given sector, 
the JTIs were a means to implement the Strategic Research Agendas (SRAs) of a limited 
number of ETPs, whose scale and scope of the objectives required a dedicated governance 
mechanism, that the various ETPs were not able to provide (EC 2015b). Stemming from 
various pilot projects launched within FP6, IMI was formally launched as a JTI in 2008. 
As observed by an IMI representative: 
IMI was a bet, something absolutely innovative in the political landscape of the time, 
in the relationship between industry and the EC. Apparently, IMI had a great return, so 
much that the EC wanted to invest more. There was a lot of interest towards IMI. IMI 
strived to obtain visibility and credibility, and apparently, today, that goal has been 
reached. Possibly, among the JTIs, IMI is the one that reached the higher visibility, 
which was among the key objectives set forth by the governing board of the EC and 
EFPIA. 
Interview with IMI representative 
Notwithstanding its continuity in scope and governance, the development of IMI 
occurred in two distinct phases. The first phase was the so–called (retrospectively) IMI1, 
which lasted from 2008 to 2013, and coupled in collaborative endeavors various academic 
institutions and EFPIA–members companies. Within the framework of IMI1 around 40 
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collaborative projects, for the most part still ongoing, have been launched (EBiSC being 
one of them), in areas spanning from antibiotic resistance to cancer. Overall endowment of 
the program was €2 billion – €1 billion each from the European Union and the 
pharmaceutical industry through EFPIA. Crucially, as I will expound below, while the 
public contribution is in cash, the contribution of the industry occurs through ‘in kind’ 
provisions. That is, EFPIA members involved in IMI projects contribute to the overall 
budget by providing their own equipment, resources and staff time.  
Building on the experience of IMI1, IMI2 was launched in 2014, within the framework 
of Horizon2020, with an increased overall endowment of €3.3 billion, and a prolonged 
timeframe of six years (it will last until 2020). While for most parts it follows in the 
footsteps of the previous program, IMI2 maintains two important differences with respect 
to its progenitor. First, its projects are more translation–oriented, and cover areas of 
research that are closer to clinical application (thus shifting the projects’ focus from 
biomarkers, data management, pre-clinical stage to proof-of-concepts clinical 
investigations, patients recruitment, phase II/III trials). Second, it involves the added 
participations of actors other than academia and the pharmaceutical industry, such as small 
and medium enterprises (SMEs) and non–profit organizations. 
 
6.2 IMI’s translational goals. 
The overarching strategy of IMI1 was outlined in a Strategic Research Agenda (SRA) 
of IMI (SRA of IMI 2005), which was developed since 2005 by the Research Directorate 
of the EC and EFPIA through consultations that included stakeholders such as academic 
scientists, regulatory authorities and patient groups (Kamel et al. 2008). The scope and 
goals of IMI2 were similarly defined through the issue, in Spring 2014, following a similar 
path of consultations, of the Strategic Research Agenda of IMI2 (SRA of IMI2 2014).  
While framing issues in slightly different ways (whose detailed analysis transcends the 
scope of this dissertation), the two agendas advance largely coinciding priorities. In 
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particular, both re-produce and articulate a well establish “discursive code” (Gottweiss 
1998) the ties together the acceleration of clinical translation to industrial growth and the 
capitalization of the biotechnologies, where the urgency for action at EU level stems from 
a purported lag vis-à-vis the US: 
The mission of the Innovative Medicines Initiative (IMI) is to contribute to creating 
biomedical research and development (RandD) leadership for Europe to benefit 
patients and society. To this end the two key aims of IMI are to support the faster 
discovery and development of better medicines for patients and to enhance Europe’s 
competitiveness (SRA of IMI). 
The United States of America remains dominant in the field of health and life 
sciences. The US therefore remains an attractive destination for researchers resulting 
in the ‘brain drain’ from Europe. The rapidly expanding science base of emerging 
economies such as Brazil, China and India further exacerbates this issue. It is therefore 
essential that Europe continue to drive innovation in order to remain competitive in 
biomedical research (SRA of IMI2). 
As the primary means to achieve this twofold objective, the SRAs point to the need of 
an organization gearshift centered on the establishment of linkages among public and 
private actors, and the design of a governance model, the PPP, that builds on the seamless 
flow of knowledge between the academic and industrial domains.  
Hence, IMI represents a paradigmatic instantiation of organizational innovation 
implemented to accelerate the pace clinical translation (see chapter 1). As such, it follows 
in the footsteps of similar initiatives pioneered in the US a few years earlier. In 2004, 
following publication of an influential report on Stagnation/Innovation, the FDA launched 
its Critical Path Initiative, as a means to implement public-private partnerships (PPP) to 
share data, expertise, and resources in order "drive innovation in the scientific processes 
through which medical products are developed, evaluated, and manufactured" (FDA 2004; 
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Goldman 2012). To this end, the C-Path Institute was created. An Arizona-based non-
profit body, the institute was meant to support this initiative by fostering collaborations 
between industry, academia and regulators. Funding sources were varied and included 
grant funding from the FDA, fees from participating member organizations, donations 
from private and philanthropic organizations (Goldman 2012). 
Around the same time, as an outgrow of the NIH Roadmap (analyzed in chapter 1), the 
NIH initiated its Public-Private Partnership program, with the goal of developing an 
advisory support with various non-governmental organizations, such as industry, 
foundations, and advocacy organizations, in setting up complex, multi-sector arrangements 
oriented to the acceleration of translation of laboratory research findings. 
 
6.3 The rise of Public–Private Partnerships as public policy tools. 
Enjoying remarkable acclaim in both official and scholarly circles, Public-Private 
Partnerships gathered momentum in the political milieu of the 1980s, and have since 
become a widespread public policy tool, increasingly endorsed at the EU level (Kinnock 
1995), to structure relationships between the public and private sectors. Normatively, the 
implementation of PPPs draws from two conceptual and ideological referents. 
First, PPPs are frequently viewed as epitomes of the neoliberal turn of the 1980s, when, 
under the ascendancy of the Thatcher and Reagan governments in the UK and the US, 
free-market advocates and conservative politicians joined in common cause against the 
liberal welfare state, promoting a marketization agenda consisting of market promotion 
and state-shrinking provisions (i.e. public asset sales, outsourcing, divestitures) (Starr 
1998; Harvey 2005). 
However, while at first sight the implementation of PPPs might appear as a by-product 
of the privatization movement, aimed at stretching one sector by shrinking the other, its 
relationship with it is actually more nuanced.  
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For one thing, partnerships often represent a strategic fallback option, in areas where 
full privatization seemed less tractable (for instance due to technical problems attending 
the assignment of property rights), feasible or even desirable (as it is the case with the 
capital-intensive projects of the biomedical sector). As Linder notes (Linder 1999):  
 [PPPs] have been viewed as a retreat from the hard-line advocacy of privatization. 
From this perspective, they serve a strategic purpose, enlisting the support of more 
moderate elements that are less opposed to state action on principle. Partnerships are 
accomodationist; they hold back the specter of wholesale divestiture and, in exchange, 
promise lucrative collaborations with the state. 
Moreover, the hallmark of PPPs is cooperation, not competition. As such, the 
establishment of partnerships maintains a key difference from outright privatization: rather 
than shifting the boundaries of the public and the private, with the former inevitably ceding 
ground to the latter, PPPs set out to blur them, eliding “demarcations that defined roles and 
set the rules of engagement between business and government since the Progressive Era” 
(Linder 1999). Hence, partnerships remove the adversarial character of the public-private 
interaction, and confound the points of reference defining this binary separation (insofar as 
they require actors from each sector to adopt points of view that used to define the 
identities of their counterparts, and, in so doing, to redefine their own identity). 
Accordingly, as Linder argues (Linder 1999): 
“to say that partnerships are yet another anti-liberal effort to shrink the state by 
privatizing its functions is to misconstrue the significance of the partnership idea. [... 
F]iguratively stretching one sector by shrinking the other simply no longer applies (if it 
ever did) because the meaning of the sectors themselves, through the partnership, is 
shifting.”  
Therefore, as a number of scholars have observed (Ferlie et al. 1996; Joldersma and 
Winter 2002; Skelcher 2005), PPPs are inherent hybrid entities, and, as such, they 
	   165	  
represent a paradigmatic instantiation of the socio–economic hybridity that defines 
biomedical platforms (see chapter 3). As “contingent settlements between plural 
institutional logics within one organizational entity” (Skelcher and Smith 2013), not only 
do PPPs combine the features and organizing principles of public and private sector actors; 
more radically, they develop a “blended hybrid model that adapts or moves beyond 
[them]” (Skelcher and Smith 2013, italics mine).  
 
A second normative influence on the design and implementation of PPPs comes from 
the management prescriptions coalescing under the New Public Management rubric (which 
in itself largely draws from the same neoliberal ideological background) (Pollit, van Thiel 
and Homburg 2007).  
Conceived as one among a number of management reforms (such as the development of 
performance indicators and result-oriented processes, the disentangling of administration 
from policy, the implementation of contract-like relationship, the adoption of a client-
service ethos), partnerships are seen as a tool that could normalize the governance of the 
public sector on private sector models. Exposing the public sector to the market constraints 
that “discipline” the functioning of businesses, so the argument goes, would change the 
way the former functions, while promoting efficiency gains without divesting from it 
altogether.  
Seen from this perspective, however, the collaboration “resembles more of a mentoring 
relationship than a joint undertaking. The flow of know-how appears asymmetric. 
Government managers are expected to become more like their business counterparts, rather 
than viceversa” (Linder 1999). 
 
While the sets of proposed reforms are largely the same in different political and 
cultural contexts, the practical realization of PPPs differs, according to the specific aims 
and the local circumstances underpinning their implementation. 
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For one thing, the mechanisms of legitimacy differ. For instance, while in some political 
contexts PPPs arise as a mean to reduce the public sector footprint, and are hence 
conceived as an opportunity to lessen state interference, in others they are seen as a mean 
to achieve new solutions for existent problems through a joined-up government of public 
and private actors parties (Pollit, van Thiel and Homburg 2007). 
Moreover, according to the different aims being pursued, PPPs can be implemented in 
different ways. Among the different institutional forms PPPs can take are contracting out 
models, in which the public sector contracts out the provision of a service to a business or 
non-profit organization deemed to offer a higher quality solution at lower costs; joint 
ventures, aimed at financing public infrastructure projects with private capital; public 
leverage models, in which governments maintain a strong steering function, deploying 
their legal and financial resources to foster the alignment of private sector's activities with 
public policy goals; and strategic partnership, in which “there is boundarylessness in terms 
of the distinctions between the constituent parties” (Skelcher 2005): partnerships are here 
intended to yield mutual beneficial outcomes, and to cement a collaborative endeavor 
between public and private actors on a trust-based relationship and joint decision-making 
basis. Both the latter cases are highly relevant insofar as they represent some of the most 
employed forms of PPPs in the life sciences, where both strong ethical concerns, the 
intensity of capital required to set up projects, as well as a tradition that sees science as a 
public good have prevented a complete privatization of its underpinning research 
structures. 
 
Building on the growing endorsement attributed at EU level to PPPs (Kinnock 1995), 
IMI was shaped on this governance and organizational template. Drawing from this 
general overview of the key tenets of PPPs, I now move to account for IMI’s specific 
configuration, and how the latter is brought to bear on stem cell research practice at the 
European level. 
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6.4 “Having a structuring effect on Europe”: creating a unified EU research 
landscape. 
 
Speaking at the IMI Stakeholders Forum held in Brussels in May 2014, Aidan 
Courtney, CEO of Roslin Cells, a leading partner in the EBiSC consortium, put himself in 
the analyst’s shoes to conceptualize the sociotechnical imaginary (Jasanoff and Kim 2009, 
2015) being articulated through IMI’s endeavor. As he said (Courtney 2014): 
IMI projects are big. And we are here not just to deliver the research, but actually to 
have a structuring effect on Europe, and change the way we do research in Europe. 
As I have previously observed, the notion of mobilizing both public and private funding 
at European level to consolidate a European research community is not new, and dates 
back to the mid-1970s (Gusmão 2001; Aguilar et al. 2013). What changes here are thus the 
distinctive resources being drawn upon in the implementation of the program; its specific 
objectives; the way agency and control are allocated among actors. In what follows, I 
expound IMI’s performativity in shaping a significant portion of European–supported 
biotechnology. In particular, I contend that IMI’s envisioned “structuring effect” is brought 
to bear on both the macro–level of IMI’s governance structure, and the micro–level of 
iPSC research practice. 
 
First, consistent with the PPP template sketched above, IMI is aimed at tracing a new 
geography of European biomedical research, so as to create a “truly unified space” (field 
notes 2015) of science and technology at the European level, overcoming a longstanding 
fragmentation of the main (academic and industrial) actors involved in it. As explained by 
the principal scientific officer at the DG Research and Innovation of the European 
Commission: 
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The main aim is to have people from different countries and institutions working 
together, to avoid wasting money, repeating some of the infrastructures, etc. That is one 
of the key features for the EU policy and for getting things going… 
Interview with principal scientific officer, DG Research and Innovation, EC 
The establishment of this new European scientific and technological ‘space’ was 
achieved through a number of reconfigurations of entrenched arrangements. First, it 
proceeded by significantly altering the process of biomedical knowledge–production, 
through the reconfiguration of the identities, roles and functions performed by industrial 
and academic actors. On the one hand, whereas in common conceptions of RandD 
pipelines the pharmaceutical industry traditionally focuses on the ‘development’ stage of a 
product, i.e. on the translation of lab–generated knowledge into a commercializable 
therapy, in the IMI framework the industry is instead prompted to play a first hand role in 
the generation of that early–stage knowledge itself. For, early industry involvement in the 
process of knowledge–production is seen as conducive to generate a kind of knowledge 
that could be then more easily translated into clinical products. As an IMI representative 
observed: 
The goal of the IMI program was precisely to sustain the development of a new 
knowledge at the industrial level, since it was noticed that, otherwise, there was no 
meaningful progress... There is no doubt that this program has been conceived to help 
the industry bringing forward the thresholds of knowledge. 
Interview with IMI representative 
Conversely, the reconfiguration brought forth by IMI projects requires that European 
academia, through sustained interaction with the pharmaceutical industry, develops its own 
capacity to become akin to its American counterpart, so as to exploit commercially the 
knowledge it generates. In the words of an EBiSC partner, IMI was conceived as an 
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“emergency procedure” intended to make European academia a site of innovation in its 
own right: 
I think academia in Europe still does not see the whole of the translational chain. It 
is basic research, but it does not go all the way towards the clinic, towards commercial 
exploitation. Universities in Europe don't have functional TT units. If a professor comes 
up with something worth of commercial exploitation, it's complex, there is not the 
infrastructure in play, the translation still doesn't work very well. In the US they are 
much more professionalized. The IMI projects are supposed to be a way to stop this…. I 
think there was a feeling at the EU level that initiatives put in place in the past [to foster 
commercialization of academic research] were not done efficiently. Universities have 
the knowledge, but they don't exploit that efficiently. IMI-funded projects are then 
something like an emergency procedure. 
Interview with partner in IMI’s project 
These points concerning the need for creating stronger linkages between public and 
private actors, while reconfiguring their identities in the process, are stressed by EU 
functionaries themselves. Recalling the evolution of the EU science policy landscape in the 
last decade, an official from the EC observes that: 
Personally, I think that 10-15 yrs ago, in the early days, the industrial–
manufacturing landscape in the EU was quite different. The idea was, if academia 
comes up with good ideas, they would have been picked up by industry and developed. 
And there was almost a kind of antipathy between academia and the industry. But what 
we have seen is that at the EU level the resources going into biomedical research have 
increased in recent years through the different framework programs, largely because of 
the EU parliament and their influence, and they are representing the citizens of EU, 
who wants to see something back for their investment. To demonstrate that money is 
justified we need to see something come out of it - and the upstream, more fundamental 
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part of research is seen as a bit of a luxury. That's been the reason. Now the whole 
debate about the EU project, referenda being in the balance in some cases... So the 
trend, the driver, has been to connect more with citizens, and try to get something out of 
it. That's my take on the change in emphasis... 
 On the luxury side, this is the public perception of scientists in academic/public labs 
in today's cold, wintery world in Northern Europe, that they have got a nice lab, a 
permanent staff, they are doing something which they like, it's probably their hobby. In 
contrast to the precarious world outside... 
Interview with principal scientific officer, DG Research and Innovation, EC 
 
Furthermore, a second feature of the redefinition of the European research landscape is 
the alleged creation of boundaries internal to the pharmaceutical industry itself. A main 
requirement of the IMI grant agreement, signed by EFPIA and the EC, is indeed that only 
costs sustained within the European Union and partner countries (such as Switzerland) are 
eligible for IMI funding. In turn, this requirement underpins the framing of something like 
the ‘European’ pharmaceutical industry, i.e. the creation of a (supra)national identity and 
citizenship for quintessentially global institutions, registered overseas, operating on global 
markets on a trans-continental scale. However, this framing plays out more as a legitimacy 
strategy for justifying funding, rather than an effective provision for enacting a profound 
reconfiguration in the inner organization structure of the pharmaceutical industry. For, a 
special provision that amended the original IMI grant agreement allows the industry to 
sustain a large chunk of its operating costs (up to 30% in total, which can however reach 
the 100% for a single project) outside Europe. As an IMI representative explained: 
In our contract, it is clearly stated that only EU costs are eligible for funding. 
However, 2–3 years ago, on the basis of the dynamics… of the different conformation of 
the market of the industry… there was a board decision that allowed a special provision 
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according to which the industry can sustain up to 30% of the costs outside Europe. For 
a single project, that could even amount to 100%... 
Interview with IMI representative 
 
Third, the creation of a unified scientific and technological landscape hinges on a 
further crucial aspect, the removal of entrenched competitive barriers among industries. 
Aside from creating closer connections between academia and the industry, IMI was 
indeed primarily geared to foster the establishment of collaborative relationships among 
industries themselves, overcoming a longstanding competitive culture that prevented 
different companies from sharing resources and data (in a way that led to cost–duplication 
and project overlapping) by carving out and enacting a ‘pre–competitive space’ of 
collaboration. The latter notion is ubiquitous in IMI’s parlance and projects, and refers to 
what Webster and Eriksson (2008) design as the realm of “basic innovation”, i.e. a non–
competitive domain of research at the early–stage of product development. As recalled by 
an IMI representative: 
For EFPIA, one of the first priorities that led to the establishment of the program 
was to optimize resources of all the companies conducting the same kind of research, to 
identify and address more rapidly and at a lower cost issues that everyone had (but 
everyone was working in its own corner, thus duplicating expenses), without competing 
in that specific domain. For instance, if we find out that a certain compound is toxic (or 
not)… this information if of interest for everyone. IMI was launched to ease the worries 
of the industry in sharing these kinds of data. 
Interview with IMI representative 
6.5 The leading role of the industry in IMI’s projects. 
As what observed so far already makes clear, in IMI a central role is performed by the 
pharmaceutical industry, and programmatically so. As the former IMI chairman, Michel 
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Goldman, has observed: “A key difference between the IMI and other public–private 
initiatives in the health-care area is that IMI projects stem primarily from pharmaceutical 
companies.” (Goldman 2012) In particular, the leading role of industrial actors in IMI 
projects can be appraised from at least two different perspectives.  
First, the agenda setting and topic definition is the industry’s prerogative. IMI projects 
take their inception from having a group of industries agreeing on a common area of 
research. Then, they elaborate a call and find suitable academic partners. Finally, once the 
consortium is assembled, the project receives IMI funding, and can thus start its 
operations. As an IMI project manager argued – and displaying, in so doing, a peculiar 
understanding of the notion of causality: 
Under IMI and IMI2, because industry is giving half of the contribution, the topic 
idea is coming from industry… Generally, [the topic] is something on which the 
industry is already working on, and the proposal they put forward relates to that. It 
would be very difficult for them to commit to a totally new idea, the ideas have to come 
internally. 
Interview with IMI project manager 
As such, if IMI projects are meant to create a new, unified landscape for biomedical 
research in Europe, the industry is empowered to define the boundaries of such landscape, 
while the public funding provided by the European Commission takes the form of an overt 
subsidy to the industry’s RandD strategy.  
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Figure	  17.	  IMI	  project:	  topic	  definition	  (source:IMI). 
Second, the pharmaceutical industry’s contributions are ‘in kind’. That is, rather than 
committing their financial resources, EFPIA members involved in IMI projects contribute 
to the overall budget by providing their own equipment, resources and staff time. This 
way, not only is the industry able to achieve significant financial savings. Most crucially, it 
is able to ensure that the process of knowledge–generation is geared towards industry–
compatible standards.  As observed by an IMI project manager: 
The € 1 billion from EFPIA is in staff research effort, so they are not giving cash and 
do the academics do the work, but they are dedicating their own personnel. And this is a 
key point: we fund a collaborative project, and to have staff from pharma working on 
that project is really important, because of the cross-fertilization of ideas, and because 
results from the project can be immediately applied to the pharmaceutical industry. 
Interview with IMI project manager 
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IMI: a new geography of European biomedical research: 
From a fragmented research landscape ⇒ to a unified space of collaborative endeavor 
⇓      ⇓      ⇓ 
Step 1: Reconfiguration of the identities, roles and functions of academia and industry: 
Industry: from product development ⇒ to knowledge generation 
Academia: from knowledge generation ⇒ to product development 
Step 2: Framing of a ‘European’ pharmaceutical industry 
Step 3: Creation and enactment of a ‘pre–competitive space’ of industrial collaboration 
Step 4: Leading role performed by the pharmaceutical industry: 
(i) Agenda–setting and topic definition prerogatives 
(ii) ‘In kind’ contributions ⇒ establishment of industry–compatible 
standards 
Table	  3:	  Synopting	  overview	  of	  IMI’s	  endeavor. 
 
The previous sections represent an overview of IMI that has become, since its inception, 
a mainstay of the European bioeconomic sector as well as an established tool in the EU 
science policy. In what follows, I investigate how this governance tool is brought to bear 
on iPSC research practice, through the establishment of the European Bank for induced 
Pluripotent Stem Cells. 
 
6.6 The European Bank for induced Pluripotent Stem Cells. 
EBiSC was launched, in February 2014, as one of the two flagship stem cell projects 
sponsored by IMI. EBiSC was created as a consortium, comprising 25 European 
organizations, ranging from academic research centers, to SMEs, to major pharmaceutical 
corporations. A leading role in the project is performed by Pfizer (in charge of the private 
side of the consortium), and by Roslin Cells, a small company specialized in iPSC 
manufacturing, that originated as a spin–off of Geron–funded Roslin Institute (the 
birthplace of Dolly the sheep) at Edinburgh University (Roslin Cells which is in charge of 
the public part of the consortium). 
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The overarching aim of the project is to establish a pan–European iPSC repository, 
manufacturing and distribution facility, with the goal of addressing the increasing demand 
by iPSC researchers and pharmaceutical companies for quality-controlled, disease-relevant 
iPSC lines, data and cell services. EBiSC’s main facility, which undertakes expansion, 
quality control and characterization of cell lines, is led by Roslin Cells and is located at the 
Babraham Research Campus in Cambridge, UK. In charge of coordinating cell line 
distribution is the European Cell Culture Collection (ECACC) of Public Health England 
and the UK Department of Health. Fraunhofer IBMT in Saarbrücken, Germany, is instead 
a ‘mirror site’ in charge of providing comprehensive operational back up.  
More in detail, the first objective of EBiSC is to establish a ‘Foundational Collection’ 
(henceforth: FC) of iPSC lines, which represents the core component of the EBiSC 
catalogue, to be then widely distributed to academic labs and pharmaceutical research 
centers in Europe. The FC comprises both already existent cell lines from EBiSC partner 
labs (such as, most notably, the large iPSC library established at the Sanger Institute), and 
new lines that are generated by partners in EBiSC using funding resources in response to 
demand from project partners or third parties. 
At first, EBiSC was conceived as a € 70 million project, that would have had to last 6 
years, with the aim of deriving around 10.000 iPSC lines. However, following reduction in 
funding to € 35 million by IMI, project–duration was shortened to 3 years, at the end of 
which EBiSC is meant to evolve into a not-for-profit iPSC bank. Interestingly, budget–
reduction did not prevent the project from going through. As observed by an academic 
partner in the project:  
What's going to happen is that we'll be able to collect lot less, it's a much smaller 
resource, which will come with a commercial entity at the end of the project, and will be 
part of Pfizer and Roslin Cells. And this has partly to do with the fact that commercial 
partners aim for short-term commercial benefits, rather than long-term collaborations, 
and part with the fact that IMI cut funding significantly. It was supposed to be a 6 years 
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project, 70 million, and now is 3 years, 35 million. Again, what's interesting is the 
difference in interaction. If such a reduction of funding happens with academic 
partners, they would say “we can't do this”, and would revise the proposal, and say 
“this is what we can promise”. Commercial partners are instead “ok, we'll try!”, even 
though everyone knows it won't happen what they promise... 
Interview with EBiSC partner 
 
6.7 “Having a structuring effect on Europe”: constructing ‘European’ iPSC 
research. 
As a flagship IMI project, EBiSC has been designed and implemented as “the missing 
infrastructure” in the European iPSC research landscape (interview with CEO, Roslin 
Cells). Borrowing language laden with economic connotations, EBiSC partners have 
described the initiative in terms of a “structural investment” in the whole iPSC sector in 
Europe (field notes 2015), one which is meant to establish the “whole supply chain” (field 
notes 2015) of iPSC research, from tissue sample procurement through appropriate consent 
from donors, to iPSCs derivation, expansion and distribution. As such, EBiSC is meant to 
accomplish a number of different objectives.  
A first aim is to establish connections among the so far disjointed different steps of 
iPSC research, and synergies among the various institutions at different stages involved in 
it.  
A second important objective is to create a unified space and a marketplace for 
European iPSC research through a governance–by–standards approach (Webster and 
Eriksson 2008). A defining characteristic of the initiative is indeed the strong focus on 
standardization – in order to address a twofold shortcoming in current iPSC research 
practice, the heterogeneity in both iPSC culture conditions and consenting practices, which 
in turn allows the distribution of high–quality, well–characterized and commercializable 
cell lines. To this end, EBiSC set out to homogenize reprogramming methods and culture 
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conditions among the partner labs, as well as to establish a single informed consent form, 
that could guarantee the widespread circulation of cell lines. As argued by the CEO of 
Roslin Cells:  
At the moment, the problem is not making iPSC, it is the procurement. The delays are 
upstream. You do the collaboration, you work on the cell lines, get some nice things, 
then go out to the OTT, and you discover that the initial consent is not in line with the 
commercialization! That's why pharma in EBiSC is very interested in standardizing the 
upstream part. 
Interview with CEO, Roslin Cells 
The rationale of the project is, thus, twofold. First, to agree on common standards 
among all partner labs, which represent some leading iPSC research centers at EU level. 
Second, to adopt a ‘trickle–down’ approach to standardization, facilitating the diffusion of 
the standards being adopted in EBiSC to the rest of the iPSC research field on the 
continent, that which could lead to the standardization of the entire field. As explained by 
EBiSC’s project leader: 
“The iPSC field is still in transition. But I think that the IMI scheme of funding 
allows us to change that whole landscape… What we are doing is to create a large 
infrastructure that in itself will engage with a number of different partners across 
Europe, and therefore facilitate the building of consensus. The consensus will then lead 
to the standardization. […] And also, it's a degree of normalization of the product, that 
at this phase it helps to grow and validate the market."  
Interview with EBiSC Project Leader 
 
Finally, consistent with the leading role of the industry in IMI projects, industrial actors 
are seen as ‘natural’ beneficiaries of EBiSC (field notes 2015). First, through EBiSC, the 
industry can reach out to academia and “understand how to use the technology” (interview 
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with representative from Roslin Cells). Second, the establishment of a large repository of 
iPSC lines can facilitate the pharmaceutical companies’ access to a greater amount of 
standardized and commercializable cell lines. Furthermore, public funding made available 
by the EU commission performs the crucial function of taming risk for the companies 
involved in the project, while also facilitating their capacity–building process. As 
explained by a Roslin Cells’ representative: 
 EBiSC is tremendously important to us, because it's a grant-funded activity so it's 
the best also if you are losing money. What it allows our company to do is to achieve 
scale, which is a key competitive advantage over other companies.  
Interview with representative of Roslin Cells 
 
6.8 Conclusions. 	  
In the European Union, amid profound and largely unresolved difficulties that define 
the contours of a critical challenge for its political identity, the life sciences and 
biotechnology, in reason of the innovation potential they entail, are increasingly being 
recruited to frame the basic elements of the supranational order–in–the–making. Major 
initiatives in science policy, such as IMI, are thus bound to provide the resources through 
which an important component of the European political identity is negotiated and 
constructed.  
Specifically, in this chapter I have analyzed how the commitment advanced by EBiSC – 
as a flagship project established within the IMI framework – to create close linkages 
amongst public and private actors is encoded and materialized in its efforts at operating a 
thorough standardization of iPSC research practices, ranging from donors’ consenting 
procedures to reprogramming methods and cell culture conditions. Articulating a 
translational vision that revolves around the blurring of institutional boundaries and the 
reconfiguration of the roles and functions performed by the industry and academia – with 
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the former geared to become a site of knowledge–production, and the latter a producer of 
innovation – EBiSC set out to standardize the field of iPSC research at the European level, 
so as to enable the seamless flow of knowledge between the academic and industrial 
research centers. 
In light of these features, the development of European iPSC research has taken a 
markedly different path from its American counterpart. Expounding these differences is 
aim of the following, concluding chapter of this dissertation. 
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Conclusions	  
 
 
This work set out, in chapter 1, by sketching the contours of the translational turn in 
biomedicine, and the ever–increasing importance being attributed, in biomedical as well as 
policy circles, to the acceleration of biomedical innovation. In this respect, the derivation 
of iPSCs by Japanese scientist Shinya Yamanaka in 2006 was hailed as a paradigm 
changer, one that not only rewrote chapters in biology textbooks, but also led to the swift 
adoption of iPSC–based technologies for widespread translational efforts. 
Against this background, this dissertation has thus taken a comparative approach to 
analyze the emergence and consolidation of iPSCs as translational devices by juxtaposing 
three leading iPSC research organizations, NYSCF, HSCI, and EBiSC, operating in two 
different political contexts, the US and the EU. Probing these platforms as simultaneous 
sites of innovation across science and governance, I traced the key junctures of their 
developmental trajectories, highlighting how the manipulations of cell fate and the 
governance arrangements at the heart of the three platforms established a catalysis of 
mutual reprogramming that yielded three distinct models of socio-technical innovation 
around stem cells.  
In these concluding remarks, I would now like to go through the main themes that have 
emerged in the course of the dissertation, and expand some of the lines of analysis that 
have been left implicit in the empirical analysis of my case studies. 
 
In this work I have drawn from the notion of biomedical platforms (Keating and 
Cambrosio 2003), focusing in particular on the hybrid performativity of normative and 
epistemic practices that characterize their endeavors (see chapter 3). Deploying this notion 
within a co-productionist framework (Jasanoff 2004), I uncovered two distinct ways of 
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applying the co–productionist lenses to the study of biomedical platforms: what I have 
termed the endogenous and exogenous forms of co–production (see also Marelli and Testa 
forthcoming).  
Harnessing this methodological toolkit for the analysis of my case studies, I probed, 
first, how the three platforms enact three distinct models of iPSC-based innovation, 
through the endogenous co-production of mutually reinforcing governance and epistemic 
standards, whereby: (i) divergent normative visions become crystallized in equally distinct 
governance and organizational structures; and (ii) the standardization practices for taming 
the unruliness of human pluripotency encode and reinforce these different institutional 
orders. Specifically, my analysis led to the following findings. 
For one thing, NYSCF and HSCI were revealing case studies of the multi–faceted 
imaginary revolving around clinical translation in the US, and the different approaches to 
translational iPSC research emerging within the very same political context. Both NYSCF 
and HSCI set out from a common twofold objective: the creation of institutional structures 
that could insulate stem cell research from unwarranted political interferences, while 
enacting modes of scientific investigation and epistemic practices that could accelerate the 
translation of stem cell–based discoveries to the clinic. The scope and outcomes of their 
endeavors, however, differed remarkably one from the other.  
As expounded in chapter 4, NYSCF has programmatically strived to challenge 
established experimental practices in the stem cell field, accruing agency within the 
organization in order to catalyze a change in paradigm of Kuhnian revolutionary salience. 
To this end, it adopted a venture philanthropy model of governance, one that borrows 
concept and practices from the disruptive innovation approach of Wall Street financiers 
and New York City venture capitalists, and one that is geared to the pursuit of “high–risk, 
high–return projects” that would normally not receive funding or attention by risk–adverse 
funding and research institutions. The creation of the first fully automated robotic system 
for iPSC derivation, expansion and differentiation – a project deemed by NYSCF’s 
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investigators themselves as being “so high risk that it is not known whether it is going to 
be rewarding” – best epitomizes the all–out translational thrust of this organization.  
Probing the entrenchment of stem cell research at a bastion of American academic 
research, Harvard University, chapter 5 focused on the establishment of the Harvard Stem 
Cell Institute and the iPS Core facility. Differently from NYSCF, HSCI advances a 
translational research agenda that is geared to sustain established research practices in the 
field of stem cell research. It also upholds the agenda–setting prerogatives of Harvard’s 
stem cell community through the construction and fortification, against President Bush 
siege on stem cell research, of a self–governing citadel of science insulated from the 
underlying socio-political context, thus re-enacting the cherished post-world war II model 
of science governance, that frames scientific autonomy as a fundamental principle for the 
effective translation of scientific advances into societal benefits. In parallel, HSCI has 
aimed to “strike the right balance” between ‘basic’ and ‘applied’ stem cell research, that 
which required, along with the implementation of explicitly translational programs, 
preliminary significant investments in basic science. 
Moving to the European context, chapter 6 analyzed how the commitment advanced by 
EBiSC – as a flagship project established within the IMI framework, the largest public–
private partnership in the life sciences – to create close linkages among public and private 
actors is encoded and materialized in its efforts at operating a thorough standardization of 
iPSC research practices, ranging from donors’ consenting procedures to reprogramming 
methods and cell culture conditions. Articulating a translational vision that revolves around 
the blurring of institutional boundaries and the reconfiguration of the roles and functions 
performed by the industry and academia – with the former geared to become a site of 
knowledge–production, and the latter a producer of innovation – EBiSC set out to 
standardize the field of iPSC research at the European level, so as to enable the seamless 
flow of knowledge between academic and industrial research centers.  
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Against this backdrop, table 1 provides a comparative overview of the main governance 
and epistemic arrangements of the three organizations analyzed in this work. 
 
 NYSCF HSCI EBiSC 
Institutional 
setting 
Non-
profit/Venture 
philanthropy 
Academic (US-style) Public–Private 
Partnership (PPP) 
Imaginary and 
model of 
innovation 
Disruptive 
innovation 
 
(centralization) 
Sustaining 
innovation 
 
(customization) 
Standardization of 
EU research 
landscape 
(standardization) 
Organizational 
structure 
Translational hub 
(centralization of 
agency) 
Virtual network 
(distribution of 
agency) 
PPP 
(reconfiguration of 
agency) 
Governance and 
Steering 
Venture 
philanthropy 
Harvard Faculty European 
Commission and 
EFPIA 
Propensity to 
epistemic and 
financial risk in 
advancing 
translation 
High Low Medium to high (due 
to risk mitigation 
ensured by public 
funding) 
Standardization 
technologies 
Global Stem Cell 
Array (disruptive 
automation) 
iPS Core Facility 
(trained 
craftmanship) 
Partner labs 
(governance–by–
standards) 
Table	  4.	  Synoptic	  overview	  of	  NYSCF,	  HSCI	  and	  EBiSC	  models	  of	  iPSC–based	  innovation. 
 
Other than accounting for a platform’s endogenous dynamics, the methodological 
toolkit developed in this dissertation is further conducive to bring into relief the dynamics 
occurring at the platform–context interface, thus probing the exogenous co–production of 
scientific and normative orders at a higher scale of political significance. In conclusion, I 
would thus like to bring to the fore and address two sets of questions typically neglected by 
the scholarship on platforms, namely: (i) how do pre–existing socio–economic–political 
regimes affect the platforms’ own innovation dynamics? (ii) What are the normative 
implications for the socio–political macro–order that are raised by the platforms’ 
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endeavors? In other words, what is the ‘reprogramming’ role that platforms perform on 
their broader context? 
 
Notwithstanding the irreducible performativity that characterizes each single platform 
(see chapter 3), the configuration of the political landscape in which platforms are situated 
greatly affects their innovation dynamics. This aspect becomes patent by juxtaposing the 
political developments in the US and the EU.  
In the US, the federal funding ban enacted by President Bush in August 2001 has led to 
the development of stem cell research in a sort of political vacuum, which was conducive 
to the establishment of privatized regimes of stem cell innovation. For, constituencies not 
accustomed to be science policy leaders, namely individual states and organizations 
(Thompson 2013), strived to “take up the slack” that the federal government was leaving 
(Cook 2004) through bottom–up initiatives largely devoid of any coordination with 
governmental agencies such as the NIH. In turn, this triggered significant experimentation 
in science policy: those empty spaces opened up by the retreat of the federal government 
from a key area of biomedical innovation had to be filled by innovative and more flexible 
regimes of governance (Nowotny and Testa 2011), advanced by new biomedical 
collectives tinkering with new norms, standards and forms of regulation. Notably, this 
policy configuration further led to the rise of endeavors, such as NYSCF’s, geared to open 
up the field of stem cell research through the introduction and dissemination of new 
standards, protocols and experimental practices.  
The development of European stem cell research, on the contrary, has proceeded 
through a marked top–down approach, in which institutional actors such as the European 
Commission, as well as established organizations traditionally involved in biomedical 
research, such as major pharmaceutical corporations, have maintained a strong 
performative function, steering the evolution of the entire field. The European dimension 
takes on further significance insofar as it imbues stem cell research with a distinctive 
	   185	  
(supra)nation–building commitment, conspicuously absent from its American counterpart. 
Driven by the intent to construct an integrated biomedical research landscape at EU level, 
EBiSC is symmetrically aimed at advancing the innovation strategy of the EU, which is 
seen as a cornerstone of its process of political consolidation, and at creating a distinctively 
‘European iPSC research’. To this latter aim, EBiSC is thus meant to reach a closure on a 
set of common standards to be agreed by partners lab, and to be widely disseminated to the 
entire iPSC field. 
 
iPSC research United States European Union 
Actors involved New biomedical 
collectives 
Institutional and 
established actors 
(European Commission, 
pharmaceutical 
corporations) 
Approach Bottom–up Top–down 
Aims of standardization 
practices 
Opening–up the field Reaching a closure 
Sociotechnical imaginary Privatized regimes of 
innovation 
(Supra)nation–building 
commitment 
Table	  5.	  How	  differences	  in	  political	  regimes	  affect	  configuration	  of	  stem	  cell	  research	  in	  US	  and	  
EU. 
 
As for the normative implications of the stem cell initiatives mapped in this dissertation, 
the two political contexts, again, present interesting differences.  
In the US, the federal funding ban contributed to the articulation of a specific form of 
neoliberal biopolitics, in which definitions and potential uses of life were no longer the 
exclusive prerogative of the US government and federal legislation, but were partially left 
to the forces of a market composed of entrepreneurs, philanthropists, scientists, and 
medical doctors (Thompson 2013).  
The neoliberal character of initiatives such as NYSCF lends itself to analytic scrutiny in 
at least a twofold respect. First, vis–à–vis the retreat of the federal government from the 
field of stem cell research, the devolution of the agenda–setting prerogatives to an active 
array of wealthy philanthropists and patients advocates had the effect of redrawing (or 
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gerrymandering) the boundaries of the polity having jurisdiction over stem cell research 
policy, empowering a subpopulation of stakeholders (who became the de iure public for 
stem cell research) and turning them in proxies for the public good in place of the general 
public. In spite of the universalistic claims they advance, these initiatives maintain in fact a 
marked privatistic stance (for, Thompson (2013) notes, patients advocates do not intend to 
speak for everybody). Accordingly, Benjamin (2013) argues, the power of forms of claim–
making based on biological citizenship (Rose and Novas 2005) – which is centered around 
a biological conception of a shared identity and which represents a hallmark of 
contemporary neoliberal subjectivity – increasingly tended to displace social and political 
citizenship claims, based on “interest–group politics” (concerned, for instance, with social 
justice issues), and the expression of substantive normative views by means of the 
(allegedly regular, albeit contested) electoral process which lead to the election of 
President Bush. 
Second, insofar as “biological citizenship claims presume an autonomous individual 
working on his or her body in a more or less private arena free of state regulation” 
(Benjamin 2013), they actively supports a framing of stem cell research as a ‘personal 
health’ issue, as opposed to a ‘public health’ issue. In so doing, such claims advance an 
“upwardly tilted public agenda” (Sckopcol 2004, quoted in Benjamin 2013) rooted in a 
neoliberal and consumerist stance concerned more with promoting the market availability 
and expansion of innovative stem cell technologies, than with guaranteeing fair and shared 
access to the future proceeds of innovation. As noted by Benjamin (2013): 
Stem cell advocates are concerned with expanding and protecting a consumer–based 
liberalism, ensuring access to future biomedical goods and services, and in that way 
they are very similar to other public interest and citizen advocacy groups that have 
been ascendant for some time. In one study of this trend, scholars describe a 
“postmaterialist” liberalism thriving in the civic sphere, increasingly focused on issues 
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that appeal to their middle–class supporters, which “have become less likely over time 
to ally with traditional liberal groups on behalf of re–distributive social programs”.  
From a science policy perspective, initiatives such as NYSCF’s, based on a venture 
philanthropy model of governance, entail an important conceptual change, that sets them 
apart from established models of science steering and governance. For, philanthropy–based 
governance actively seeks to grant private philanthropists exclusive access to science's 
“control room”, something that not even the "new social contract for science" (Jasanoff 
2005) - aimed at forging closer ties between academia and industry, from the 1980s 
onwards - had envisaged to such depth. Whereas in fact in this latter model the scientific 
agenda, while exposed to the influence of private capital, was still at least in principle 
subjected to public scrutiny and oriented towards the production of social goods (Guston 
2000) - however polluted in practice by continuingly arising conflicts of interest the goal 
may be (Mirowski 2011) - in the venture philanthropy model the agenda-setting 
prerogatives are programmatically devolved to private philanthropists, who, in times of 
austerity and reduced public budgets, are able to play an “outsized role in who withers and 
who grows" (Bradach and Kim 2012, quoted in Grossman et al. 2013) by redistributing 
excess capital accumulation to targeted projects, designed to carry out their vision, without 
a public mandate and with little oversight as to the programs supported.  
Far from being an isolated case confined to NYSCF, the spread of (venture) 
philanthropic science across the whole spectrum of scientific disciplines in the United 
States is relevant, and has a significant impact in re-orienting research priorities, the 
deployment of material and cognitive resources, as well as the very role of science in 
society (Nature 2008; Krimsky 2011; Barkan 2011; Broad 2014). As a March 2014 New 
York Times article - aptly titled Billionaires With Big Ideas Are Privatizing American 
Science - framed the issue, "American science, long a source of national power and pride, 
is increasingly becoming a private enterprise, becoming shaped less by national priorities 
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or by peer-review groups and more by the particular preferences of individuals with huge 
amounts of money” (Broad 2014).  
In the European Union, amid profound and largely unresolved difficulties that define 
the contours of a critical challenge for its political identity, the life sciences and 
biotechnology, in reason of the innovation potential they entail, are increasingly being 
recruited to frame the basic elements of the supranational order–in–the–making. Major 
initiatives in science policy, such as IMI, are thus bound to provide the resources through 
which an important component of the European political identity is negotiated and 
constructed. In that regard, aimed primarily at tracing a new geography of European 
biomedical research, IMI set out to create a “unified space” (field notes 2015) of science 
and technology at the European level through the coupling of public and private actors. In 
so doing, rather than attributing equal agenda–setting priorities to the different actors 
involved, IMI programmatically devolves to EFPIA–associated companies a leading role 
in the steering of its projects, thus empowering the industry to define the boundaries of the 
integrated research landscape that it strives to construct.  
Therefore, in conclusion it should be noted how, in spite of their differences, the 
American and European initiatives mapped in this dissertation nonetheless maintain a 
common feature, upholding a bioconstitutional framing of the position of science within 
the polity (Jasanoff 2005; Jasanoff 2011) that sideskirts the stream of recent efforts aimed 
at 'opening up' science substantively to public engagement (see, e.g., Nowotny, Scott, 
Gibbons 2001, Prainsack 2011). 	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Appendix	  I	  –	  Methodological	  note	  
	  
 
This thesis is based on analysis of published materials (scientific, policy, regulatory 
documents, journal articles, and videos) as well as on ethnographic fieldwork, which 
started at HSCI in October 2013, at NYSCF in April 2014, and at EBiSC in September 
2014. Fieldwork has consisted in multiple visits to the two facilities, attendance to a 
number of closed-door meetings (between scientists, clinicians, and representatives from 
multinational pharmaceutical companies, instruments manufacturers, software developers, 
and others), access to confidential documents, and semi-structured interviews with relevant 
stakeholders, ranging from graduate students to the CEO and executive director of the 
organizations (a complete list follows). All but two of the interviews were recorded, 
transcribed, and coded. All interviewees gave verbal consent to be interviewed. Some of 
them required that their statements be anonymized. 
 
 
List of semi-structured interviews: 
 
Harvard: 
October 3, 2013; April 3, 2014; April 7, 2014; May 28, 2014, Cambridge (MA), Leader of 
iPS Core Facility, HSCI 
October 2013-November 2014 (multiple interviews, n>10), Cambridge (MA) Head of iPS 
Core Facility, HSCI 
October 22, 2013, Cambridge (MA), (former) Head, Genome Editing Service, iPS Core 
Facility, HSCI 
October 24, 2013, Cambridge (MA), (former) FHS Project Manager, iPS Core Facility, 
HSCI 
November 6, 2013, Cambridge (MA), Lab Manager, Kevin Eggan Lab  
February 2, 2014, Cambridge (MA), Regulatory Affairs Manager, iPS Core Facility, HSCI 
April 22, 2014, Cambridge (MA), Research Assistant, iPS Core Facility, HSCI 
July 23, 2014, Cambridge (MA), Executive Director, HSCI 
August 7, 2014, Boston (MA), Biomedical Science Liaison, Eagle-i, Harvard Catalyst 
August 7, 2014, Cambridge (MA), Executive Director, HSCRB 
October 2, 2014, Skype interview, Director, HSCI 
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Other relevant stakeholders involved in iPS Core Facility projects: 
November 8, 2013, Skype interview, Director of Marketing and Sales, bio–imaging 
company 
April 8, 2014, Cambridge (MA), manager and representatives from Japanese corporation 
May 7, 2014, Telephone interview, Head of Stem Cell Program, pharmaceutical 
corporation 
May 9, 2014, Cambridge (MA), Research Coordinator/Genetic Counselor, Boston 
Children's Hospital 
 
NYSCF: 
April 10, 2014; May 22, 2014, New York City (NY) and Skype interview, Scientific 
Programs Director, NYSCF 
April 10, 2014, New York City (NY), Principal Investigator, NYSCF 
April 10, 2014, New York City (NY), Automation Systems and Stem Cell Biology 
Director, NYSCF 
April 10, 2014, New York City (NY), Staff Scientist, NYSCF 
April 10, 2014, New York City (NY), Senior Systems Architect, NYSCF 
April 10, 2014, New York City (NY), lab manager, NYSCF 
April 10, 2014, New York City (NY), Human Subjects Research Coordinator, NYSCF 
July 24, 2014, Skype interview, Helmsley Investigator, NYSCF 
July 30, 2014, Skype interview, CEO, NYSCF 
November 21, 2014, Skype Interview, SCRO Committee Chair, NYSCF 
February 12, 2015, Skype Interview, Chief of Staff, NYSCF 
 
iPS Core Facilities affiliated to the COREdinates consortium: 
April 17, 2014, Boston (MA), Principal Investigator, hESC Core Facility, Boston 
Children's Hospital 
July 15, 2014, Skype Interview, Director, iPSC Core Facility, Penn Institute for 
Regenerative Medicine, University of Pennsylvania, PA 
July 18, 2014, Skype interview, Manager, SKI Stem Cell Research Facility, Memorial 
Sloan Kettering Cancer Center, NY 
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July 26, 2014, Skype interview, Director, iPSC/hESC Shared Resource Facility, Mount 
Sinai School of Medicine, NY 
 
Cellular Dynamics International: 
October 2, 2014; November 28, 2014, Telephone interviews, Vice President of Research 
and Development, Manufacturing and Quality Systems and Chief Operating Officer, 
CDI 
November 26, 2014, Telephone interview, Vice President and Chief Commercial Officer, 
CDI 
 
EBiSC/IMI/EU: 
September 26, 2014, Milan (Italy), Director, Center for Ethics and Law in the Life 
Sciences (CELLS), University of Hannover 
December 5, 2014, Brussels (Belgium), Principal Scientific Officer, DG Research and 
Innovation, European Commission 
December 8, 2014, Brussels (Belgium), Scientific Project Manager, IMI 
February 17, 2015, Brussels (Belgium), Legal Officer, IMI 
February 17, 2015, Brussels (Belgium), EBiSC Project Manager, IMI 
April 28, 2015, Edinburgh (United Kingdom), CEO, Roslin Cells Ltd. 
April 28, 2015, Edinburgh (United Kingdom), Head of Development Oprations, Roslin 
Cells 
April 28, 2015, Edinburgh (United Kingdom), Business Development Manager, Roslin 
Cells 
April 29, 2015, Potters Bar (United Kingdom), Director, UK Stem Cell Bank 
 
 
 
Closed–doors meetings attended at Harvard: 
Automation Project meetings: October 21, 2013 (Technical and General meeting); January 
8, 2014 (Technical and General meeting); April 7, 2014 (Technical and General meeting); 
August 5, 2014 (Technical and General meeting); October 31, 2014 (General meeting) 
Pharmaceutical Company Project meetings: November 15, 2013; April 16, 2014 
FHS Project standardization meeting: January 15, 2014 
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Protocol standardization meeting: December 18, 2013 
Kevin Eggan Lab meetings: from October to December 2013 
 
IMI/EBiSC/EU meetings: 
EBiSC Ethics Advisory Board, Hannover, February 19, 2015 
 
Other case studies-specific stem cell conferences attended: 
May 8, 2014, The Next Gen Stem Cell Annual Conference (Stem Cell Core Facilities 
Session), Saratoga Springs (NY) 
October 22-23, The New York Stem Cell Foundation Annual Translational Conference, 
New York City (NY) 
 
Internship in Giuseppe Testa Lab at the European Institute of Oncology (IEO): 
May 2013 - August 2014: attendance to weekly group meetings and practical involvement 
in laboratory activities 
September 2014 - ongoing: attendance to weekly group meetings 
 
Other relevant (but not case-studies related) interviews: 
May 5, 2015, Sheffield (United Kingdom), Stem Cell Scientist, Sheffield University 
May 12, 2015, Milan (Italy), Director, Drug Discovery Unit, European Institute of 
Oncology (IEO) 
 
Other relevant (but not case-studies related) meetings attended: 
February 18, 2015, EuroStemCell Meeting, Brussels (Belgium) 
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